Updated 07/14/2025

Gil G. Mor, MD, PhD

Professor and Director

John M. Malone Jr. MD, Endowed Chair on Women Health
Scientific Director of The C.S. Mott Center for Human Growth and Development.

Associate (Vice) Chair for Research
Department of Obstetrics and Gynecology Wayne State University School of Medicine

Past-President, American Society for Reproductive Immunology

Gil G. Mor, MD, PhD

Research Interests

1. Immunology of Pregnancy

Research Summary

The main objective of our studies is to understand the communication between the maternal and fetal components of pregnancy and how pathogens contribute to the disruption of this crosstalk leading to pregnancy complications and abnormal fetal development. Research in our laboratory includes the following areas:

Trophoblast Biology. Trophoblast response and regulation to inflammatory responses.

Our previous work has demonstrated the expression of Toll-like receptors on trophoblast cells and ligation of these receptors produce a cytokine/chemokine network in response to either endogenous or exogenous stimuli at the maternal fetal interface. Therefore, trophoblast cells serve as sensors for the recognition and response to the environment throughout implantation and gestation, suggesting that the trophoblast itself might act as an innate immune cell by recognizing microbial products. One of the main pathways responsible for immune modulation and anti-microbial protection is the Type I Interferon Pathway (IFN). We currently are investigating the tight regulation of TLR function and type I IFN beta signaling in trophoblast and how this contributes to maternal and fetal health.

Immune cells regulation and function at the maternal/fetal interface. Maternal/fetal macrophages' role in tolerance to bacterial infections and response to persistent viral infections.

In recognizing and responding to the uterine microenvironment, trophoblast may recruit immune cells such as macrophages and regulate their distribution and function. We are currently investigating how trophoblast cells induce differentiation of macrophages immune response to bacteria to prevent an inflammatory response.

Infection in Pregnancy. Mechanisms of immune, placental and decidual responses to pathogens leading to preterm labor. In vivo model of preterm in polymicrobial disease.

The laboratory is actively investigating how viral infection may disrupt the fetal-maternal interaction by modifying the function of TLRs and Type I IFN signaling pathways. Our studies have shown that a viral infection of the placenta and decidua will lead to a disruption in immune cell distribution and function and consequently preterm labor. To further understand the role of infection in pregnancy we have developed in vivo and in vitro models to elucidate the cellular and molecular mechanisms in polymicrobial disease at the maternal/fetal interface and preterm labor.

Impact of Environmental factor on placental function and its implications on the development of the fetal immune system

Exposure to volatile organic compounds (VOCs) is an important determinant of maternal-offspring health, with implications for preterm birth and associated adverse health outcomes. VOCs contaminate shallow soils and groundwater of post-industrial cities at Superfund, residential, commercial, and industrial properties, leading to exposures via vapor intrusion. We postulate, that exposure to VOCs induce Maternal Immune Activation (MIA), which will induce generalized and persistent changes towards the function of the fetal immune system. Our central hypothesis is that inflammation in the placenta and decidua due to maternal exposure to VOCs, alters the development of the fetal immune system, which results in an aberrant post-natal immune response to infections. Our preliminary studies suggest that although the fetus may be protected against microbial infection, the outcome of maternal VOC exposure, protective or deleterious, depends on the nature of the immune response and the severity of the inflammatory process at the implantation site (placenta-decidua interface). The mechanisms underlying the response of the fetal immune system and how indirect training by the maternal inflammation takes place is unclear and understudied.

2. Ovarian Cancer Program

Research Summary

The objectives of the laboratory are to understand the role of ovarian cancer stem cells in the process of tumor formation, recurrence and chemoresistance. Research in our laboratory includes the following areas:

Origin of Ovarian Cancer. Identifying the signals originating from the ovaries that have the capacity to attract malignant tumor-initiating cells

We are currently investigating the origin of ovarian cancer. Studies in the laboratory have shown that tumor-initiating cells are attracted to the ovaries following ovulation and once the malignant cells reach the ovaries the ovaries are able to provide a “fertile soil” that can support tumor initiation. These findings have opened the opportunity for the development of new venues to

prevent ovarian cancer by inhibiting the factors associated with the recruitment of transformed cells towards the ovaries. Furthermore, it has provided the identification of new markers for early detection. We have developed a unique in vivo model for Stage I and II ovarian cancer.

In vivo model of recurrence. We have developed an intra-peritoneal (i.p.) recurrent ovarian cancer animal model that mimics the clinical profile observed in patients with EOC.

This animal model has allowed the identification of key factors involved in the promotion of metastasis and chemoresistance. Using this model, we have identified specific chemotherapy-induced tumor modifications that contribute to the development of metastasis and chemoresistance. The Mor Lab has established an active drug screening system for the identification of novel compounds that can prevent recurrence and target chemoresistant recurrent disease. In addition, our model has allowed identification of markers for predicting chemoresponse and therefore can aid in therapy selection or Personalized Medicine, which is a major objective of Dr. Mor's laboratory.

This animal model is currently being used to develop a novel drug delivery system that specifically targets tumor blood vessels and not normal blood vessels.

Tumor Immune Interactions. Our objective is to elucidate the mechanisms associated with tumor immune tolerance and to develop new therapeutic modalities to restore immune surveillance.

The objective of our studies is to develop an immunotherapy to treat recurrent and refractory ovarian cancer and potentially other peritoneal carcinomatosis based on CARG-2020. We have demonstrated that (i) CARG-2020 prevents the establishment of recurrent ovarian disease in mice, (ii) it has a major impact on their survival, (iii) it induces a strong and long-lasting memory to protect the host from future establishment of vascularized metastases from dormant cancer cells and; (iv) CARG-2020-mediated destruction of cancer cells result in in situ vaccination generated from the release of tumor derived neoantigens. Our next step is to test the efficacy of CARG2020 on a Phase I clinical trial.

Clinical Research: Our goal is to bring together basic and translational research in order to improve the quality of life for our communities. We established the Clinical Research Center at the C.S. Mott Center for Human Growth and Development to conduct cutting-edge medical research by highly-skilled medical investigators and support staff with unparalleled clinical expertise. We strive to treat our patients with the highest level of compassionate care while providing world-class research services to the investigators and sponsors we support.

GIL MOR, MD, PhD
The C.S. Mott Center for Human Growth and Development
Department of Obstetrics and Gynecology
Wayne State University School of Medicine
275 E Hancock Avenue, Detroit. MI 48201
(313)-577-1337
gmor@med.wayne.edu

PERSONAL DATA

Date of birth: December 23, 1960.

Citizenship: USA, Israeli

Languages: English, Hebrew, and Spanish.

Web Page: https://mott.med.wayne.edu/

ORCID: https://orcid.org/0000-0002-5499-3912

Lab website: https://mott.med.wayne.edu/mor-lab-home/

Clinical Center: https://mott.med.wayne.edu/crc/

STATISTICS

RCR	737
Citations:	40,341
Google h-index	108
i10 Index	289
World	Top 2%
D-Index	105
World Ranking	521
National Ranking	302

EDUCATION:

1993 **Ph.D**., Immunoendocrinology, Hormone Research Department, Weizmann Institute of Science, Rehovot, Israel

1988 **M.Sc.**, Neuroendocrinology, Neurology Department, Hadassah Hospital, Hebrew University, Jerusalem, Israel

1987 **M.D.**, Hebrew University Medical School, Jerusalem, Israel

TRAINING

1994-1996 Postdoctoral Fellow, Laboratory of Immunobiology, Center for Biologics Evaluation and Research, FDA, National Institutes of Health, Bethesda, MD

1991-1992 Fellowship, Reproductive Endocrinology, Max-Planck Institute fur Experimental Endocrinologie, Hanover, Germany

1990-1993 Clinical training in Reproductive Endocrinology, Department of Obstetrics and Gynecology, Kaplan Hospital, Rehovot, Israel

1988-1993 PhD thesis research in the laboratory of Prof. Fortune Kohen, Department of Hormone Research, The Weizmann Institute of Science, Rehovot, Israel

1986-1988 M.Sc. thesis research in the laboratory of Prof. Shaul Feldman, Neurology Department, Hadassah Hospital, Hebrew University, Jerusalem, Israel

ACADEMIC APPOINTMENTS

2019-present John M. Malone Jr. MD, Endowed Chair of Women's Health Research

2019-present Scientific Director of The C.S. Mott Center for Human Growth and Development. Wayne State University School of Medicine

2020-preent Director Clinical Research Center C.S. Mott Center for Human Growth and Development. Wayne State University School of Medicine

2023-2026 Advisory Professor. Huazhong University of Science and Technology, Tongji Medical College, Wuhan China

2019-present Associate (Vice) Chair for Research. Department of Obstetrics and Gynecology Wayne State University School of Medicine

2020-2022 Chair (Interim) Department of Physiology, Wayne State University School of Medicine

2012-2018 Director, Division of Reproductive Sciences, Department of Obstetrics, Gynecology & Reproductive Sciences, Yale University School of Medicine, New Haven, CT

2010-2019 Professor, Tenure, Department of Obstetrics, Gynecology & Reproductive Sciences,

Yale University School of Medicine, New Haven, CT

2008-2010 Associate Professor, Tenure, Department of Obstetrics, Gynecology & Reproductive Sciences, Yale University School of Medicine, New Haven, CT

2004-2019 Director, Discovery to Cure Translational Research Program, Department of Obstetrics, Gynecology & Reproductive Sciences, Yale University/Yale Cancer Center

2003-2007 Associate Professor, Department of Obstetrics, Gynecology & Reproductive Sciences, Yale University School of Medicine, New Haven, CT

1998-2002 Assistant Professor, Department of Obstetrics, Gynecology & Reproductive Sciences, Yale University School of Medicine, New Haven, CT

1997 Adjunct Lecturer, University of New Haven, New Haven, CT

1997-1998 Associate Research Scientist, Department of Obstetrics, Gynecology & Reproductive Sciences, Yale University School of Medicine, New Haven, CT

TEACHING EXPERIENCE

2023- Present Director Course on Human Reproduction. Huazhong University of Science and Technology, Wuhan China

2022 Director Course on Reproductive Biology, 150 students, Serial Lectures. Huazhon University of Science and Technology, Wuhan China

2020 – Present Lectures on Reproductive Immunology. Principles of Reproductive Biology PSL. 7690. Wayne State University

2019 - Present Co-Director, Introductory Course on Reproductive Biology. Principles of Reproductive Biology PSL 7690. Wayne State University

2016-2017 Course on Reproductive Immunology. 25 students, PhD, MD. Serial lectures. Huazhong University of Science and Technology, Wuhan China

2017-2018 Course on Ovarian Cancer. 35 students, PhD, MD. Serial lectures. Huazhong University of Science and Technology, Wuhan China

2018-2019 Course on Reproductive Immunology. 216 students, PhD, MD. Serial lectures. Huazhong University of Science and Technology, Wuhan China

2010-2019 Path690: Molecular Mechanisms of Diseases. Ovarian Cancer. 15 students, PhD, MD lecture. Yale University

2005-2015 Cell Biology. Graduate level. Yearly semester course. Lecture-discussion, 25 students. 3h/weekly class, 10 weeks duration. Yale University

2004 Reproductive Immunology. Graduate and medical students. Lectures, 2h/weekly class, 4 weeks duration. Yale University

2004 Conference: Topics on cancer therapeutics. Pharmacology Department. Yale University

2003 Seminar on Apoptosis and Cancer. Undergraduate students. 1 hour/weekly class, 4 weeks duration. Yale University

2002-2019 Immunology. Graduate level. Yearly semester course. Lectures, 22-28 students, 3h/weekly classes, 10 weeks duration. Yale University

2001-2008 Developmental Biology. Graduate level. Yearly semester course. Lecture-discussion. 15 students. 3h/weekly classes, 10-week duration

2001-2008 Endocrinology . Graduate level. Semester course every two years. Lecture-discussion. 15 students. 3h/weekly classes, 10-week duration

1999-2019: Undergraduate level, Lecturer on Reproductive Immunology. Course: Human Reproduction

1997-1998 Instructor, School of Health Sciences, San Francisco's University, Quito, Ecuador. Medical Biology.

Courses and Educational Material

2024-present Director course in Clinical Research, Ob/Gyn Residents and Medical students

2023 Director Course on Clinical Reproductive Immunology. American Society for Reproductive Immunology

2022 Director Course on Clinical Reproductive Immunology. American Society for Reproductive Immunology

2004 Reproductive Immunology Course. Course Director

2004 Course pack on Reproductive Immunology for Medical Students and Residents. Gil Mor, Editor. Landes Bioscience

MENTORSHIP

Donna Neale	SMFM/AAOGF Scholarship Award 2004
Donna Neale	NIH, LRP 2002-2004
Shawn Chavez	PEO Foundation Scholarship Award 2005
David O'Malley	Research Award - Gynecologic Cancer Foundation 2004
Michael Kelly	NIH, LRP 2005
Shawn Chavez	John Spangler Nicholas Dissertation Award 2006
Aliza Leaser	Program of Excellence Award Grant, Ovarian Cancer Research Fund 2007
Aliza Leaser	NIH, LRP 2007-2008
Rui Chen	President's Award, Society for Gynecologic Investigation 2008
Rui Chen	John Spangler Nicholas Dissertation Award 2008
Kaori Koga	Blackwell Award, American Association for Reproductive Immunology 2008
Ingrid Cardenas	Travel Award, American Association for Reproductive Immunology 2009
Ilana Chefetz	Life Sciences Research Foundation Postdoctoral Fellowship 2009-2012;
Ilana Chefetz	AACR Scholar-in-Training Award 2010; Young Scientist Program Travel Fellowship
Laura Fraccaroli	Fulbright Scholar Award 2012
Yang Yang-Hartwich	Ovarian Cancer Research Fund 2014
Yang Yang-Hartwich	Ovarian Cancer Academy Award-Early Career Investigator 2015

ACADEMIC AWARDS:

Professional Honors or Recognition

A) National

2023	Member Academy of Scholars Wayne State University
2023	Distinguished Service Award. American Society for Reproductive Immunology.
2023	ASRI Leadership Award.

2021 Keynote Speaker Annual meeting of the American Society for Reproductive Immunology

2016 Keynote Speaker "Twenty-second Annual Dr. Raymond O. Berry Memorial lecture". Texas A&M University

2015 Keynote Speaker "Ellen Reed Memorial lecture" ovarian cancer.

2012 American Journal of Reproductive Immunology Award, American Society for Reproductive Immunology

2010 MAH, Yale University

2008 Harold Behrman Award, Yale University

2007 J. Christian Herr Award, American Society of Reproductive Immunology

2004 Placental Association of the Americas, Research Award (Mentor)

2002 Society for Maternal-Fetal Medicine, Research Excellence Award (Mentor); Annual Meeting

2001 American Society of Reproductive Immunology, New Investigator Award (Mentor), Annual Meeting

2000 American Society of Reproductive Immunology Award (Mentor), Annual Meeting

2000 Society for Gynecologic Investigation, Blue Ribbon Presentation

1999 American Society of Reproductive Immunology Award (Mentor), Annual Meeting

1995 ORISE Fellowship Award

1993 Guerchenson Scholarship Award

B) International

2024 2024-Huaxia Medical Science Award, presented by the China Preventive Medicine Association and the Huaxia Medical Association.

2023 International Society for Reproductive Immunology Mentor Award. Hamburg Germany

2023 Advisory Professor. Huazhong University of Science and Technology. Wuhan China

2018 Pearl River Professor. Jinan University Guangzhou China

2017 President Award from the Korean Society of Maternal Medicine. Seoul South Korea

2016 Scientific Advisor of the Shenzhen Key laboratories for Reproductive Immunology and peri-implantation, Shenzhen China

2015 Member International Advisory Committee for the Sino-American Center of Translational Medicine. Southern Medical University, China

2015 Kiril Bratanov Medal Award" in Reproductive Immunology. Varna Bulgaria.

2015 Guest Professor, Huazhong University of Science and Technology, Wuhan China

2011 Honorary Professor, Second Affiliated Hospital of Medical College of Xi'An, Jiaotong University. Xi'An China

2010 Presidential Lecture, Yonsei University College of Medicine. Seoul Korea

2007 Keynote Speaker, Japan Society for Immunology of Reproduction, Japan

2005 Honorary Member, Obstetrics and Gynecologic Society – Ecuador

2004 Honorary Member, Argentine Society of Gynecologic Endocrinology

2003 Honorary Member, Menopause Society – Argentina

2002 Honorary Member, Climacteric Society – Paraguay

2000 Honorary Member, Menopause Society – Chile

1991 Minerva Training Fellowship Award

1991 Israel Endocrine Society Award in Basic Endocrine Science

Professional Service

Peer Review Groups/Grant Study Sections

2024 **Co-Chair:** ZRG1 EMS-A Study Section NIH

2024 **Ad Hoc Member:** ZRG1 EMS-A Study Section NIH

2023 **Ad Hoc Member:** CCH1 U19 Study section NIH

2022 **Pennsylvania Health Research program**. Reviewer

2022 **Ad Hoc Member:** NIH Director's New Innovator Award

2020 **Ad Hoc Member:** PN Study section NIH

2019 **Austrian Science Fund**.

2018 **Ad Hoc Member:** PN Study section NIH

2014 **Israel Science Foundation**: Reviewer

2014 **Ad Hoc Member**: NCI SPORE II, NCI, NIH

2014 **Ad Hoc Member**: Special Emphasis panel ZAI1 FDS-(M1) 1 NIAID, NIH

2014 **U.S. – Israel Binational Science Foundation**: Reviewer

2014 **Ad Hoc Member**: Special Emphasis panel, ZAI1-MFH-M-M1, NIAID, NIH

2011 **Ad Hoc Member:** Special Emphasis Panel - ZRG1 OTC-C(02) Cancer Immuno Therapeutics, NCI, NIH

2011 **U.S. – Israel Binational Science Foundation**: reviewer

2011 **Ad Hoc Member**: MONC-Study Section, NCI, NIH

2010 **Ad Hoc Member:** MONC-Study Section, NCI, NIH

2008 **Ad Hoc Member**: SPORE in Breast, Gynecologic and Genitourinary Cancers, NCI, NIH

2007 **Ad Hoc Member**: HED-1 Study Section, NICHD, NIH

2007 **U.S. – Israel Binational Science Foundation**: Reviewer

2004-2010 **MRC, London England:** Grant Reviewer

2003 **Ad Hoc Member**: HED-1 Study Section, NICHD, NIH

2003 **Wellcome Trust, London England:** Grant Reviewer

2002 **Ad Hoc Member:** Integration Panel Meeting, USAMRDC Ovarian Cancer Research Program

Professional Organizations

2022-2023 **Guest Editor**: Multiple signals in Ovarian Cancer. Cancers

2021-2022 **Guest Editor**: Immunology of Pregnancy. Immunological Review

2022-2023 **Co-Chair** Annual Meeting of the American Society for Reproductive Immunology. Santa Fe NM

2021-present **Co-Chair** Clinical Course on Reproductive Immunology

2021-Present **Editor,** Reproductive Immunology Book Series. Elsevier

2020-present **Editor,** (Americas) Placenta Journal

2020 present **Funder** and **Co-Director** of Fellowship program on Reproductive Immunology. American Society for Reproductive Immunology

2021-2022 **Past-President** American Society of Reproductive Immunology

2018-2021 **President** American Society of Reproductive Immunology

2016-2018 **President-elect** American Society of Reproductive Immunology

2014 **Chair Session** on Inflammation at the Maternal Fetal Interface: NICHD/NIH workshop on immune Mechanisms at the Maternal Fetal Interface

2014 **Chair Session** on Immune System and the Placenta: NICHD/NIH workshop on the Human Placenta Project

2014 **Member, Advisory Board**, Scientific Reports, Nature

2013 **Co-Chair,** ISIR/ASRI Annual Meeting, Boston, MA

2012 **Elected Councilor,** International Society for Immunology of Reproduction

2010-2018 **Editor-in-Chief**, American Journal of Reproductive Immunology

2011-present **Editor**, Medical Journals

2008-2010 **Elected Treasurer**, American Society of Reproductive Immunology

2006 **Member, Editorial Board**, Recent Patents in Inflammation & Allergy

2006 **Chief Scientific Officer**, Archimedical USA Ltd.

2005-2008 **Elected Secretary**, American Society of Reproductive Immunology

2005 **Member, Editorial Board,** Eureka Bioscience

2005 **Member Editorial Board,** American Journal of Reproductive Immunology

2004-2013 **Scientific Committee,** American Society of Reproductive Immunology Annual Meeting

2004 **Member, Editorial Board,** Reproductive Sciences

2003 **Program Chairman and Organizer,** American Society of Reproductive Immunology Annual Meeting, Yale University, New Haven CT

2001-2005 **Elected Councilor,** American Society of Reproductive Immunology

Yale University Service –

Medical School Committees

2013-present **Fellow**, Trumbull College, Yale University

2013-2019 **Director, WRHR,** Yale University School of Medicine

2010-2019 **Appointments and Promotions Committee**, Department of Obstetrics, Gynecology & Reproductive Sciences, Yale University School of Medicine

2010-2019 **Organizer and Director, Discovery to Cure International Clinical & Research Fellowship**, Yale University School of Medicine

2006 **Translational Research Committee**, Yale Cancer Center

2004 **Advisory Panel**, **WRHR,** Yale University School of Medicine

2004 **Advisory Committee Member**, Yale CME, Yale University School of Medicine

2003 **CME Task Force**, Yale University School of Medicine

2003-2019 **Organizer and Director**, **Discovery To Cure High School Internship**, Yale University School of Medicine

2003 **Web Master,** Department of Obstetrics, Gynecology & Reproductive Sciences, Yale School of Medicine

Wayne State University Service –

- Chair, Search Committee for the Chair of Physiology
- Member, Search Committee for the Chair of Ob/Gyn Department
- Interdisciplinary Research Committee (IRC)
- Chair Ob/Gyn Search Committee
- Translational Commercialization Committee-Karmanos
- Interin Chair Department of Physiology
- Organizer and Director, Discovery To Cure High School Internship

MEMBERSHIPS:

· American Association for Cancer Research
· American Association for the Advancement of Science
· American Society of Reproductive Immunology
· Yale Comprehensive Cancer Center
· Society for Reproductive Investigation (formerly Society for Gynecologic Investigation)
· American Society of Immunology

PROFESSIONAL SERVICES

Consultant: Cyvek

Consultant: Teva-Oncotest Israel

Consultant: Novogen Ltd.

Consultant: Champion

Consultant: Archimedical USA

Consultant: Microgenesis

Board Member: Carestream

Board Member: CanTX

Board Member: Carogen

START UP COMPANIES

SurExam: China/USA

Archimedical: USA/Europe

Mazor Oncology: USA

MBH Diagnostics: Israel

CanTx: USA

REVIEWER: Editorial Board

Science

Biology of Reproduction

NeuroImmunoModulation

European Journal of Obstetrics & Gynecology and Reproductive Biology

Molecular Human Reproduction

Journal of Reproductive Immunology

Laboratory Investigation

American Journal of Reproductive Immunology

Obstetrics and Gynecology

Breast Cancer Research and Treatment

Oncogene

Journal of the Society for Gynecologic Investigation

Journal of Immunology

Human Reproduction

Cancer Research

Clinical Cancer Research

Gynecologic Oncology

PLOS one

Placenta

CLINICAL TRIALS-Investigator Initiated

The Clinical Research Center: The Clinical Research Center (CRC) at the C.S. Mott Center for Human Growth and Development brings together basic and translational research in order to improve the quality of life for our communities. Our cutting-edge medical research is conducted by highly-skilled medical investigators and support staff with unparalleled clinical expertise. We strive to treat our patients with the highest level of compassionate care while providing world-class research services to the investigators and sponsors we support.
https://mott.med.wayne.edu/crc/

Past protocols Investigator initiated clinical trials.

- Phase Ib/II study of Phenoxodiol in patients with recurrent ovarian, fallopian and primary peritoneal cancer that is resistant to second line chemotherapy. 2002-2003
- Phase I study of Neodjuvant use of oral Phenoxodiol in patients with primary diagnosis of squamous adeno-carcinoma of the cervix, vagina and vulva. 2004-2005
- A non interventional, prospective study of the accuracy of the Precision Therapeuthics, Inc. chemoresponse assay in patients with stage II-IV recurrent epithelial ovarian or primary peritoneal cancer. 2004-2005
- Multi-center, Phase Ib Safety and Preliminary Efficacy Study of Phenoxodiol (Intravenous Dosage Form) as a Chemo-Sensitizing Agent for Cisplatin and Paclitaxel in Recurrent Epithelial Ovarian Cancer. 2004-2005
- A Randomized Placebo-Controlled Phase Ib/IIa Safety, Tolerability and Efficacy Study of Oral Phenoxodiol in Combination with Docetaxel versus Docetaxel Alone in Patients with Recurrent Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer. 2005-20012.
- HIC Protocol # 10425: The role of Fas Ligand system in gynecologic malignancies and pregnancy
- HIC Protocol # 0606001587: The role of MyD88 expression in chemoresistance and disease progression in epithelial ovarian cancers

PATENTS

Publication number: 20170281588

Abstract: The present invention provides the eutomeric isomer of the compound of formula (I), or a salt or solvate thereof, which can be used to treat epithelial cancer in a subject. In certain embodiments, the compound of formula (I) can be used in combination with AICAR and/or cisplatin.

Type: Application

Filed: March 28, 2017

Publication date: October 5, 2017

Inventor: Gil G. MOR, Ayesha ALVERO

IDENTIFICATION OF CANCER PROTEIN BIOMARKERS USING PROTEOMIC TECHNIQUES

Publication number: 20170138950

Abstract: The claimed invention describes methods to diagnose or aid in the diagnosis of cancer. The claimed methods are based on the identification of biomarkers which are particularly well suited to discriminate between cancer subjects and healthy subjects. These biomarkers were identified using a unique and novel screening method described herein. The biomarkers identified herein can also be used in the prognosis and monitoring of cancer. The invention comprises the use of leptin, prolactin, OPN and IGF-II for diagnosing, prognosis and monitoring of ovarian cancer.

Type: Application

Filed: September 16, 2016

Publication date: May 18, 2017

Inventors: GIL G. MOR, DAVID C. WARD, PATRICIA BRAY-WARD

- **Identification of cancer protein biomarkers using proteomic techniques**

  Patent number: 9470688

Abstract: The claimed invention describes methods to diagnose or aid in the diagnosis of cancer. The claimed methods are based on the identification of biomarkers which are particularly well suited to discriminate between cancer subjects and healthy subjects. These biomarkers were identified using a unique and novel screening method described herein. The biomarkers identified herein can also be used in the prognosis and monitoring of cancer. The invention comprises the use of leptin, prolactin, OPN and IGF-II for diagnosing, prognosis and monitoring of ovarian cancer.

Type: Grant

Filed: January 22, 2015

Date of Patent: October 18, 2016

Assignee: Yale University

Inventors: Gil G. Mor, David C. Ward, Patricia Bray-Ward

- **REMISSION THERAPY OF CANCER WITH ISOFLAVONOIDS**

  Publication number: 20120251630

  Abstract: Provided herein is a method of reducing incidences of cancer recurrence. The method involves administering to an individual in cancer remission an isoflavonoid. In specific instances, the treated individual is in remission from epithelial cancer, such as ovarian cancer or breast cancer.

  Type: Application

  Filed: March 29, 2012

  Publication date: October 4, 2012

  Applicant: MARSHALL EDWARDS, INC.

  Inventors: Ayesha B. Alvero, Daniel P. Gold, Gil G. Mor

- **Drug resistance and methods of reversing**

  Patent number: 7985538

  Abstract: Described herein is a cellular marker, MyD88, useful for assessing an individual's (patient's) sensitivity (or resistance) to chemotherapy, particularly sensitivity (or resistance) to chemotherapeutic drugs, such as plant alkaloids (e.g., a taxane, such as paclitaxel or docetaxel). As described herein, Applicants provide a method by which it is possible to determine whether an

individual (cancer cells in an individual) is sensitive to chemotherapy with plant alkaloids (e.g., a taxane, such as paclitaxel or docetaxel). Early identification of chemoresistance in patients with cancer is of utmost importance, particularly since it makes it possible to provide the most appropriate therapy.

Type: Grant

Filed: February 23, 2007

Date of Patent: July 26, 2011

Assignee: Yale University

Inventor: Gil G. Mor

- **Identification Of Cancer Protein Biomarkers Using Proteomic Techniques**

  Publication number: 20100311047

  Abstract: The claimed invention describes methods to diagnose or aid in the diagnosis of cancer. The claimed methods are based on the identification of biomarkers which are particularly well suited to discriminate between cancer subjects and healthy subjects. These biomarkers were identified using a unique and novel screening method described herein. The biomarkers identified herein can also be used in the prognosis and monitoring of cancer. The invention comprises the use of leptin, prolactin, OPN and IGF-II for diagnosing, prognosis and monitoring of ovarian cancer.

  Type: Application

  Filed: December 22, 2009

  Publication date: December 9, 2010

  Applicant: Yale University

  Inventors: Gil G. Mor, David C. Ward, Patricia Bray-Ward

- **Methods of determining whether a pregnant woman is at risk of developing preeclampsia**

  Patent number: 7790463

  Abstract: The present invention provides methods and compositions related to biomarker profiles for each trimester of pregnancy. The present invention also provides methods for identifying patients at risk of developing a complication of pregnancy, such as preeclampsia. In further

embodiments, the present invention relates to methods for the diagnosis of patients with preeclampsia.

Type: Grant

Filed: February 2, 2006

Date of Patent: September 7, 2010

Assignees: Yale University, The United States of America as represented by the Department of Health and Human Services

Inventors: Gil G. Mor, Donna Neale, Roberto Romero

- **Identification of cancer protein biomarkers using proteomic techniques**

  Patent number: 7666583

  Abstract: The claimed invention describes methods to diagnose or aid in the diagnosis of cancer. The claimed methods are based on the identification of biomarkers which are particularly well suited to discriminate between cancer subjects and healthy subjects. These biomarkers were identified using a unique and novel screening method described herein. The biomarkers identified herein can also be used in the prognosis and monitoring of cancer. The invention comprises the use of leptin, prolactin, OPN and IGF-II for diagnosing, prognosis and monitoring of ovarian cancer.

  Type: Grant

  Filed: January 18, 2005

  Date of Patent: February 23, 2010

  Assignee: Yale University

  Inventors: Gil G. Mor, David C. Ward, Patricia Bray-Ward

- **Drug Resistance and Methods of Reversing**

  Publication number: 20090220427

  Abstract: Described herein is a cellular marker, MyD88, useful for assessing an individual's (patient's) sensitivity (or resistance) to chemotherapy, particularly sensitivity (or resistance) to chemotherapeutic drugs, such as plant alkaloids (e.g., a taxane, such as paclitaxel or docetaxel). As described herein, Applicants provide a method by which it is possible to determine whether an individual (cancer cells in an individual) is sensitive to chemotherapy with plant alkaloids (e.g., a

taxane, such as paclitaxel or docetaxel). Early identification of chemoresistance in patients with cancer is of utmost importance, particularly since it makes it possible to provide the most appropriate therapy.

Type: Application

Filed: February 23, 2007

Publication date: September 3, 2009

Applicant: Yale University

Inventor: Gil G. Mor

- **In vitro test to detect risk of preeclampsia**

  Patent number: 7541182

  Abstract: The present invention provides methods for identifying patients at risk of developing preeclampsia. In further embodiments, the present invention relates to methods for the diagnosis of patients with preeclampsia.

  Type: Grant

  Filed: February 13, 2004

  Date of Patent: June 2, 2009

  Assignees: Yale University, The United States of America as represented by the Department of Health and Human Services

  Inventors: Gil G. Mor, Donna Neale, Roberto Romero

FUNDED RESEARCH GRANTS and AWARDS

GRANT HISTORY

ACTIVE:

Agency: National Institutes of Health, NCI

ID#: 1R44CA287489

Title: Artificial Oncolytic virus delivering three immune modulators for ovarian cancer

PI: Gil Mor and Val Nakaar

Percent effort: 15%

Direct Cost per year: $ 1,000,000.00

Total Cost: $2,250,000

Period: 11/2023 – 02/2025

Agency: National Institutes of Health, NICHD

ID#: 1R01HD111146-01

Title: Impact of benzene-induced MIA on fetal T cell development

PI: Gil Mor

Percent effort: 30%

Direct Cost per year: $ 350,000.00

Total Cost: $2,250,000

Period: 03/2024 – 02/2026

Agency: National Institutes of Health, NIEDH

Project Number: 1 P42 ES030991-01A1

PI Project 4: Gil Mor, Impact of BTEX Chemical Exposure During Pregnancy to Maternal and Fetal Well-Being

Title: Center for Leadership in Environmental Awareness and Research

Name of PD/PI: MILLER, CAROL JEAN/ RUNGE-MORRIS, MELISSA A

Total Award Amount (including Indirect Costs): $ 13,175,442

Period: 10/2022 – 09/2027

Agency: National Institutes of Health, NIAID

ID#: 1R01AI145829-01

Title: Mechanisms of trophoblast-induced immune modulation

PI: Gil Mor

Percent effort: 30%

Direct Cost per year: $ **250,000.00**

Total Cost: $2,180,000

Period: 20019-2024

Agency: Burros Foundation

Title: Metabolic adaptation as mechanism for chemoresistance in ovarian cancer

PI: Gil Mor

Percent effort: 0%

Direct Cost per year: $ **125,163.00**

Total Cost: $**247,433.00**

Period: 20019-2024

Agency: National Institutes of Health, NICHD

ID#: R25HD072591

Title: Discovery to Cure Summer Program

Role Project: PI

Percent effort: 10%

Direct Cost per year: $93,493

Total Cost: $465,989

Period: 2018-2024

Agency: National Institutes of Health, NICHD

ID#: 5P30oCA022453-431

Title: Cancer Training and Education Coordination

Role Project: CI

Percent effort: 5%

Direct Cost per year: $59,333

Agency: National Institutes of Health, NIEHS

ID#: R01ES035692

Title: PFAS increases susceptibility to infection-mediated PTB

Role Project: CI

Percent effort: 5%

Direct Cost per year: $ $351,789

Total Cost per year : $533,723

PREVIOUS GRANTS

Agency: National Institutes of Health, NICHD

ID#: 1R01AI131613

Title: Role of Hofbauer Cells in Fetal Infection/Inflammation .

Role Project: Co-investigator

Percent effort: 10%

Direct Cost per year: $247,055

Total Cost: $2,180,000

Period: 2017-2022

Agency: National Institutes of Health, NICHD

ID#: RO1AI121183

Title: Mechanisms regulating fetal membrane and neutrophil responses to polymicrobial infection.

Role Project: Co-investigator

Percent effort: 10%

Direct Cost per year: $338,297

Total Cost: $2,180,000

Period: 2016-2021

Agency: National Institutes of Health, NCI

ID#: RCA199004A

Title: Targeting the vascularity for delivery of inhibitors of metastasis in ovarian cancer

PI: Gil Mor

Percent effort: 30%

Direct Cost per year: $ **636,016.00**

Total Cost: $3,180,000

Period: 20015-2020

Agency: National Institutes of Health, PRB, NICHD

ID#: NICHD. 3N01 HD23342

Title: Studies of infection During Pregnancy

PI: Gil Mor

Percent effort: 10%

Direct cost per year: $134,000

Total Cost: 224,508

Period: 20017-2018

Agency: The Cancer Data Initiative

Title: Maping chemoresistance

Project Role: PI

Direct Cost: $80,000

Period: 2018-2019

Agency: McKern Award

Title: Infection and pregnancy

Project Role: PI

Direct Cost: $200,000

Period: 2015-2017

Agency: CanTx

Title: New Therapies for cancer stem cells

Project Role: PI

Direct Cost: $1.5million

Period: 2014-2017

Agency: Sands Foundation

Title: New approaches for detection and treatment of ovarian cancer

P.I: Gil Mor

Direct Cost per year: $50,000

Total Cost: $ 500,000

Period: 2007-2018

Agency: National Institutes of Health, NCI

ID#: R01-CA127913

Title: MyD88 bearing tumors in immune regulation and chemoresitance

PI: Gil Mor

Percent effort: 30%

Direct Cost per year: $250,000

Total Cost: $2,068,021

Period: 2008-2014

Agency: National Institutes of Health, NCI

ID#: 1R56AI124356-01

Title: Effect of polymicrobial infection on trophoblast-macrophage interactions

PI: Gil Mor

Percent effort: 10%

Direct Cost per year: $ 241,317

Total Cost: $401,793

Period: 20015-2016

Agency: National Institutes of Health, NICHD

ID#: PO1 HD054713-01

Title: Function of TLRs throughout gestation

Role Project: Program Director/PI Project I

Percent effort: 30%

Direct Cost per year: $744,391

Total Cost: $6,593,337

Period: 2009-2015

Agency: National Institutes of Health, NCI

ID#: R01 CA-05-011

Title: CT of exercise on ovarian cancer prognosis

PI: Melinda Irwin

Role on Project: Co-investigator

Percent effort: 5%

Direct Cost per year: $99,986

Total Cost: $499,932

Period: 2009-2014

Agency: National Institutes of Health, PRB, NICHD

ID#: NICHD. 3N01 HD23342

Title: Studies of Toll-like Receptors and Trophoblast Apoptosis During Pregnancy

PI: Gil Mor

Percent effort: 10%

Direct cost per year: $165,000

Total Cost: $1,107,708

Period: 2005-2014

Agency: Janet Burros Foundation

Title: Characterization of the Human Ovarian cancer stem cells

PI: Gil Mor

Percent effort: 10%

Direct Cost per year: $150,000

Total Cost: $450,000

Period: 2008-2011

Agency: NCI, National Institutes of Health

ID#: R01 CA97237-01

Title: Apoptosis and Cancer

PI: Gil Mor

Percent effort: 20%

Direct Cost per year: $190,000

Total Cost: $1,571,380

Period: 2007-2012

Agency: BSF

ID#: 2009125

PIs. Gil Mor/Nava Dekel

Total Cost: $ 152,000

Direct Cost per year: $ 38,000

Agency: Merck

ID#: LKR58172

Title: Aurora inhibitors fro treatment of ovarian cancer

PI: Gil Mor

Percent effort: 0%

Direct Cost per year: $147,558

Total Cost: $147,558

Period: 2010-2011

Agency: National Institutes of Health, PRB, NICHD

ID#: NCI, AS0042

Title: Apoptosis and ovarian Cancer

PI. Gil Mor

Percent effort: 0%

Direct cost per year: $102,000

Total Cost: $168,810

Period: 2009-2011

Agency: National Institutes of Health. National Cancer Institute, EDRN

ID#: M127068

Title: Markers for Early detection of Ovarian Cancer

PI: Gil Mor

Percent effort: 5%

Direct Cost per year: $50,000

Total Cost: $150,000

Period: 2006-2008

Agency: National Institutes of Health. National Cancer Institute, EDRN

ID#: 1 U01CCA084986

Title: Multiplex Serum Biomarker For Ovarian Cancer

PI: Gil Mor

Percent effort: 10%

Direct Cost per year: $83,000

Total Cost: $ 267,000

Period: 2007-2009

Agency: Orthobiotech

Title: Effect of Doxil on MyD88 positive ovarian cancer tumors

PI: Gil Mor

Percentage Effort: 10%

Direct Cost per year: $ 50,000

Total Cost: $57,500

Period: 2007-2008

Agency: LabCorp of America

ID#: R06972

Title: Develop of New Tests for Early Detection

PI: Gil Mor

Percentage Effort: 15%

Direct Cost per year: $ 150,000

Total Cost: $450,000

Period: 2006-2009

Agency: Brady Foundation

ID#: 52111A

Title: New Treatments for Ovarian cancer.

PI: Gil Mor

Percentage effort: 0%

Total Cost: $2,000,000

Period: 2004-2009

Agency: Astra Zeneca

Title: Effect of AZD6244 in ovarian cancer cells

PI: Gil Mor

Percentage Effort: 0%

Direct Cost per year: $ 50,000

Total Cost: $57,500

Period: 2006-2007

Agency: National Institutes of Health. NCI

ID#: R01 CA92435-01

PI: Gil Mor

Title: Fas/FasL system in Normal Mammary gland Development

Effort: 70%.

Total Cost: 750,670

Total Cost per year: $200,000

Period: 07/01/2001-06/30/2005

Agency: National Institutes of Health. NICHD

ID#: RO1HD37137-01A2

Title: Immune Acceptance of pregnancy

PI: Dr. Gil. Mor

Effort: 30%. Total Cost: $636,670

Total Cost per year: $147,748

Period: 9/1/2000-8/31/2003

Agency: National Institutes of Health. NICHD

Title: Polymorphism in IL-10 Locus predispose to preterm birth

Role: Consultant

Effort: Consultant fee: $10,000

Total Cost: $255,986

Period: 2001-2006

Agency: Glaxo-Smith-Klein

Title: Preclinical study of Phenoxodiol in combination with Topotecan

PI: Gil Mor

Total Cost: $25,000

Period: 2005-2006

Agency: Marshall Edwards PTY Limited

ID#R06913

Title: Preclinical Studies For Nv128 As A Chemosensitizer

PI: Gil Mor

Direct Cost per year: $65,000

Total Cost: $89,925

Period: 2006-2007

Agency: Array Biopharma

Title: Effects of Kinase inhibitors in ovarian cancer

PI: Gil Mor

Direct Cost per year: $53,000

Total Cost: $60,000

Period 2006-2007

Agency: Jeff Mayersohn Foundation

Title: Ovarian Cancer: New Therapies for Ovarian Cancer.

PI: Gil Mor

Direct Cost per year: $440,000

Total Cost: $500,000

Period: 2004-2007

Agency: Marshall Edwards PTY Limited

Title: Characterization of the molecular mechanism of action of NV 143

PI: Gil Mor

Direct Cost per year: $195,000

Total Cost: $265,000

Period: 2004-2007

Agency: National Institutes of Health. NICHD

ID #: RO1HD049446-01

Title: Innate Immune Responses of Trophoblasts in Pregnancy

PI: Vikki M Abrahams

Role on project: Co-Investigator
Percentage Effort: 20%
Direct Cost per year: $168,000
Total Cost: $1,809,000
Period: 2005-2010

Agency: Fannie E. Rippel Foundation
Title: Use of a Novel siRNA Delivery System to Restore Chemosensitivity to Epithelial Ovarian Cancer Cells
PI: Yingqun Huang
Role in the Project: Co-investigator
Percentage Effort: 5%
Total Cost: $75,000
Period: 12/15/2005 – 12/14/2006

Agency: Marshall Edwards PTY Limited
Title: Phase I study of Neoadjuvant use of oral phenoxodiol in patients with primary diagnosis of squamous adenocarcinoma of the cervix, vagina or vulva
PI: Masoud Azodi
Role in the Project: Co-investigator
Percentage Effort: 10%
Total Cost: $600,000

Agency Marshall Edwards PTY Limited
Title: Multi-Center Phase Ib/II Study of Phenoxodiol in Patients with Recurrent Ovarian, Fallopian and Primary Peritoneal Cancer that is Resistant to Second Line Chemotherapy
Role: Co-Investigator
Total Cost: $960,000
Period: 11/2002-10/2004

Agency: Merck Research Grant

Title Regulation of apoptosis by Cox-2 inhibitors.
PI:
Total Cost: $65,000
Period: 2003-2004

Agency: The Ethel F. Donaghue Women's Health Investigator Program
Title: Trophoblast Viability: Can It Be Used As a Predictor of Preeclampsia?
PI: Donna Neale
Effort: Co-investigator 5%
Total Cost: $50,000
Period: 7/1/2003 - 6/30/2004

Agency: Department of Defense
ID#: BC972770
Title: "Macrophages, estrogen and the microenvironment in breast cancer"
PI: Frederick Naftolin
Effort: 75% Co-investigator
Total Cost: $210,000
Period: 04/01/1998-03/31/2001

Agency: Office of Research on Women's Health (ORWH)/NICHD
ID#: 1R55HD37137-01A1 "Immune Acceptance of Pregnancy"
P.I.: Dr. Gil. Mor
Effort: 40%
Total cost: $75,000
Period: 9/1/1999-8/31/2001

Agency: AVENTIS Research Grant
Title: Fas-mediated apoptosis in ovarian cancer cells.
PI: Gil Mor
Total Cost: $81,000

Period: 2001-2002

Agency: NOVOGEN Research Grant
Title: Phenoxodiol for the treatment of ovarian cancer
PI: Gil Mor
Total cost: $ 80,000
Period: 2002-2003

Agency: NOVOGEN Research Grant
Title: Characterization of the mechanism of action of NV compounds on immune and cancer cells.
PI: Gil Mor
Total Cost: $ 50,000
Period: 2001-2002

Agency: Johnson & Johnson
Title: Genestein and the immune system
PI: Gil Mor
Total Cost: $16,000
Period: 2000

Agency: Solvay Research Grant
Title: Effects of Methyltestosterone on aromatase activity of normal and breast cancer cells.
PI: Gil Mor
Total Cost: $89,000
Period: 2000-2002

Agency: Office of Research on Women's Health, National Institutes of Health
ID#: 1R55HD37137-01A1
Title: Immunology of pregnancy
PI: Gil Mor

Total Cost: $100,000

Period: 1999-2001

Agency: Eli Lilly Research Grant

Title: Raloxifene regulation of Fas Ligand expression on breast cancer

PI: Gil Mor

Total Cost: $50,000

Period: 1999

Agency: Hellman Fellowship Award

Title: Immunology of normal and pathologic Pregnancies

PI: Gil Mor

Total Cost $20,000

Period: 1999

PEER REVIEWED PUBLICATIONS

RCR: 737. Citations: 34,344. Google h-index 99. i10 Index: 266. World: Top 2%

1. Mor G, Saphier D, & Feldman S (1986) Inhibition by corticosterone of paraventricular nucleus multiple-unit activity responses to sensory stimuli in freely moving rats Experimental Neurology, 94(2), 391-399.

2. Mor G, Saphier D, & Feldman S (1987) Neural pathways that mediate the effects of afferent stimuli on paraventricular nucleus multiunit activity in freely moving rats. Journal of Neuroscience Research 17(4), 452-458.

3. Mor G Saphier D, & Feldman S (1986) Effects of Corticosterone (CS) upon paraventricular nucleus (PVN) multiunit activity (MUA) following neurogenic stimulation. Israel Journal of Medical Sciences: 22:, 503-503

4. Saphier D, Abramsky O, Mor G, & Ovadia H (1987) Multiunit electrical activity in conscious rats during an immune response. Brain Behavior and Immunity, 1(1), 40-51.

5. Saphier D, Abramsky O, Mor G, & Ovadia H (1987) A neurophysiological correlate of an immune response. Annals of the New York Academy of Sciences, 496(354), 354-9.

6. Saphier D, Mor G, & Feldman S (1988) Neurogenic stimuli alter preoptic area and amygdala unit activity: Central effects of olfactory projections on paraventricular nucleus units. Experimental Neurology, 100(1), 71-82.

7. Mor G (1988) Neural Responses to Neurogenic Stimuli: Effects of Lesions and Glucocorticoids. Thesis. Master of Sciences, The Hebrew University.

8. Ovadia H, Saphier D, Mor G, Maimon A, & Abramsky O (1991) Changes in brain during an immune response. Journal of Neuroimmunology, 17, 253-263.

9. Saphier D, Mor G, Ovadia H, Maimon A, & Abramsky O (1991) Absence of neural responses following suppression of the immune response. International Journal of Neuroscience, 56(1-4), 277-282.

10. Bernard G, Mor G, Amir-Zaltsman Y, & Kohen F (1992) Idiometric assay, anti-idiotypes and molecular mimicry. Communication Laboratory and Medicine, 3, 57-62.

11. Mor G, Amir-Zaltsman Y, Barnard G, & Kohen F (1992) Characterization of an antiidiotypic antibody mimicking the actions of estradiol and its interaction with estrogen receptor. Endocrinology, 130(6), 3633-40.

12. Amir-Zaltsman Y, Mor G, Globerson A, Thole H, & Kohen F (1993) Expression of Estrogen Receptors in Thymocytes. Endocrine, 1, 211-217.

13. Ben-Hur H, Mor G, Blickstein I, Likhman I, Kohen F, Dgani R, Insler V, Yaffe P, & Ornoy A (1993) Localization of estrogen receptors in vertebrae of human fetuses. Calcified Tissue International, 53, 91-96.

14. Mor G, Amir-Zaltsman Y, Barnard G, Ben-Hur H, & Kohen F (1993) Evidence for the expression of Estrogen Receptors in Monocytes. Endocrine, 1, 387-395.

15. Sömjen D, Mor G, Amir-Zaltsman Y, Jaccard N, Weizman Y, Kaye AM, Kohen F (1994) Cell specific stimulation of bone-cells by gonodal-steroids in-vivo and in-vitro. Calcified Tissue International, 54 (4), 342-346.

16. Ben-Hur H, Mor G, Blickstein I, Dgani R, Insler V, Amir-Zaltsman Y, & Kohen F (1995) Immunofluorescent assessement of estrogen receptor distribution in normal and pathological human endometrium. Acta Obstetricia et Gynecologica Scandinavica . 74: 97-102.

17. Ben-Hur H, Mor G, Insler V, Blickstein I, Amir-Zaltsman Y, Sharp A, Globerson A, & Kohen, F (1995) Menopause is associated with a significant decrease in the expression of estrogen receptors in human peripheral monocytes. American Journal of Reproductive Immunology. 34: 363-369.

18. Sömjen D, Amir-Zaltsman Y, Mor G, Jaccard N, Weizman Y, Barnard G, & Kohen F (1995) Anti-idiotipic antibody as an estrogen mimetic: Rremoval of the Fc fragment converts agonist to antagonist. Journal of Endocrinology. 145: 409-416.

19. Hagiwara E, Mor G, Abbasi F, Klinman D (1995) Phenotype and frequency of cells secreting IL-2, IL-4, IL-6, IL-10, INFg and TNFa in the peripheral Blood. Cytokines. 7: 815-822.

20. Mor G, Klinman D, Shapiro S, Hagiwara E, Sedegha M, Norman JA, Hoffman LS, Steinberg A (1995) Complexity of the cytokine and antibody response elicited by immunizing mice with PyCSP plasmid DNA. Journal of Immunology. 155: 2039-2046.

21. Mor G, Yamshchikov G, Sedegah M, Takeno M, Wang R, Hoffman S, Klinman DM (1996) Induction of Neonatal Tolerance by Plasmide DNA Vaccination. Journal of Clinical Investigation. 98 (12): 2700-2705.

22. Naftolin F, Mor G, Luquin S, Horvath TL, Kohen F, & Garcia-Segura L (1996) Synaptic remodeling in the arcuate nucleus during the estrous cycle is induced by estrogen and precedes the midcycle gonadotrophin surge. Endocrinology. 137: 5576-5580.

23. Sömjen D, Amir-Zaltsman Y, Mor G, Gayer B, Lichter S, Barnard G, & Kohen F (1996) Anti-idiotipic antibody as an estrogen mimetic in vivo: Stimulation of creatine -kinase specific activity in rat animal models. Journal of Endocrinology. 149: 305-312.

24. Ben-Hur H, Dgani R, Insler V, Lifschitz B, Blickstein I, Mor G, Kohen F, Shani A, Biran H (1996) Hyperestrogenemia and presence of estrogen receptors associated with epithelial ovarian tumor of low malignant potential. European Journal of Gynecological Oncology. 17(4): 260-263.

25. Mor G, Singla M, Steinberg AD, Hoffman L, Okuda K, Klinman DM (1997) Do DNA Vaccines Induce Systemic Autoimmunity? Human Gene Therapy. 8: 293-300.

26. Dayan M, Zinger H, Kalush F, Mor G, Amir-Zaltsman Y, Kohen F, Sthoeger Z, & Mozes E (1997) Tamoxifen and anti-estradiol antibody treatment have a beneficial effect on experimental Systemic Lupus Erythematosus and modulate cytokine secretion to normal levels. Immunology. 90: 101-108.

27. Sthoege RZ, Dayan M, Zinger H, Kalush F, Mor G, Amir-Zaltsman Y, Kohen F, Mozes E. (1997) Treatments with tamoxifen and an anti-estradiol antibody have beneficial effects on experimental SLE via cytokine modulation. Annals of the New York Academy of Science. 815: 367-368.

28. Sömjen D, Tordjman K, Weizman A, Mor G, Amir-Zaltsman Y, Kohen F, Kaye AM (1997) Estrogen stimulation of creatine kinase B specific activity in 3T3L1 adipocytes after their differentiation in culture: Dependence on estrogen receptor. Journal of Steroid Biochemistry and Molecular Biology. 62 (5): 401-408.

29. Klinman DM, Takeno M, Ichino M, Gu M, Yamshchikov G, Mor G, Conover J, (1997) DNA vaccines: safety and efficacy issues. Springier Seminars in Immunopathology. 19(2): 245-256.

30. Mor G, (1998) Plasmid DNA: A new era in vaccinology. Biochemical Pharmacology. 55:1151-1153.

31. Gutierrez L, Janzen A, Mor G, (1998) Fas Ligand expression in normal, hyperplastic and neoplastic prostate. Modern Pathology. 78 (1) 601.

32. Mor G, Gutierrez LS, Eliza M, Kahyaogili F, Arici A (1998) Induction of apoptosis mediated by the Fas-Fas ligand system in human placental trophoblast and gestational trophoblastic disease. American Journal of Reproductive Immunology: 40:89-94

33. Kohen F, Abel L, Sharp A, Amir-Zaltsman Y, Sömjen D, Luria S, Mor G, Thole H, Globerson A. (1998) Oestrogen receptor expression in thymocytes as function of age. Developmental Biology. 5: 277-285.

34. Sömjen D, Amir-Zaltsman Y, Mor G, Gayer B, Lichter S, Nevo N, & Kohen F (1998) A monoclonal antibody to oestradiol attenuates the stimulation of the specific activity of the brain type creatine kinase by estrogen in vivo and in vitro. Journal of Steroid Biochemistry and Molecular Biology. 64:297-304.

35. Bechmann I, Mor G, Nilson J, Eliza M, Nisch R, Naftolin F (1998) F. FasL (APO-1-L, CD95L) is expressed in the intact human and rat brain and forms an immunological brain barrier. European Journal of Neuroscience. 10 (Supp.) :61-61

36. Mor G, Yue W, Santen RJ, Gutierrez L, Eliza M, Bernstein L, Harada N, Wang J, Lysiak J, Diano S, Naftolin, F (1998) Macrophages, estrogen and the microenvironment of breast cancer. Journal of Steroid Biochemistry and Molecular Biology: 67: 403-411

37. Mor G, Naftolin F (1998) Estrogen Menopause and the Immune system. Journal of the British Menopause Society: 4 (1): 4-8

38. Nilsen J, Mor G, Naftolin F (1998) Raloxifene induces neurite outgrowth in estrogen receptor positive PC12 cells. Menopause: 5: 211-216

39. Diano S, Horvath T, Mor G, Register T, Adams M, Harada N, Naftolin F (1998) Aromatase and estrogen receptor immunoreactivity in the coronary arteries of monkeys and humans. Menopause: 6 (1) 21-28

40. Ichino M, Mor G, Conover J, Weiss WR, Takeno M, Ishii KJ, Klinman DM (1999) Factors associated with the development of neonatal tolerance after the administration of a plasmid DNA vaccine. Journal of Immunology. 162: 3814-3818

41. Gutierrez L, Eliza M, Niven-Fairchild T, Mor G. (1999) Fas/Fas-Ligand system induced apoptosis in human breast carcinoma: A mechanism for immune evasion. Breast Cancer Research and Treatment. 54 (3):245-253.

42. Garcia-Velascol J, Arici A, Naftolin F, Zreick T, Mor G (1999) Macrophage-derived growth factors regulate Fas Ligand expression in endometrial stromal cells. A role in endometriosis. Molecular Human Reproduction. 5:642-650.

43. Santen RJ, Yue W, Naftolin F, Mor G, Bernstein L, (1999) Potential role of aromatase overexertion in the genes of breast carcinoma. Endocrine Related Cancer 6:235-243.

44. Senturk LM, Seli E, Gutierrez LM, Mor G, Zeyneloglu HB, Arici A (1999) Monocyte Chemoattractant Protein-1 expression in human corpus luteum. Molecular Human Reproduction 5:697-702

45. Bechmann, I, Mor G, Nilsen J, Eliza M, Nitsch R, Naftolin, F (1999) FasL (CD95L) is expressed in normal rat and human brain and forms an Immunological Brain Barrier (IBB). Glia. 27:62-74

46. Mor G, Nilson, J, Horvath T, Bechmann I, Garcia-Segura LM, Naftolin F (1999) Estrogen and microglia: a regulatory system that affects the brain. Journal of Neurobiology. 40: 484-496

47. Ben-Hur H, Gurevich P, Berman V, Tendler Y, Huszar M, Tchanishev R, Hagay Z, Ben-Arie A, Mor G, Arie-Zaltsman Y, Kohen F, Zusman I (1999) Apoptosis and apoptosis related proteins (Fas, FasL, bcl-2, p53) in the epithelium of human ovarian tumors: Immunohistochemical and morphometric studies. European Journal of Obstetric Oncology: 20:249-253.

48. Mor G (1999) Menopause, estrogens and the immune system Boletin de la Sociedad Chilena de Climaterio 4:14-16

49. Silva I, Rodriguez MA, Mor G, Naftolin F. (2000) Alzheimer's Disease and Estrogens. Advances in obstetrics and Gynecology. 52:285-293

50. Aschkenaszi S and Mor G (2000) Sex hormones, the immune system and menopause. Menopause Management. 9(2):6-13

51. Mor G, Kohen F, Garcia Velasco J, Nilsen J, Brown W, Song J, Naftolin F (2000) Regulation of Fas Ligand expression in breast cancer cells by estrogen: Functional differences between estradiol and tamoxifen. Journal of Steroid Biochemistry and Molecular Biology 73:185-194

52. Ben-Hur H, Gurevich P, Huszar M, Berman V, Tendler Y, Zinder O, Tchanishev R, Gershon S, Ben-Arie A, Mor G, Zaltsman Y, Kohen F, Zusman I (2000) Apoptosis and apoptosis-related proteins in lymphoid elements of human ovarian tumors. European Journal of Gynecology and Oncology. 21(1):53-7.

53. Ben-Hur H, Gurevich P, Ben-Arie A, Huszar M, Berman V, Tendler Y, Tchanishev R, Mor G, Gershon S, Zusman I (2000) Apoptosis and apoptosis-related proteins (Fas, Fas ligand, bcl-2, p53) in macrophages of human ovarian epithelial tumors. European Journal of Gynecology and Oncology. 21(2):141-5.

54. Bechmann I, Lossau S, Steiner B, Mor G, Gimsa U, Nitsch R (2000) Reactive Astrocytes upregulate Fas (CD 95) and Fas Ligand (CD 95L) expression but do not undergo cell death in the course of anterograde degeneration. Glia. 32:25-41

55. Nilsen J, Mor G, Naftolin F (2000) Estrogen -regulated developmental neuronal apoptosis is determined by estrogen receptor subtype and the Fas/Fas ligand system. Journal of Neurobiology. 43: 64-78

56. Yue W, Mor G, Naftolin F, Pauley R, Shim WS, Harvey HA, Santen RJ (2000) Use of aromatase inhibitors in breast carcinoma. Endocrine Management of Breast Cancer

57. Jefcoate CR, Liehr JG, Santen RJ, Sutter TR, Yager JD, Yue W, Santner SJ, Tekmal R, Demers L, Pauley R, Naftolin F, Mor G, Berstein L (2000) Tissue-specific synthesis and oxidative. J Natl Cancer Inst Monogr. 27: 95-112.

58. Song J, Sapi E, Brown WD, Nilsen J, Naftolin F, Mor G (2000) Mammary Gland Remodeling: Expression and Role of the Fas/Fas Ligand System during Pregnancy, Lactation and Involution. Journal of Clinical Investigation. 106:1209-1224.

59. Rutherford T, Brown WD, Spai E, Aschkenazi S, Muñoz A, Mor G. (2000) Absence of estrogen receptor-beta expression in metastatic ovarian cancer. Obstet. Gynecol. 96(3):417-21

60. Song J, Sapi E, Brown W, Nilsen J, Tartaro K, Kacinski BM, Craft J, Naftolin F, Mor G. (2000) Roles of Fas and Fas ligand during mammary gland remodeling. J Clin Invest. 106(10):1209-20

61. Hsu CD, Basherram H, Lu LC, Meaddough E, Lee, IS, Harirah H, Mor G. (2001) Elevated serum ` Fas in preeclampsia. American Journal of Obstetrics and Gynecology. 97:530-532

62. Mor G, Aschkenazi S, Song J. (2001) Sex hormones, apoptosis and the fas/fas ligand system in normal endometrial tissue remodeling. ScientificWorldJournal. 1: 95-99

63. Silva I, Mor G, Naftolin F (2001) Estrogen and the aging brain. Maturitas: 38:95-101

64. Mor G, Muñoz A, Redlinger, Jr. R, Silva, I, Song J, and Kohen F (2001) The role of the Fas/Fas ligand system in the estrogen-induced thymic alteration American Journal of Reproductive Immunology. 46, (6): 4298-307

65. Mor G, Eliza M (2001) Plasmid DNA vaccines: immunology, tolerance and autoimmunity. Molecular Biotechnology. 19 (3): 245-251

66. Seli E, Belgin S, Mor G, Kayisili U, Pehlivan T, Arici A. (2001) Estradiol regulates MCP-1 in human coronary artery smooth muscle cells: a mechanism for its anti-atherogenic effect. Menopause. 8(4):296-301.

67. Song R, Mor G, McPherson RA, Song J, Zhang Z, Wang P, Santen RJ. (2001) Activation of Fas/FasL pathway linked estrogen-induced apoptosis in human breast cancer cells. Journal of the National Cancer Institute. 93:1714-1723

68. Mor G, Eliza M, Song J, Naftolin F (2001) Methyl-testosterone inhibits aromatase expression in Jar choriocarcinoma cell culture. Journal of Steroid Biochemistry and Molecular Biology 79: :239-246

69. Hsu CD, Harirah H, Basherra H, Mor G. (2001) Serum Soluble Fas levels in preeclampsia. Obstet Gynecol 97(4):503-2

70. Song RX, Mor G, Naftolin F, McPherson RA, Song J, Zhang Z, Yue W, Wang J, Santen RJ. (2001) Effect of longterm estrogen deprivation on apoptotic responses of breast cancer cells to 17beta-estradiol. J Natl Cancer Inst. 93(22):1714-23

71. Mor G, Eliza M, Song J, Wiita B, Chen S, Naftolin F. (2001) 17alpha-methyl testosterone is a competitive inhibitor of aromatase activity in Jar choriocarcinoma cells and macrophage-like THP-1 cells in culture. J Steroid Biochem Mol Bio; 79(1-5):239-46

72. Song J, Rutherford T, Brown S, and Mor G (2002) Hormonal regulation of Fas and FasL expression and apoptosis in the normal human endometrium: Molecular Human Reproduction: 8 (5):447-455

73. Aschkenazi S, Strazewski S, Verwer K, Foellmer H, Rutherford T, Mor G. (2002) Differential Regulation and Function of the Fas/Fas Ligand System in Human Trophoblast Cells. Biology of Reproduction: 66:1853-1861

74. Sapi E, Brown W, Aschkenazy S, Tartaro K, Lim C, Munoz A, Kacinski BM, Rutherford T, Mor G. (2002) Regulation of Fas Ligand expression by estrogen in normal ovary. Journal of the Society for Gynecologic Investigation. 9 (4): 243-250

75. Mor G, Straszewski S, Kamsteeg M (2002) The Fas/FasL System in Reproduction: Survival and Apoptosis: The ScientificWorld Journal. 2:1828-1842

76. Mor G, Straszewski S, Kamsteeg M (2002) The role of the Fas/Fas Ligand System in female reproductive organs: Survival and apoptosis. Biochemical Pharmacology: 64: 1305-1315

77. Bechman I, Steiner B, Gimsa U, Mor G, Beyer B, Zipp F, Nitsch R (2002) Astrocyte-induced T cells apoptosis is FasL dependent. Journal of Neuroimmunology. 132:60-65

78. Neale D, Demasio K, Illuzi J, Chaiworapongsa T, Romero R. and Mor G (2003) Induction of Sensitivity To Fas Mediated Apoptosis In Trophoblast Cells By Preeclamtic Sera. Journal of Maternal-Fetal Medicine. 13:39-44

79. Wang S, Pudney J, Song J, Mor G, Schwartz PE, Zheng W (2003) Mechanisms involved in the evolution of Progestin resistance in human endometrial hyperplasia-precursor of endometrial cancer. Gynecol ogic Oncol ogy: 88(2):108-17

80. Mor G, Song J, Sapi E, Abraham V, Hao XY, Amir-Zaltsman Y, Muzaffar S, Kohen F (2003) Interaction of The Estrogen Receptor With The Fas Ligand Promoter In Human Monocytes. Journal of Immunology: 170:114-122

81. Kamsteeg M, Rutherford T, Sapi E, Shahabi S, Brown D, and Mor G (2003) Phenoxodiol Induces Fas-Mediated Apoptosis Of Ovarian Cancer Cells. Oncogene: 22:2611-2620

82. Horvath TL, Diano S, Miyamoto S, Barry S, Gatti S, Alberati D, Livak F, Lombardi A, Moreno M, Goglia F, Mor G, Hamilton J, Kachinskas D, Horwitz B, Warden CH (2003) Uncoupling proteins-2 and 3 influence obesity and inflammation in transgenic mice. International Journal of Obesity 27(4):433-42

83. Chu MC, Mor G, Lim C, Parkash V, Schwartz PE (2003) Low grade endometrial stromal sarcoma: hormonal aspects. Gynecologic Oncology: 90:170-176

84. Abrahams V, Straszewski S, Kamsteeg M, Hanczaruk B, Schwartz PE, Rutherford TJ, Mor G (2003) Epithelial Ovarian Cancer Cells secrete Functional Fas Ligand. Cancer Research: 63(17):5573-5581

85. Wu B, Abbott T, Fishman D, McMurray W, Mor G, Stone K, Ward D, Williams K, Hongyu Z (2003) Comparison of Statistical Methods for Classification of Ovarian Cancer Using a Proteomics Dataset. Bioinformatics: 19(13): 1636-1643

86. Pal L, Kayisli UA, Ergur AR, Cohen H, Mor G, Palter S (2003) Comparison of efficacy of different cryoprotectant solutions for mouse ovarian tissue. Fertility and Sterility: 80(S3):145

87. Abrahams V, Kamsteeg M, Mor G (2003) The Fas/FasL system and cancer: Immune privilege and apoptosis. Molecular Biotechnology: 25(1): 19-30.

88. Neale D, Demasio K, Illuzi J, Chaiworapongsa T, Romero R, Mor G (2003) Maternal serum of women with pre-eclampsia reduces trophoblast cell viability: evidence for an increased sensitivity to Fas-mediated apoptosis. J Matern Fetal Neonatal Med.

89. Abrahams, VM, Kim YM, Straszewski S, Romero R, Mor G (2004) Macrophages and apoptotic cell clearance during pregnancy. American Journal of Reproductive Immunology: 51:275-282.

90. Straszewski SL, Abrahams VM and Mor G (2004) XIAP Confers Human Trophoblast Cell Resistance to Fas-Mediated Apoptosis. Molecular Human Reproduction. 10 (1): 33-41

91. Abrahams VM, Straszewski, SL, Mor G (2004) First Trimester Trophoblast Cells Secrete Whole Fas Ligand Which Induces Fas-Mediated Apoptosis In Immune Cells. Molecular Human Reproduction. 10 (1): 55-63

92. Flick M, O'Malley D, Rutherford T, Rodov S, Kamsteeg M, Hao XY, Schwartz P, Kacinski B, Mor G. (2004) Apoptosis-Based Evaluation of Chemosensitivity in Ovarian Cancer Patients. Journal of the Society for Gynecologic Investigation. 11/4: 252-259

93. Lareef MH, Tahin Q, Song J, Russo IH, Mihaila D, Slater CM, Balsara B, Testa JR, Broccoli D, Grobelny JV, Mor G, Cuthbert A, Russo J (2004) Chromosome 17 p13.2 transfer reverts transformation phenotypes and Fas mediated apoptosis in breast epithelial cells. Molecular Carcinogenesis: 39(4): 234-46.

94. Krikun G, Mor G, Alvaro A, Guller S, Schatz F, Sapi E, Rahman M, Caze R., Qumsiyeh M, Lockwood CJ (2004) A novel immortalized human endometrial stromal cell line with normal progestational response. Endocrinology: 145(5): 2291-6.

95. Collins Y, Tan DF, Pejovic T, Mor G, Qian F, Rutherford T, Varma R, McQuaid D, Driscol D, Jiang M, Deeb G, Lele S, Odunsi K (2004) Identification of differentially expressed genes in clinically distinct groups of serous ovarian carcinomas using cDNA microarrays. International Journal of Molecular Medicine. 14(1): 43-53.

96. Kim YM, Romero R Chaiworapongsa T, Kim GJ, Kim MR, Kuivaniemi SH, Tromp G, Abrahams VM and Mor G. (2004) Protein and mRNA expression for the pattern recognition receptors Toll-like receptor-2 and –4 are increased in spontaneous labor at term and histologic chorioamnionitis. American Journal of Obstetrics and Gynecology; 191(4):1346-55

97. Abrahams VM, Aldo P, Kim YM, Straszewski-Chavez S, Chaiworapongsa T, Romero R, Mor G. (2004) Divergent Trophoblast Responses To Bacterial Products Mediated By Toll-Like Receptors. Journal of Immunology: 173:4286-4296

98. Zhang JX, Labaree, DC, Mor, G., Hochberg, RB (2004) Estrogen to antiestrogen with a single methylene group resulting in an unusual steroidal selective estrogen receptor modulator. Journal of Clinical Endocrinology and Metabolism: 8 9(7):3527-35.

99. Sapi E, Chen W, O'Malley D, Ying X, Dwipoyono B, Kamsteeg M, Rutherford T, Mor G (2004). Resistance of Ovarian Cancer Cells to Taxotere (Docetaxel) is XIAP Dependent and Reversible by Phenoxodiol. Oncology Research. 14, (11-12) 567-578

100. Wang ZX, Koay DC, Edwards A, Lu Z, Mor G, Ocal IT, DiGiovanna M (2005) In Vitro and In Vivo Effects of Combination of Trastuzumab (Herceptin) and Tamoxifen in Breast Cancer. Breast Cancer Research and Treatment 92(3):251-263

103. Krikun G, Mor G, Huang J, Schatz F, Lockwood CJ (2005) Metalloproteinase expression by control and telomerase immortalized human endometrial endothelial cells. Histol Histopathol. 20(3):719-24

104. Mor G, Romero R, Aldo P, Abrahams VM (2005) Is the trophoblast an immune regulator? The role of TLRs during pregnancy. Critical Reviews of Immunology 25(5):375-8

105. Mor G, Visintin I, Lai Y, Zhao H, Schwartz P, Rutherford T, Yue L, Bray-Ward P, Ward DC (2005) Serum protein markers for early detection of ovarian cancer. Proc Natl Acad Aci USA: 102:7677-7682

106. Kim YM, Romero R, Oh S, Kim GJ, Kilburn BA, Armant DA, Nien JK, Gomez R, Mazor M, Saito S, Abrahams VM, and Mor G (2005) Toll-like Receptor 4: A potential link between "Danger signals", the innate immune system and preeclampsia? American Journal of Obstetrics and Gynecology; 193:921-7,

107. Krikun G, Mor G, Lockwood C (2005) The immortalization of human endometrial cells. Methods Molecular Medicine; 121:77-82

108. Abrahams VM, Visintin I, Aldo PB, Guller S, Romero R, Mor G. (2005) Toll Like Receptors and trophoblast cells in the regulation of immune cells migration. Journal of Immunology: 176:8096-8104

109. Neale DM, Mor G (2005) The role of Fas mediated apoptosis in preeclampsia. Journal of Perinatal Medicine. 2005 33:471-7.

110. Alvero A, O'Malley D, Brown D, Kelly G, Garg M, Chen W, Rutherford T, Mor G (2006) Molecular mechanisms of Phenoxodiol-induced Chemo-sensitivity in Refractory Ovarian Cancer. Cancer: 106(3):599-608.

111. Ma Y, Mor G, Abrahams VM, Buhimschi I, Buhimschi C, Guller S (2006) Alteration in syncytiotrophoblast cytokine expression following treatment with lipopolysaccharide. American Journal of Reproductive Immunology: 55(1): 12-8

112. Alvero AB, Chen C, Sartorelli AC, Schwartz P, Rutherford T. and Mor G (2006) Triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone) induces apoptosis in ovarian cancer cells. Journal of the Society for Gynecologic Investigation. 13(2):145-52.

113. Hills FA, Abrahams, VM, González-Timón B, Francis J, Cloke B, Hinkson L, Rai R, Mor G, Regan L, Sullivan M, Lam EW-F Brosens J J (2006) Heparin prevents programmed cell death in human trophoblast. Molecular Human Reproduction:,12:237-243.

114. Kelly M, Alvero AB, Chen R, Abrahams VM, Chan S, Visintin I, Rutherford T, and Mor G (2006) TLR-4 Signaling Promotes Tumor Growth And Paclitaxel Chemo-Resistance In Ovarian Cancer. Cancer Research. 66:3859-68

115. Mor G, Fu HA, Alvero A (2006) Phenoxodiol, a novel approach for the treatment of ovarian cancer. Current Opinion in Investigational Drugs: 7 (6): 542-548

116. Abrahams VM, Schaefer TM, Fahey JV, Visintin I, Wright JA, Aldo PB, Romero R, Wira CR, Mor G (2006) Expression and secretion of antiviral factors by trophoblast cells following stimulation by the TLR-3 agonist, Poly(I : C). (2006) Human Reproduction. 3 21(9):2432-9.

117. Kim, YM, Romero, R, Chaiworapongsa, T, Espinoza, J, Mor G, Kim C J, (2006) Dermatitis as a Component of the Fetal Inflammatory Response Syndrome is Associated with Activation of Toll-like Receptors in Epidermal Keratinocytes. Histopathology 49(5):506-14.

118. Mor G, Straszewski-Chavez SL, Abrahams VM. (2006) Macrophage-trophoblast Interactions. Methods Mol Med;122:149-63

119. Fest S, Aldo PB, Abrahams V, Visintin I, Alvero A, Chen R, Chavez S, Romero R and Mor G (2007) Trophoblast-macrophage interactions: a regulatory network for the protection of pregnancy. American Journal of Reproductive Immunology: 57(1):55-66.

120. Chen R, Ayesha AB, Silasi D-A, Mor G (2007) Inflammation, Cancer and Chemoresistance: Taking Advantage of the Toll-Like Receptor Signaling Pathway. American Journal of Reproductive Immunology. 57(2): 93-107

121. Kluger H, McCarthy M, Alvero A, Sznol M, Halaban R, Camp, RL, Rimm D, Mor G (2007) The X-linked inhibitor of apoptosis protein (XIAP) is up-regulated in metastatic melanoma and is associated with chemotherapy resistance Journal of Translational Medicine. 26;5(1):6

122. Agarwal R, Alvero A, Visintin I, Lai Y, Schwartz P, Rutherford, T, Ward D, and Mor G (2007) Macrophage Migration Inhibitory Factor expression in ovarian cancer. American Journal of Obstetrics and Gynecology 196(4):348.e1-5

123. Chavez, S, Visintin I, Karassina N, Los G, Liston P, Halaban P, Fadiel A, Mor G (2007) Xaf1 Mediates Tnf-Alpha-Induced Apoptosis And Xiap Cleavage By Acting Through The Mitochondrial Pathway. The Journal of Biological Chemistry. 282 (17): 13059-13072

124. Alvero A, Brown D, Montagna M, Matthews M, Mor G (2007) Phenoxodiol-Topotecan co-administration exhibit significant anti-tumor activity without major adverse side effects. Cancer Biology and Therapy: 6 (4): e1-e6

125. Silasi D-A, Illuzzi JL, Kelly M, Rutherford T, Mor G, Azodi, M, Schwartz, PE (2007) Carcinoma of the ovary. International Journal of Cancer: April 19 on line

126. Krikun G, Lockwood CJ, Abrahams VM, Mor G, Paidas M, Guller S (2007) Expression of Toll-like receptors in the human decidua. Histology and Histopathology 22(8):847-54.

127. Ma, YY, Krikun G, Abrahams VM, Mor G, Guller S (2007) Cell Type-Specific Expression and Function of Toll-Like Receptors 2 and 4 in Human Placenta. Placenta: 8: 1024-1031

128. Aldo P, Krikun G, Visintin I, Lockwood C, Romero R, Mor G (2007) A Novel Three-Dimensional In Vitro And In Vivo System To Study Trophoblast–Endothelium Cell Interactions. American Journal of Reproductive Immunology: 58(2): 98-110

129. Koga K and Mor G (2007) Toll-Like Receptors and Pregnancy. Reproductive Sciences 14: 297-301

130. Silasi D-A, Alvero A, Illuzi J, Kelly M, Chen R, Fu H, Schwartz P, Rutherford T, Azodi M, Mor G (2007) MyD88 predicts chemoresistance to paclitaxel in epithelial ovarian cancer. Yale Journal of Biology and Medicine 79(3-4): 153-63

131. Hudson ME, Pozdnyakova I, Haines K, Mor G, Snyder M (2007) Identification of differentially expressed proteins in ovarian cancer using high-density protein microarrays. Proc Natl Acad Sci U S A. Oct 22

132. Smith, S, Su D, Schwartz P, Rutherford T, Mor G, Puopolo M, Rigault de la Longrais IA, Yu H, Katsaros D (2007) ERCC1 SNP at codon 118 and mRNA expression in relation to ovarian cancer survival among patients treated with platinum-based chemotherapy with or without Taxol. Journal of Clinical Oncology: 20; 25(33): 5172-9.

133. Wu B, Abbott T, Fishman D, McMurray W, Mor G, Stone K, Ward D, Williams K, Zhao H. (2007). Ovarian Cancer Classification based on Mass on Spectrometry Analysis of Sera. Cancer Inform;17;2:123-32

134. Fest S, Brachwitz N, Schumacher A, Zenclussen ML, Khan F, Wafula PO, Casalis PA, Fill S, Costa SD, Mor G, Volk HD, Lodel HN, Zenclussen AC (2008) Supporting the hypothesis of pregnancy as a tumor: survivin is upregulated in normal pregnant mice and participates in human trophoblast proliferation. American Journal of Reproductive Immunology 59: 75-83

135. Silasi D-A, Steffensen KD, Mor G (2008) Cancer take their Toll: The function and regulation of Toll Like Receptors in cancer cells. Oncogene: 7; 27(2):225-33

136. Zhang K, Wang Q, Xie Y, Mor G, Sega E, Low PS, Huang Y (2008) Receptor-mediated delivery of siRNAs by tethered nucleic acid base-paired interactions. Journal of RNA. 14(3): 577-83

137. Visintin I, Alvero A, Lai Y, Tenthorey J, Leiser A, Flores R, Rutherford T, Schwartz P, Ward D, Mor G, (2008) Diagnostic Markers for Early Detection of Ovarian Cancer, Clinical Cancer Research. 14(4):1065-72

138. Guller S, Ma YY, Fu H, Krikun G, Abrahams VM, Mor G (2008) The placental syncytium and the pathophysiology of preeclampsia and Intrauterine growth restriction: a novel assay to assess syncytial protein expression. New York Academy of Science: 1127:129-133

139. Mor G. (2008) Inflammation and Pregnancy: The role of TLRs in Trophoblast immune interaction. New York Academy of Science: 1127:121-128

140. Chen R, Alvero A, Silasi, D-A, Kelly M, Fest, S, Leiser A, Schwartz P, Rutherford T, Visintin I, Mor G (2008) Regulation of IKKβ by mir-199 affects NF-κB activity in ovarian cancer cells. Oncogene: Apr 14:1-12

141. Abrahams VM, Aldo P, Murphy SP, Visintin I, Romero R, Sharma S, Mor G (2008) Tlr6 protects trophoblast cells from TLR2/TLR1 mediated apoptosis. Journal of Immunology: 180:6035-6043

142. Koga K and Mor G. (2008). Expression and Function of TLR at the maternal fetal interface. Reproductive Science: 15(3): 231-42.

143. Mor G and Koga K (2008) Macrophages and Pregnancy Reproductive Science: 15(3): 435-436

144. Alvero AB, Kelly M, Rossi P, Leiser A, Brown D, Rutherford T, Mor G (2008). Anti-tumor activity of phenoxodiol: from bench to clinic. Future Oncology. Aug;4(4):475-82.

145. Mor G, Schwartz PE, Yu H. (2008) In Response. Clinical Cancer Research. Oct 23.

146. Lui H, Wang J, Mor G, and Sklar J (2008) A Neoplastic Gene Fusion Mimics Trans-Splicing of RNAs in Normal Human Cells. Science : 321: 1357-1361

147. Plaks V, Birnberg, T, Berkutzki, T, Kalchenko, V, Mor G, Dekel N, Neeman M, and Jung S (2008) Uterine Dendritic cells are crucial for Decidua Formation during Embryo Implantation. Journal of Clinical Investigation. 118 (2): 3954-65

148. Abrahams VM, Aldo PB, Murphy SP, Visintin I, Koga K, Wilson G, Romero R, Sharma S, Mor G. (2008).TLR6 modulates first trimester trophoblast responses to peptidoglycan. Journal of Immunology. 180(9):6035-43.

149. Alvero AB, Montagna MK, Mor G. (2008)Correlation of caspase activity and in vitro chemo-response in en epithelial ovarian cancer cell lines. Methods Mol Biol;414:79-82.

150. Silasi D-A, Alvero AB, Mor J, Chen R, Fu HH, Montagna MK, Mor G. (2008) Detection of cancer- related proteins in fresh-frozen ovarian samples using laser capture microdissection. Methods Mol Biol.414:35-45. Review.

151. Mor G, Montagna MK, Alvero AB. Modulation of apoptosis to reserve chemoresistance. (2008) Modulation of apoptosis to reserve cheoresistance. Methods Mol Biol.;414:1-12. Review

152. Fraccaroli L, Alfieri J, Larocca L, Calafat M, Mor G, Pérez Leirós C, Ramhorst, R. (2009) A potential tolerogenic immune mechanism by trophoblastic through the activation of chemokine-induced t cell death and t -regulatory cells modulation. Human Reproduction: 24(1):166-75

153. Koga K, Cardenas I, Aldo, P, Abrahams, V, Peng, B, Fill S, Romero, R, Mor G (2009) Activation of TLR3 in the trophoblast is associated with preterm labor. American Journal of Reproductive Immunology: 61(3):196-212

154. Alvero A, Chen R, Fu H, Montagna M, Schwartz PE, Rutherford T, Silasi D-A, Steffensen KD, Waldstrom M, Visintin I, and Mor G (2009) Molecular phenotyping of human ovarian cancer stem cells unravel the mechanisms for repair and chemo-resistance. Cell Cycle: 8: 158-166

155. Kim, K., Visintin I, Aver AB, Mor G (2009) Development and validation of a proteinbased signature for the detection of ovarian cancer. Clinical Laboratory Medicine:29: 47-55

156. Silasi D-A, Alvero AB, Rutherford TJ, Brown D, Mor G. (2009) Phenoxodiol: pharmacology and clinical experience in cancer monotherapy and in combination with chemotherapeutic drugs. Expert Opinion of Pharmacotherapy. 10(6): 1059-67.

157. Koga K, Aldo PB, Mor G. (2009) Toll-like receptors and pregnancy: Trophoblast as modulators of the immune response. Journal of Obstetrics and Gynaecolologic Research. 35(2):191-202.

158. Alvero AB, Montagna MK, Chen R, Kim KH, Kyungjin K, Visintin I, Fu HH, Brown D, Mor G. (2009) NV-128, a novel isoflavone derivative, induces caspase-independent cell death through the Akt/mammalian target of rapamycin pathway Cancer Jul 15;115(14):3204-16. PMID:19472408 (PubMed – indexed for MEDLINE)

159. Kim KH, XieY, Tytler EM, Woessner R, Mor G, and Alvero AM (2009) KSP inhibitor ARRY-520 as a substitute for Paclitaxel in Type I ovarian cancer cells. Journal of Translational Med: Jul 20;7:63

160. Levina VV, Nolen B, Su Y, Godwin AK, Fishman D, Liu J, Mor G, Maxwell LG, Herberman RB, Szczepanski MJ, Szajnik ME, Gorelik E, Lokshin AE. (2009) Biological significance of prolactin in gynecologic cancers. Cancer Research. 15; 69(12):5226-33.

161. Guo JP, Shu SK, He L, Lee YC, Kruk PA, Grenman S, Nicosia SV, Mor G, Schell MJ, Coppola D, Cheng JQ. (2009) Deregulation of IKBKE Is Associated with Tumor Progression, Poor Prognosis, and Cisplatin Resistance in Ovarian Cancer. American Journal of Pathology. 175(1):324-33.

162. Alvero AB, Fu HH, Holmberg J, Visintin I, Mor L, Marquina CC, Oidtman J, Silasi DA, Mor G. 2009 Stem-Like Ovarian Cancer Cells can serve as tumor vascular progenitors, Stem Cell: 27:2405-2413.

163. Trinh QD, Izumi Y, Komine-Aizawa S, Shibata T, Shimotai Y, Kuroda K, Mizuguchi M, Ushijima H, Mor G, Hayakawa S (2009). H3N2 influenza A virus replicates in immortalized human first trimester trophoblast cell lines and induces their rapid apoptosis. American Journal of Reproductive Immunology.; 62(3): 139-46.

164. Straszewski-Chavez, SL, Abrahams, VM, Aldo, PB, Ma, Y., Guller, S., Romero, R., and Mor, G. (2009) The Isolation and Characterization of a Novel Telomerase Immortalized First Trimester Trophoblast Cell Line, Swan 71. Placenta 30(11):939-48.

165. Green JM, Alvero AB, Kohen F, Mor G. (2009) 7-(O)-Carboxymethyl daidzein conjugated to N-t-Boc-hexylenediamine: A novel compound capable of inducing cell death in epithelial ovarian cancer stem cells. Cancer Biology and Therapy. 7;8(18).

166. Straszewski-Chavez SL, Abrahams VM, Aldo PB, Romero R, Mor G, (2009). AKT Controls Human First Trimester Trophoblast Cell Sensitivity to FAS-Mediated Apoptosis by Regulating XIAP Expression. Biology of Reproduction.

167. Dekel N, Gnainsky Y, Granot I, Mor G (2010). Inflammation and implantation. Am J Reproductive Immunology. ; 63(1): 17-21.

168. Xie F, Turvey SE, Williams MA, Mor G, von Dadelszen P. (2010) Toll like receptor signaling and pre-eclampsia. American Journal of Reproductive Immunology. 63(1): 7-16.

169. Atay S, Gercel-Taylor C, Suttles J, Mor G, Taylor DD, (2010). Trophoblast-Derived Exosomes Mediate Monocyte Recruitment and Differentiation, American Journal of Reproductive Immunology.; PMID: 20560914.

170. Cardenas I, Mor G, Aldo P, Lang SM, Stabach P, Sharp A, Romero R, Mazaki-Tovi, S, Gervasi MT, Means RE, (2010) Placental Viral Infection Sensitizes to LPS-Induced Pre-Term Labor: The Double Hit Hypothesis, American Journal of Reproductive Immunology.

171. Aldo PB, Mulla MJ, Romero R, Mor G, Abrahams VM, (2010) Viral ssRNA induces first trimester trophoblast apoptosis through an inflammatory mechanism, American Journal of Reproductive Immunology. 64 (1):27-37 Epub PMID: 20175771

172. Sharp AN, Heazell AE, Crocker IP, Mor G, (2010) Placental Apoptosis in Health and Disease, American Journal of Reproductive Immunology. PMID: 20367628.

173. Gnainsky Y, Granot I, Aldo PB, Barash A, Or Y, Schechtman E, Mor G, Dekel N., (2010) Local injury of the endometrium induces an inflammatory response that promotes successful implantation, Fertility& Sterility, PMID: 20338560.

174. Aiyar SE, Park H, Aldo PB, Mor G, Gildea JJ, Miller AL, Thompson EB, Castle JD, Kim S, Santen RJ, (2010) TMS, A chemically modified herbal derivative of Resveratrol, induces cell death by targeting Bax, Breast Cancer Research and Treatment. Nov;124(1):265-77. Epub May 20. PMID: 20490654.

175. Yin G, Chen R, Alvero AB, Fu HH, Holmberg J, Glackin C, Rutherford T, Mor G, (2010) TWISTing Stemness, inflammation and proliferation of epithelial ovarian cancer cells through MIR199A2/214, Oncogene. 29(24): 3545-53. PMID: 20400975.

176. Koga K, Mor G, (2010) Toll-Like receptors at the maternal-fetal interface in normal pregnancy and pregnancy disorders, American Journal of Reproductive Immunology.;63(6):587-600. PMID 20367625.

177. Cardenas I, Means RE, Aldo PB, Koga K, Lang SM, Booth C, Manzur A, Oyarzun E, Romero R, Mor G, (2010) Viral infection of the placenta leads to fetal inflammation and sensitization to bacterial products predisposing to preterm labor. Journal of Immunology;185(2):1248-57. PMID: 20554966.

178. Mor G, Cardenas I, (2010) The immune system in pregnancy: a unique complexity, American Journal of Reproductive Immunology.;63(6):425-33. PMID: 20367629.

179. Peng B, Koga K, Cardenas I, Aldo P, Mor G (2010) Phagocytosis of apoptotic trophoblast cells by human endometrial endothelial cells induces proinflammatory cytokine production. American Journal of Reproductive Immunology.;64(1):12-9.

180. Cocco E, Casagrande F, Bellone S, Richter CE, Bellone M, Todeschini P, Holmberg JC, Fu HH, Montagna MK, Mor G, Schwartz PE, Silasi D-A, Azodi M, Rutherford TJ, Abu-Khalaf M, Pecorelli S, Santin AD (2010) Clostridium perfringens enterotoxin carboxy-terminal fragment is a novel tumor-homing peptide for human ovarian cancer. BMC Cancer Jul 2;10:349

181. Cardenas I, Mor G, Aldo P, Lang SM, Stabach P, Sharp A, Romero R, Mazaki-Tovi S, Gervasi M, Means RE (2011) Placental Viral Infection Sensitizes to Endotoxin-Induced Pre-Term Labor: A Double Hit Hypothesis. American Journal of Reproductive Immunology. Feb;65(2):110-7

182. Leizer AL, Alvero AB, Fu HH, Holmberg JC, Cheng YC, Silasi DA, Rutherford T, Mor G (2011) Regulation of Inflammation by the NF-κB Pathway in Ovarian Cancer Stem Cells. American Journal of Reproductive Immunology. Apr; 65(4):438-47

183. Toti P, Arcuri F, Tang Z, Schatz F, Zambrano E, Mor G, Niven-Fairchild T, Abrahams VM, Krikun G, Lockwood CJ, Guller S. (2011) Focal Increases of Fetal Macrophages in Placentas from Pregnancies with Histological Chorioamnionitis: Potential Role of Fibroblast Monocyte Chemotactic Protein-1. American Journal of Reproductive Immunology. May;65(5)470-9 Epub. Nov 19. PMID: 21087336 (PubMed – indexed for MEDLINE)

184. Kelly MG, Mor G, Husband A, O'Malley DM, Baker L, Azodi M, Schwartz PE, Rutherford TJ (2011) Phase II Evaluation of Phenoxodiol in Combination With Cisplatin or Paclitaxel in Women With Platinum/Taxane-refractory/Resistant Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancers. Int J Gynecol Cancer, Mar 15 ;21(4):633-9.

185. Tang Z, Abrahams VM, Mor G, Guller S (2011) Placental Hofbauer cells and complications of pregnancy. Ann. NY Acad Sci. Mar; 1221:103-8.

186. Mor G, Cardenas I, Abrahams V, Guller S (2011) Inflammation and Pregnancy: the role of the immune system at the implantation site. Ann NY Acad Sci. Mar; 1221:80-7.

187. Mor G, Yin G, Chefetz I, Yang Y, Alvero A (2011) Ovarian Cancer Stem Cells and Inflammation. Cancer Biology Theraphy. April 15; 11(8):708-13. Epub 2011 Apr 15.

188. Mor GG, (2011) A Message from the Editor. The Role of Mucosal Immunity in the Male and Female Reproductive Tract During HIV Infection. American Journal of Reproductive Immunology. Mar;65(3):181

189. Hanlon DJ, Aldo PB, Devine L, Alvero AB, Engberg AK, Edelson R, Mor G (2011) Enhanced stimulation of anti-ovarian cancer CD8(+) T cells by dendritic cells loaded with nanoparticle encapsulated tumor antigen. American Journal of Reproductive Immunology. Jun;65(6):597-609

190. Chefetz I, Holmberg JC, Alvero AB, Visintin I, Mor G. (2011) Inhibition of Aurora A kinase induces cell cycle arrest in epithelial ovarian cancer stem cells by affecting NF-□B activity. Cell Cycle: July 1;10: (13):2206-14. Epub 2011 July 1

191. Wang X, McKernan R, Kim KH, Alvero AB, Whiting A, Thompson JA, Mor G, Saif MW, Husband AJ, Brown DM, Tytler EM. (2011) Triphendiol (NV196), development of a novel therapy for pancreatic cancer. Anticancer Drugs: on line

192. Zhu CS, Pinsky PF, Cramer DW, Ransohoff DF, Hartge P, Pfeiffer RM, Urban N, Mor G, Bast RC Jr, Moore LE, Lokshin AE, McIntosh MW, Skates SJ, Vitonis A, Zhang Z, Ward DC, Symanowski JT, Lomakin A, Fung ET, Sluss PM, Scholler N, Lu KH, Marrangoni AM, Patriotis C, Srivastava S, Buys SS, Berg CD; PLCO Project Team. (2011) A framework for evaluating biomarkers for early detection: validation of biomarkers panels for ovarian cancer. Cancer Prevention Research: 4(3):375-383

193. Cramer DW, Bast RC Jr, Berg CD, Diamandis EP, Godwin AK, Hartge P, Lokshin AE, Lu KH, McIntosh MW, Mor G, Patriotis C, Pinsky PF, Thornquist MD, Scholler N, Skates SJ, Sluss PM, Srivastava S, Ward DC, Zhang Z, Zhu CS, Urban N. (2011) Ovarian cancer performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens. Cancer Prevention Research: 4(3):365-374

194. Steffensen KD, Alvero AB, Yang Y, Waldstrom M, Hui P, Holmberg JC, Silasi DA, Jakobsen A, Rutherford T, Mor G (2011) Prevalence of epithelial ovarian cancer stem cells correlates with recurrence in early-stage ovarian cancer. Journal of Oncology. 2011:620523 Epub 2011 Aug 29.

195. Ramhorst R, Fraccaroli L, Aldo P, Alvero AB, Cardenas I, Leiros CP, Mor G (2011) Modulation and Recruitment of Inducible Regulatory T Cells by First Trimester Trophoblast Cells. American Journal of Reproductive Immunology. Aug 7, PMID: 21819477

196. Merk M, Zierow S, Leng L, Das R, Du X, Schulte W, Fan J, Lue H, Chen Y, Xiong H, Chagnon F, Bernhagen J, Lolis E, Mor G, Lesur O, Bucala R (2011) The D-dopachrome tautomerase (DDT) gene product is a cytokine and functional homolog of macrophage migration inhibitory factor (MIF). Proc Natl Acad Sci USA Aug 23;108(34):E577-85. Epub 2011 Aug 4. PMID: 21817065 (PubMed – in process)

197. Alvero AB, Montagna MK, HolmbergJC, Craveiro V, Brown D, Mor G (2011) Targeting the mitochondria activates two independent cell death pathways in ovarian cancer stem cells. Molecular Cancer Theraphy. Aug;10(8):1385-93. Epub 2011 June 15.

198. Mor GG (2011) From the Editor: Is immune contraception in the future? American Journal of Reproductive Immunology. Jul;66(1):1 PMID: 21645163 (PubMed – in process)

199. Leizer AL, Alvero AB, Fu HH, Holmberg JC, Cheng YC, Silasi DA, Rutherford T, Mor G (2011) Regulation of inflammation by the NF-kB pathway in ovarian cancer stem cells. Am J Reprod Immunol. Apr;65(4):438-47 Epub 2010 Sept 6. PMID: 20825380 (PubMed – indexed for MEDLINE)

200. Alvero A, Montagna M, Craveiro V, Liu L, Mor G (2012) Distinct subpopulations of ovarian cancer cells can differentially induce macrophages and T Regulatory cells toward a pro-tumor phenotype. American Journal of Reproductive Immunology. Sept 14 67(3):256-265

201. Atay S, Gercel-Taylor C, Suttles J, Mor G, Taylor DD (2011) Trophoblast-derived exosomes mediate monocyte recruitment and differentiation. American Journal of Reproductive Immunology. Jan;65(1):65-7. PMID 20560914

202. Pizzonia J, Holmberg J, Orton S, Alvero A, Viteri O, McLaughlin W, Feke G, Mor G (2012) Multimodality Animal Rotation Imaging System (MARS) for In Vivo Detection of Intraperitoneal Tumors. American Journal of Reproductive Immunology. 67 (1) 84-89 PMID: 21951577

203. Wang B, Koga K, Osuga Y, Cardenas I, Izumi G, Takamura M, Hirata T, Yoshino O, Hirota Y, Harada M, Mor G, Taketani Y (2011) Toll-Like Receptor-3 Ligation-Induced Indoleamine 2, 3-Dioxygenase Expression in Human Trophoblasts. Endocrinology Sept 27 (Epub ahead of print) PMID: 21952237

204. Holmberg JC, Haddad S, Wunsche V, Yang Y, Aldo PB, Gnainsky Y, Granot I, Dekel N, **Mor G**. (2012) An in vitro model for the study of human implantation (2012) American Journal of Reproductive Immunology. 67 (2):168-78 PMID: 22151560

205. Yin G, Alvero AB, Craveiro, V, Holmberg JC, Fu HH, Montagna MK, Yang Y, Chefetz I, Nuti, S, Rossi M, Silasi DA, Rutherford T, and Mor G. (2012) Constitutive Proteasomal Degradation of TWIST-1 in Epithelial Ovarian Cancer Stem Cells Impacts Differentiation and Metastatic Oncogen: 32(1):39-49. PMID: 22349827

206. Gervasi MT, Romero R, Bracalente G, Chaiworapongsa T, Erez O, Dong Z, Hassan SS, Yeo L, Yoon BH, **Mor G**, Barzon L, Franchin E, Militello V, Palù G. (2012) Viral invasion of the amniotic cavity (VIAC) in the midtrimester of pregnancy. J Matern Fetal Neonatal Med. 2012 Apr 23. PMID: 22524157

207. Silasi M, **Mor G**. (2012) Decidual stromal cells as regulators of T-cell access to the maternal-fetal interface. American Journal of Reproductive Immunology (Epub ahead of print). PMID: 22935072

208. Liu, M, **Mor G**, Cheng H, Xiang H, Hui P, Rutherford T, Yin G, Rimm DL, Holm berg J, Alvero A, Silasi DA (2012) High Frequency of Putative Ovarian Cancer Stem Cells With CD44/CK19 Coexpression Is Associated With Decreased Progression-Free Intervals in Patients With Recurrent Epithelial Ovarian Cancer. Reprod Sci. 2012 Nov 20. PMID: 23171677

209. Chefetz I, Alvero, AB, Holmberg JC, Lebowitz N, Craveiro V, Yang-Hartwich, Y, Yin G, Squillace L, Gurrea Soteras M, Aldo P, **Mor G**. (2013) TLR2 enhances ovarian cancer stem cell self-renewal and promotes tumor repair and recurrence. Cell Cycle 2013 Jan 16;12(3). PMID: 23324344

210. **Mor G**, Alvero A. (2013) The Duplicitous Origin of Ovarian Cancer. Rambam Maimonides Medical Journal. 30;4(1):e0006. doi: PMID: 23908856

211. Racicot KE, Wünsche V, Auerbach B, Aldo P, Silasi M, **Mor** G. (2013) Human Chorionic Gonadotropin Enhances Trophoblast-Epithelial Interaction in an In Vitro Model of Human Implantation. Reproductive Science. 2014 Feb 11. PMID:24520082

212. Craveiro V, Yang-Hartwich Y, Holmberg JC, Sumi NJ, Pizzonia J, Griffin B, Gill SK, Silasi DA, Azodi M, Rutherford T, Alvero AB, **Mor** G (2014) Phenotypic modifications in ovarian cancer stem cells following Paclitaxel treatment. Cancer Medicine. 2(6):751-62.

213. Joo, WD, Visintin I, **Mor G** (2013) Targeted cancer therapy- are the days of systemic chemotherapy numbered? Maturitas. 2013 Dec; 76(4):308-14. PMID: 24128673

214. Racicot K, Cardenas I, Wünsche V, Aldo P, Guller S, Means RE, Romero R, **Mor G** (2013) Viral infection of the pregnant cervix predisposes to ascending bacterial infection. Journal of Immunology. 2013 Jul 15;191(2):934-41. PMID: 23752614

215. Mor G (2013) The American Journal of Reproductive Immunology: last printed issue. American Journal of Reproductive Immunology. 2013 Decl70(6):430-3.

216. Grasso E, Paparini D, Aguero M, **Mor G**, Pérez Leirós C, Ramhorst R. (2014) VIP contribution to the decidualization program: regulatory T cells recruitment. Journal of Endocrinology: PMID:24492467

217. Yoshinaga K, PrabhuDas M, Davies C, White K, Caron K, Golos T, Fazleabas A, Paria B, **Mor G**, Paul S, Ye X, Dey SK, Spencer T, Roberts RM (2014) Interdisciplinary collaborative team for blastocyst implantation research: inception and perspectives. American Journal of Reproductive Immunology 71(1):1-11. Doi: 10.1111/ajr.12173.

218. Kwon JY, Romero R, **Mor G** (2014) New Insights into the Relationship between Viral Infection and Pregnancy Complications American Journal of Reproductive Immunology. 2014 May;71(5):387-90. doi: 10.1111/aji.12243. Epub 2014 Apr 7. PMID: 24702790 [PubMed – in process]

219. Koga K, Izumi G, **Mor G**, Fujii T, Osuga Y (2014) Toll-like Receptors at the Maternal-Fetal Interface in Normal Pregnancy and Pregnancy Complications. Am J Reprod Immunol: On Line 2014 Aug;72(2):192-205. doi: 10.1111/aji.12258. Epub 2014 Apr 23. PMID:24754320 [PubMed – in process]

220. Cohen-Fredarow A, Tadmor A, Raz T, Meterani N, Addadi Y, Nevo N, Solomonov I, Sagi I, **Mor G**, Neeman M, Dekel N. (2014) Ovarian Dendritic Cells Act as a Double-Edged Pro-Ovulatory and Anti-Inflammatory Sword. Molecular Endocrinology. 2014 Jul;28(7):1039-54. doi: 10.1210/me.2013-1400. Epub 2014 May 13. PMID: 24825398 [PubMed – in process]

221. Dekel N, Gnainsky Y, Granot I, Racicot K, **Mor G**. (2014) The Role of Inflammation for a Successful Implantation American Journal of Reproductive Immunology. On line. 2014 Aug;72(2):141-7. doi: 10.1111/aji.12266. Epub 2014 May 9. PMID: 24809430 [PubMed – in process]

222. Aldo PB, Racicot K, Craviero V, Guller S, Romero R, **Mor G** (2014) Trophoblast Induces Monocyte Differentiation Into CD14+/CD16+ Macrophages. American Journal of Reproductive Immunology. 2014 Sep;72(3):270-84. Doi: 10.1111/aji.12288. Epub 2014 Jul 3. PMID: 24995492 [PubMed – in process]

223. Racicot K, Kwon JY, Aldo P, Silasi M, **Mor G** (2014) Understanding the Complexity of the Immune System during Pregnancy. American Journal of Reproductive Immunology. 2014 Aug;72(2):107-16. doi: 10.1111/aji.12289. Epub 2014 Jul 4. PMID: 24995526 [PubMed – in process]

224. Arroyo J, Price M, Straszewski-Chavez S, Torry RJ, **Mor G,** Torry DS. (2014) XIAP protein is induced by placenta grow factor (PLGF) and decreased during preeclampsia in trophoblast cells. Syst Biol Reprod Med. 2014, Oct;60(5):263-73. Doi 10.3109/19396368.2014.927540. Epub 2014 Jul 9. PMID: 25003840 [PubMed – in process]

225. Yang-Hartwich Y, Gurrea-Soteras M, Sumi N, Joo WD., Holmberg JC, Craveiro V, Alvero AB, **Mor G** (2014) Ovulation and extra-ovarian origin of ovarian cancer. Nature Scientific Reports: On Line. Sci Reo, 2014 Aug 19;4:6116. doi: 10.1038/srep06116. PMID: 25135607

226. Gnainsky Y, Granot I, Aldo P, Barasch A, Or Y, **Mor G**, Dekel N (2014) Biopsy-induced inflammatory conditions improve endometrial receptivity: the mechanism of action. Reproduction. 2014 Oct 27. pii: REP-14-0395. PMID: 25349438

227. Yang-Hartwich Y, Romanoff E, Bingham J, Alvero AB, **Mor G**. Detection of p53 Protein Transcriptional Activity by Chromatin Immunoprecipation. Methods Mol Biol. 2015; 1219:87-93. doi: 10.1007/978-1-4939-1661-0_8. PMID: 25308264

228. Yang-Hartwich Y, Bingham J, Garofalo F, Alvero AB, **Mor G**. Methods Mol Biol. 2015;1219:75-86. doi: 10.1007/978-1-4939-1661-0_7. PMID: 25308263

229. Yang-Hartwich Y, Soteras MG, Lin ZP, Holmberg J, Sumi N, Craveiro V, Liang M, Romanoff E, Bingham J, Garofalo F, Alvero A, **Mor G**. p53 protein aggregation promotes platinum resistance in ovarian cancer. Oncogene. 2014 Sep 29. doi: 10.1038/onc.2014.296. (Epub ahead of print) PMID: 25263447

230. Nuti, SV, **Mor G**, Li P, Yin G. TWIST and Ovarian Cancer Stem Cells: Implications for Chemoresistance and Metastasis. Oncotarget. 2014 Sep 15;5(17):7260-71 PMID: 25238494

231. Alvero AB, Montagna MK, Sumi NJ, Joo WD, Graham E, **Mor G**. Multiple blocks in the engagement of oxidative phosphorylation in putative ovarian cancer stem cells: implication for maintenance therapy with glycolysis inhibitors. Oncotarget. 2014 Sep 30;5(18):8703-15. PMID: 25237928

232. Sumi NJ, Lima E, Pizzonia J, Orton SP, Craviero V, Joo W, Holmberg, JC, Gurrea M, Yang-Hartwich, Y, Alvero A, **Mor, G** Murine model for non-invasive imaging to detect and monitor ovarian cancer recurrence. J Vis Exp. 2014 Nov 2;(93):e51815. doi: 10.3791/51815. PMID 25407815 [PubMed – in process]

233. Young OM, Tang Z, Niven-Fairchild T, Tadesse S, Krikun G, Norwitz ER, **Mor G**, Abrahams VM, Guller S Toll-like receptor-mediated responses by placental Hofbauer cells (HBCs) a potential pro-inflammatory role for fetal M2 macrophages. American Journal of Reproductive Immunology 2015 Jan;73(1):22-35. doi: 10.1111/aji.12336. Epub 2014 Oct. 24. PMID:24345551 [.

234. Silasi M, Cardenas I, Kwon JY, Racicot K, Aldo P, **Mor G**, Viral infections during pregnancy. American Journal of Reproductive Immunology. 2015 Mar,73(3):199-213. doi: 10.1111/aji.12355. Epub 2015 Jan 13. PMOD 25582523

235. PrabhuDas M, Bonney E, Caron K, Dey S, Erlebacher A, Fazleabas A, Fisher S, Golos T, Matzuk M, McCune JM, **Mor G**, Schulz L, Soares M, Spencer T, Strominger J, Way SS, Yoshinaga K 2015. Nature Immunology. 2015 Mar 19;16(4):328-34.

236. Fraccaroli L, Grasso E, Hauk V, Paparini D, Soczewski E, **Mor G**, Pérez Leirós C, Ramhorst R. VIP boosts regulatory T cell induction by trophoblast cells in an in vitro model of trophoblast-maternal leukocyte interaction (2015) Journal of Leukocyte Biology. 2015 Jul;98(1):49-58. doi: 10.1189/jlb.1A1014-492RR. Epub 2015 PMID:25877932

237. Pan J, **Mor G**, Ju W, Zhong J, Luo X, Aldo PB, Zhong M, Yu Y, Jenkins EC, Brown WT, Zhong N. (2015) Viral Infection-Induced Differential Expression of LncRNAs Associated with Collagen in Mouse Placentas and Amniotic Sacs. American Journal of Reproductive Immunology. 74(3):237-257. PMID:26073538

238. Mor G. Kwon JY (2015) Trophoblast-microbiome interaction: a new paradigm on immune regulation. American Journal of Obstetrics and Gynecology. 2015 Oct;213(4 Suppl):S131-7. PMID: 26428492

239. Racicot K, Kwon JY, Aldo P, Abrahams V, El-Guindy A, Romero R, **Mor G**. (2016) Type 1 Interferon Regulates the Placental Inflammatory Response to Bacteria and is Targeted by Virus: Mechanism of Polymicrobial Infection-Induced Preterm Birth American Journal of Reproductive Immunology.75(4):451-60 PMID:6892235

240. Mor G. Placental Inflammatory Response to Zika Virus may Affect Fetal Brain Development (2016). American Journal of Reproductive Immunology. 2016 Apr;75(4):421-2. doi: 10.1111/aji.12512. PMID: 26892436

241. Alvero, A B.; Heaton, A.; Lima, E.; Pitruzzello, M.; Sumi, N.; Yang-Hartwich, Y.; Cardenas, C.; Steinmacher, S.; Silasi, DA.; Brown, D.; **Mor G.** (2016) TRX-E-002-1 induces c-jun-dependent apoptosis in ovarian cancer stem cells and prevents recurrence in vivo. Molecular Cancer Ther. 2016 Jun;15(6):1279-90. doi 10.1158/1535-7163.MCT-16-0005. PMID: 27196760

242. Aldo P, Marusov G, Svancara D, David J, **Mor G**. (2016) Simple Plex(™) : A Novel Multi-Analyte, Automated Microfluidic Immunoassay Platform for the Detection of Human and Mouse Cytokines and Chemokines. American Journal of Reproductive Immunology 5(6):678-93. doi: 10.1111/aji.12512. PMID:27170460

243. Cardenas C, Alvero AB, Yun B, **Mor G** (2016) Redefining the origin and evolution of ovarian cancer: A hormonal connection. Endocrine Related Cancers: ul 20. pii: ERC-16-0209. PMID: 27440787

244. Tian M, Zhang Y, Liu Z, Sun G, **Mor G**, Liao A. (2016) The PD-1/PD-L1 inhibitory pathway is altered in pre-eclampsia and regulates T cell responses in pre-eclamptic rats. Scientific Reports 2016 Jun 9;6:27683. doi: 10.1038/srep27683. PMID: 27277012

245. Aldo P, You Y, Szigeti K, Horvath TL, Lindenbach B, **Mor G**. HSV-2 enhances ZIKV infection of the placenta and induces apoptosis in first-trimester trophoblast cells. American Journal of Reproductive Immunology. 2016 Nov;76(5):348-357. doi: 10.1111/aji.12578 PMID 27613665

246. Roberts CM, Tran MA, Pitruzzello MC, Wen W, Loeza J, Dellinger TH, **Mor G**, Glackin CA (2016) TWIST 1 drives cisplatin resistance and cell survival in an ovarian cancer model, via upregulation of GAS6, L1CAM, and Akt signaling. Scientific Reports. 2016 Nov 23;6:37652. doi: 10.1038/srep37652. PMID: 27876874

247. Fu X, Li Y, Alvero A, Li J, Wu Q, Xiao Q, Peng Y, Hu Y, Li X, Yan W, Guo K, Zhou W, Wang Y, Liu J, Zhang Y, **Mor G**, Wen J, Yin G. (2016) MicroRNA-222-3p/GNA12/AKT axis inhibits epithelial ovarian cancer cell growth and associates with good overall survival. Oncotarget. 2016 Nov 2 doi: 10.18632/oncotarget.13017. PMID: 27811362

248. Hu XH, Tang MX, **Mor G**, Liao AH (2016) Tim-3: Expression on immune cells and roles at the maternal-fetal interface. Journal of Reproductive Immunology. 2016 Nov;118:92-99. doi: 10.1016/j.jri.2016.10.113.Review. PMID: 27792886

249. Cardena C, Montagna MK, Pitruzzello M, Lima E, **Mor G**, Alvero (2016) Adipocyte microenvironment promotes Bclxl expression and confers chemoresistance in ovarian cancer cells. Dec 23. doi: 10.1007/s10495-016-1339-x. Endocrine Reviews PMID: 28012060

250. Alvero AB, Kim D, Lima E, Sumi NJ, Lee JS, Cardenas C, Pitruzzello M, Salasi DA, Buza N, Fahmy T, **Mor G** (2017) Novel approach for the detection of intraperitoneal micrometastasis using an ovarian cancer mouse model. Scientific Reports Jan 25;7:40989. doi: 10.1038/srep40989. PMID: 28120873

251. Zambrano H, Waggoner J, Leon K, Pinsky B, Vera K, Schettino M, Rivera L, Landivar J, Granda M, Lee A, **Mor G** (2017) High incidence of Zika virus infection detected in plasma and cervical cytology specimens from pregnant women in Guayaquil, Ecuador. American Journal of Reproductive Immunology Feb;77(2). doi: 10.1111/aji.12630. PMID: 28177195

252. Racicot K and **Mor G**. (2017) Risks associated with viral infections during Pregnancy. Journal of Clinical Investigation 1;127(5):1591-1599. doi: 10.1172/JCI87490.

253. Racicot K, Aldo P, El-Guindy A, Kwon JA, Romero R, **Mor G**. (2017) Fetal/Placental type I interferon can affect maternal survival and fetal viral load during viral infection. Journal of Immunology Mar 6. pii: 1601824. doi: 10.4049/jimmunol.1601824. PMID:28264970

254. Mor G, Aldo P and **Mor G**. (2017) The unique immunological and microbial aspects of pregnancy. Nature Reviews Immunology. Jun 19. doi: 10.1038/nri.2017.64.

255. Wang W, Wang R, Zhang Q, Mor G, Zhang H. Benzo(a)pyren-7,8-dihydrodiol-9,10-epoxide induces human trophoblast Swan 71 cell dysfunctions due to cell apoptosis through disorder of mitochondrial fission/fusion. Environ Pollut. 2017 Nov 13;233:820-832. doi: 10.1016/j.envpol.2017.11.022. PMID: 29144987

256. Zhang T, Huang C, Du Y, Lian R, Mo M, Zeng Y, **Mor G**. Successful treatment with intrauterine delivery of dexamethasone for repeated implantation failure. Am J Reprod Immunol. 2017 Dec;78(6). doi: 10.1111/aji.12766. PMID 28921750

257. Cross SN, Potter JA, Aldo P, Kwon JY, Pitruzzello M, Tong M, Guller S, Rothlin CV, **Mor G**, Abrahams VM. Viral Infection Sensitizes Human Fetal Membranes to Bacterial Lipopolysaccharide by MERTK Inhibition and Inflammasome Activation. J Immunol. 2017 Oct 15;199(8):2885-2895. doi: 10.4049/jimmunol.1700870. Epub 2017 Sep 15. PMID:28916522

258.Mor G. Reproductive immunology in Asia: An international collaboration. Am J Reprod Immunol. 2017 Aug;78(2). doi: 10.1111/aji.12729. PMID: 28727255

259. Finger-Jardim F, Avila EC, da Hora VP, Santos PCD, Gonçalves CV, **Mor G**, de Martinez AMB, Soares MA. Herpes simplex virus type 2 IgG antibodies in sera of umbilical cord as a proxy for placental infection in asymptomatic pregnant women. Am J Reprod Immunol. 2018 Feb 10. doi: 10.1111/aji.12824

260. Muyayalo KP, Li ZH, **Mor G**, Liao AH (2018) Modulatory effect of intravenous immunoglobulin on Th17/Treg cell balance in women with unexplained recurrent spontaneous abortion.. Am J Reprod Immunol. Jul 9:e13018. doi: 10.1111/aji.13018.

261. Kwon JY, Aldo P, You Y, Ding J, Racicot K, Dong X, Murphy J, Glukshtad G, Silasi M, Peng J, Wen L, Abrahams VM, Romero R, **Mor G**. (2018) Relevance of placental type I interferon beta regulation for pregnancy success. Cell Mol Immunol. Jun 15. doi: 10.1038/s41423-018-0050-y.

262. Yang-Hartwich Y, Tedja R, Roberts C, Goodner-Bingham J, Cardenas C, Gurrea M, Sumi NJ, Alvero AB, Glackin CA, **Mor G**. (2018) p53-Pirh2 Complex Promotes Twist1 Degradation and Inhibits EMT. Mol Cancer Res. Aug 21. .0238.2018. doi: 10.1158/1541-7786.MCR-18-0238. PubMed PMID: 30131448.

263. Zhang Y, Ma L, Hu X, Ji J, **Mor G**, Liao A. The role of the PD-1/PD-L1 axis in macrophage differentiation and function during pregnancy. (2019) Hum Reprod. Nov 30. doi: 10.1093/humrep/dey347. PMID:30500923

264. You Y, Stelzl P, Zhang Y, Porter J, Liu H, Liao AH, Aldo PB, **Mor G**. (2019) Novel 3D in vitro models to evaluate trophoblast migration and invasion. Am J Reprod Immunol. Dec 24:e13076. doi: 10.1111/aji.13076. PMID:30582662

265. Wang LL, Li ZH, Duan YG, Yuan SQ, **Mor G,** Liao AH (2019) Identification of programmed cell death 1 and its ligand in the testicular tissue of mice. Am J Reprod Immunol. Dec 22:e13079. doi: 10.1111/aji.13079. PMID:30578744

266. Li ZH, Wang LL, Liu H, Muyayalo KP, Huang XB, **Mor G**, Liao AH. (2019) Galectin-9 Alleviates LPS-Induced Preeclampsia-Like Impairment in Rats via Switching Decidual Macrophage Polarization to M2 Subtype. Front Immunol. Jan 10;9:3142. doi: 10.3389/fimmu.2018.03142. eCollection 2018. PMID:30687334

267. Ji J, Zhai H, Zhou H, Song S, **Mor G**, Liao A. (2019) The role and mechanism of vitamin D-mediated regulation of Treg/Th17 balance in recurrent pregnancy loss. Am J Reprod Immunol. 2019 Mar 23:e13112. doi: 10.1111/aji.13112. [Epub ahead of print]
PMID: 30903715

268. Tedja R, Roberts CM, **Alvero** AB, Cardenas C, Yang-Hartwich Y, Spadinger S, Pitruzzello M, Yin G, Glackin CA, **Mor G**. (2019) Protein kinase Cα-mediated phosphorylation of Twist1 at Ser-144 prevents Twist1 ubiquitination and stabilizes it. J Biol Chem. Feb 7. pii: jbc.RA118.005921. doi: 10.1074/jbc.RA118.005921. PMID: 30733340

269. Muyayalo KP, Huang XB, Qian Z, Li ZH, **Mor G**, Liao AH. (2019) Low circulating levels of vitamin D may contribute to the occurrence of preeclampsia through deregulation of Treg /Th17 cell ratio. Am J Reprod Immunol. 2019 Oct;82(4):e13168. doi: 10.1111/aji.13168. Epub 2019 Jul 31. PMID:31299118

270. Guzman-Genuino RM, Dimova T, You Y, Aldo P, Hayball JD, **Mor G**, Diener KR. (2019) Trophoblasts promote induction of a regulatory phenotype in B cells that can protect against detrimental T cell-mediated inflammation. Am J Reprod Immunol. 2019 Sep 5:e13187. doi: 10.1111/aji.13187. [Epub ahead of print]PMID:31487409

271. Mor G, Rutherford T, Alvero A. (2019) Comment on "Osteopontin, Macrophage Migration Inhibitory Factor and Anti-Interleukin-8 Autoantibodies Complement CA125 for Detection of Early Stage Ovarian Cancer" Cancers 2019, 11, 596: Markers for Early Detection of Ovarian Cancer. Cancers (Basel). 2019 Sep 5;11(9). pii: E1307. doi: 10.3390/cancers11091307. PMID: 31491839

272. Kaislasuo J, Simpson S, Petersen JF, Peng G, Aldo P, Lokkegaard E, Paidas M, Pal L, Guller S, **Mor G**. (2019). IL-10 to TNFα ratios throughout early first trimester can discriminate healthy pregnancies from pregnancy losses. Am J Reprod Immunol. 2019 Oct 4:e13195. doi: 10.1111/aji.13195. [Epub ahead of print] PMID: 31585488

273. Liu H, Huang X, Mor G, Liao A. (2019) Epigenetic modifications working in the decidualization and endometrial receptivity. Cell Mol Life Sci. doi: 10.1007/s00018-019-03395-9.

274. Hendrix P, Tang Z, Silasi M, Racicot KE, **Mor G**, Abrahams VM, Guller S.' (2020) Herpesvirus-infected Hofbauer cells activate endothelial cells through an IL-1β-dependent mechanism. Placenta;91:59-65. doi: 10.1016/j.placenta.2020.01.010

275. Ma LN, Huang XB, Muyayalo KP, **Mor G**, Liao AH. (2020) Lactic Acid: A Novel Signaling Molecule in Early Pregnancy? Front Immunol.;11:279. doi:

276. Li J, Alvero AB, Nuti S, Tedja R, Roberts CM, Pitruzzello M, Li Y, Xiao Q, Zhang S, Gan Y, Wu X, Mor G, Yin G. (2020) CBX7 binds the E-box to inhibit TWIST-1 function and inhibit tumorigenicity and metastatic potential. Oncogene. doi:10.1038/s41388-020-1269-5.

277. Silasi M, You Y, Simpson S, Kaislasuo J, Pal L, Guller S, Peng G, Ramhorst R, Grasso E, Etemad S, Durosier S, Aldo P, **Mor G**. (2020) Human Chorionic Gonadotropin modulates CXCL10 Expression through Histone Methylation in human decidua. Sci Rep. 1;10(1):5785. doi: 10.1038/s41598-020-62593-9. PMID: 32238853

278. Liu H, Wang LL, Zhao SJ, Kwak-Kim J, **Mor G**, Liao AH. (2020) Why are pregnant women susceptible to COVID-19? An immunological viewpoint. J Reprod Immunol. 139:103122. doi: 10.1016/j.jri.2020.103122. PMID: 32244166

279. Potter JA, Tong M, Aldo P, Kwon JY, Pitruzzello M, **Mor G**, Abrahams VM. (2020) Viral infection dampens human fetal membrane type I interferon responses triggered by bacterial LPS. J Reprod Immunol;140:103126. doi: 10.1016/j.jri.2020.103126. PMID: 32289593

280. Zhang YH, Aldo P, You Y, Ding J, Kaislasuo J, Petersen JF, Lokkegaard E, Peng G, Paidas MJ, Simpson S, Pal L, Guller S, Liu H, Liao AH, **Mor G**. (2020) Trophoblast-secreted soluble-PD-L1 modulates macrophage polarization and function. J Leukoc Biol. doi: 10.1002/JLB.1A0420-012RR. PMID: 32386458

281. Alvero AB, Hanlon D, Pitruzzello M, Filler R, Robinson E, Sobolev O, Tedja R, Ventura A, Bosenberg M, Han P, Edelson RL, **Mor G.** (2020) Transimmunization restores immune surveillance and prevents recurrence in a syngeneic mouse model of ovarian cancer. Oncoimmunology. 2020 May 13;9(1):1758869. doi: 10.1080/2162402X.2020.1758869. PMID: 32566387 Free PMC article.

282. Muyayalo KP, Huang DH, Zhao SJ, Xie T, **Mor G**, Liao AH. (2020) COVID-19 and Treg/Th17 imbalance: Potential relationship to pregnancy outcomes. Am J Reprod Immunol. 2020 Jul 14:e13304. doi: 10.1111/aji.13304. Online ahead of print. PMID: 32662111

283. Hayakawa S, Komine-Aizawa S, **Mor GG**. (2020) Covid-19 pandemic and pregnancy. J Obstet Gynaecol Res Aug 10:10.1111/jog.14384. doi: 10.1111/jog.14384. Online ahead of print. PMID: 32779342 Free PMC article.

284. Wang L, Jiang P, Zhao S, Liu H, Liu L, Mor G, Liu C, Liao A. (2020) The dynamic profile and potential function of B-cell subsets during pregnancy. Cell Mol Immunol. doi: 10.1038/s41423-020-00535-1. Online ahead of print. PMID: 32879470

285. Liu H, Wang L, Wang Y, Zhu Q, Aldo P, Ding J, Mor G, Liao A. (2020) Establishment and characterization of a new human first trimester Trophoblast cell line, AL07. Placenta. 2020 Oct;100:122-132. doi: 10.1016/j.placenta.2020.08.013. Epub. PMID: 32927240

286. Simpson S, Kaislasuo J, Peng G, Aldo P, Paidas M, Guller S, Mor G, Pal L. (2020) Peri-implantation cytokine profile differs between singleton and twin IVF pregnancies. Am J Reprod Immunol. e13348. doi: 10.1111/aji.13348. Online ahead of print. PMID: 32946159.

287. Miller CJ, Runge-Morris M, Cassidy-Bushrow AE, Straughen JK, Dittrich TM, Baker TR, Petriello MC, **Mor G**, Ruden DM, O'Leary BF, Teimoori S, Tummala CM, Heldman S, Agarwal M, Roth K, Yang Z, Baker BB. (2020) A Review of Volatile Organic Compound Contamination in Post-Industrial Urban Centers: Reproductive Health Implications Using a Detroit Lens. Int J Environ Res Public Health. 2020 Nov 25;17(23):8755. doi: 10.3390/ijerph17238755. PMID: 33255777

288. Maxwell AJ, Ding J, You Y, Dong Z, Chehade H, Alvero A, Mor Y, Draghici S, **Mor G.** (2020) Identification of key signaling pathways induced by SARS-CoV2 that underlie thrombosis and vascular injury in COVID-19 patients. J Leukoc Biol. 2020 Nov 26. doi: 10.1002/JLB.4COVR0920-552RR. Online ahead of print. PMID: 33242368

289. Abrahams VM, Tang Z, **Mor G**, Guller S. (2020) NLRP3 inflammasome function and pyroptotic cell death in human placental Hofbauer cells. J Reprod Immunol. 2020 Oct 3;142:103214. doi: 10.1016/j.jri.2020.103214. Online ahead of print. PMID: 33152658

290. Hu X, Zhu Q, Wang Y, Wang L, Li Z, **Mor G**, Liao A. (2020) Newly characterized decidual Tim-3+ Treg cells are abundant during early pregnancy and driven by IL-27 coordinately with Gal-9 from trophoblasts. Hum Reprod. 2020 Nov 1;35(11):2454-2466. doi: 10.1093/humrep/deaa223. PMID: 33107565.

291. Van den Pol AN, Zhang X, Lima E, Pitruzzello M, Albayrak N, Alvero A, Davis JN, **Mor G.** (2021). Lassa-VSV chimeric virus targets and destroys human and mouse ovarian cancer by direct oncolytic action and by initiating an anti-tumor response. Virology. 2021 Mar;555:44-55. doi: 10.1016/j.virol.2020.10.009. Epub 2020 Nov 12. PMID: 33453650.

292. Walker C, Nguyen TM, Jessel S, Alvero AB, Silasi DA, Rutherford T, Draghici S, **Mor G.** (2021) Automated Assay of a Four-Protein Biomarker Panel for Improved Detection of Ovarian Cancer. Cancers (Basel). 2021 Jan 17;13(2):325. doi: 10.3390/cancers13020325. PMID: 33477343

293. Zhao S, Xie T, Shen L, Liu H, Wang L, Ma X, Wu J, Yuan S, **Mor G**, Liao A. (2021) An Immunological Perspective: What Happened to Pregnant Women After Recovering From COVID-19?. Front Immunol. 2021 Feb 3;12:631044. doi: 10.3389/fimmu.2021.631044. eCollection 2021. PMID: 33613576

294. Draghici S, Nguyen TM, Sonna LA, Ziraldo C, Vanciu R, Fadel R, Morrison A, Kenney RM, Alangaden G, Ramesh M, **Mor G**. (2021) COVID-19: disease pathways and gene expression changes predict methylprednisolone can improve outcome in severe cases. Bioinformatics. 2021 Mar 9:btab163. doi: 10.1093/bioinformatics/btab163. Online ahead of print. PMID: 33693506

295. Cassidy-Bushrow AE, Burmeister C, Birbeck J, Chen Y, Lamerato L, Lemke LD, Li J, **Mor G,** O'Leary BF, Peters RM, Reiners JJ Jr, Sperone FG, Westrick J, Wiewiora E, Straughen JK. (2021) Ambient BTEX exposure and mid-pregnancy inflammatory biomarkers in pregnant African American women. J Reprod Immunol. 2021 Mar 9;145:103305. doi: 10.1016/j.jri.2021.103305. Online ahead of print. PMID: 33725526

296. Azpiroz MA, Orguilia L, Palacio MI, Malpartida A, Mayol S, **Mor G**, Gutiérrez G. (2021) Potential biomarkers of infertility associated with microbiome imbalances. Am J Reprod Immunol. 2021 May 6:e13438. doi: 10.1111/aji.13438. Online ahead of print. PMID: 33960055

297. Liu H, Lin XX, Huang XB, Huang DH, Song S, Chen YJ, Tang J, Tao D, Yin ZN, **Mor G,** Liao AH. (2021) Systemic Characterization of Novel Immune Cell Phenotypes in Recurrent Pregnancy Loss. Front Immunol. 2021 May 28;12:657552. doi: 10.3389/fimmu.2021.657552. eCollection 2021. PMID: 34122414

298. Huang X, Wang L, Zhao S, Liu H, Chen S, Wu L, Liu L, Ding J, Yang H, Maxwell A, Yin Z, **Mor G**, Liao A. (2021) Pregnancy Induces an Immunological Memory Characterized by Maternal Immune Alterations Through Specific Genes Methylation. Front Immunol. 2021 Jun 7;12:686676. doi: 10.3389/fimmu.2021.686676. eCollection 2021. PMID: 34163485

299. Wang LL, Liu H, Zhao SJ, Shen L, Xie T, Luo J, **Mor G,** Liao AH. (2021) The metabolic landscape of decidua in recurrent pregnancy loss using a global metabolomics approach. Placenta. 2021 Sep 1;112:45-53. doi: 10.1016/j.placenta.2021.07.001. Epub 2021 Jul 8. PMID: 34273713

300. Ding J, Aldo P, Roberts CM, Stabach P, Liu H, You Y, Qiu X, Jeong J, Maxwell A, Lindenbach B, Braddock D, Liao A, **Mor G**. Placenta-derived interferon-stimulated gene 20 controls ZIKA virus infection. EMBO Rep. 2021 Aug 18:e52450. doi: 10.15252/embr.202152450. Online ahead of print. PMID: 34405956

301. Zambrano H, Anchundia K, Aviles D, Andaluz R, Calderon N, Torres E, Gonzalez-Granda N, Maxwell A, Chen K, Gonik B, **Mor G**. (2021) Seroprevalence of SARS-CoV-2 immunoglobulins in pregnant women and neonatal cord blood from a highly impacted region. Placenta. 2021 Oct 6;115:146-150. doi: 10.1016/j.placenta.2021.10.001. PMID: 34626893

302. Yuan You, Patrick Stelzl, Dana N. Joseph, Paulomi B. Aldo, Anthony J. Maxwell, Nava Dekel, Aihua Liao, Shannon Whirledge , **Gil Mor** (2021). TNF-α Regulated Endometrial Stroma Secretome Promotes Trophoblast Invasion. Fronteirs Immunology. 2021 Nov 1;12:737401. doi: 10.3389/fimmu.

303. Hu XH, Li ZH, Muyayalo KP, Wang LL, Liu CY, **Mor G**, Liao AH. (2021). A newly intervention strategy in preeclampsia: Targeting PD-1/Tim-3 signaling pathways to modulate the polarization of decidual macrophages. FASEB J. 2022 Jan;36(1):e22073. doi: 10.1096/fj.202101306R.

304. Holder B, Aplin JD, Gomez-Lopez N, Heazell AEP, James JL, Jones CJP, Jones H, Lewis RM, **Mor G**, Roberts CT, Robertson SA, Zenclussen AC. (2021) 'Fetal side' of the placenta:

anatomical mis-annotation of carbon particle 'transfer' across the human placenta. Nat Commun. 2021 Dec 3;12(1):7049. doi: 10.1038/s41467-021-26437-y.

305. Gao L, Xu QH, Ma LN, Luo J, Muyayalo KP, Wang LL, Huang DH, Xiao XJ, Cheng SB, **Mor G**, Liao AH. (2022) Trophoblast-derived Lactic Acid Orchestrates Decidual Macrophage Differentiation via SRC/LDHA Signaling in Early Pregnancy. Int J Biol Sci. 2022 Jan 1;18(2):599-616. doi: 10.7150/ijbs.67816. eCollection. PMID: 35002512

306. Zhao SJ, Muyayalo KP, Luo J, Huang D, **Mor G**, Liao AH. Next generation of immune checkpoint molecules in maternal-fetal immunity. Immunol Rev. 2022 Mar 2. doi: 10.1111/imr.13073. PMID: 35234305

307. Ding J, Maxwell A, Adzibolosu N, Hu A, You Y, Liao A, **Mor G.** Mechanisms of immune regulation by the placenta: Role of type I interferon and interferon-stimulated genes signaling during pregnancy. Immunol Rev. 2022 Mar 20. doi: 10.1111/imr.13077. Online ahead of print. PMID: 35306673

308. Zhang YJ, Shen L, Zhang T, Muyayalo KP, Luo J, **Mor G**, Liao AH. Immunologic Memory in Pregnancy: Focusing on Memory Regulatory T Cells. Int J Biol Sci. 2022 Mar 6;18(6):2406-2418. doi: 10.7150/ijbs.70629. eCollection 2022.

309. Alexandrova M, Manchorova D, You Y, **Mor G**, Dimitrova V, Dimova T. Functional HLA-C expressing trophoblast spheroids as a model to study placental-maternal immune interactions during human implantation. Sci Rep. 2022 Jun 17;12(1):10224. doi: 10.1038/s41598-022-12870-6. PMID: 35715452

310. Mor G. Introduction to the immunology of pregnancy. Immunol Rev. 2022 Jul;308(1):5-8. doi: 10.1111/imr.13102. Epub 2022 May 30. PMID: 35635382

311. Chehade H, Tedja R, Ramos H, Bawa TS, Adzibolosu N, Gogoi R, **Mor G,** Alvero AB. Regulatory Role of the Adipose Microenvironment on Ovarian Cancer Progression. Cancers (Basel). 2022 May 1;14(9):2267. doi: 10.3390/cancers14092267. PMID: 35565396

312. Lin XX, Xie YM, Zhao SJ, Liu CY, **Mor G**, Liao AH. Human leukocyte antigens: the unique expression in trophoblasts and their crosstalk with local immune cells. Int J Biol Sci. 2022 Jun 13;18(10):4043-4052. doi: 10.7150/ijbs.73616. eCollection 2022. PMID: 35844794

313. Koshko L, Scofield S, **Mor G,** Sadagurski M. Prenatal Pollutant Exposures and Hypothalamic Development: Early Life Disruption of Metabolic Programming. Front Endocrinol (Lausanne). 2022 Jul 11;13:938094. doi: 10.3389/fendo.2022.938094. eCollection 2022. PMID: 35909533

314. Liu J, Shu G, Wu A, Zhang X, Zhou Z, Alvero AB, **Mor G**, Yin G. TWIST1 induces proteasomal degradation of β-catenin during the differentiation of ovarian cancer stem-like cells. Sci Rep. 2022 Sep 19;12(1):15650. doi: 10.1038/s41598-022-18662-2. PMID: 36123378

315. Wang J, Zhao SJ, Wang LL, Lin XX, **Mor G**, Liao AH. Leukocyte immunoglobulin-like receptor subfamily B: A novel immune checkpoint molecule at the maternal-fetal interface. J Reprod Immunol. 2022 Nov 13;155:103764. doi: 10.1016/j.jri.2022.103764. PMID: 36434938

316. Wang L, Wang H, Luo J, Xie T, **Mor G**, Liao A. Decorin promotes decidual M1-like macrophage polarization via mitochondrial dysfunction resulting in recurrent pregnancy loss. Theranostics. 2022 Oct 17;12(17):7216-7236. doi: 10.7150/thno.78467. eCollection 2022. PMID: 36438479

317. Chehade H, Purandare N, Fox A, Adzibolosu N, Jayee S, Singh A, Tedja R, Gogoi R, Aras S, Grossman LI, **Mor G**, Alvero AB. MNRR1 is a driver of ovarian cancer progression. Transl Oncol. 2023 Jan 13;29:101623. doi: 10.1016/j.tranon.2023.101623. PMID: 36641875

318. Tedja R, Alvero AB, Fox A, Cardenas C, Pitruzzello M, Chehade H, Bawa T, Adzibolosu N, Gogoi R, **Mor G.** Generation of Stable Epithelial-Mesenchymal Hybrid Cancer Cells with Tumorigenic Potential. Cancers (Basel). 2023 Jan 22;15(3):684. doi: 10.3390/cancers15030684. PMID: 36765641

319. Carabulea AL, Janeski JD, Naik VD, Chen K, **Mor G**, Ramadoss J. A multi-organ analysis of the role of mTOR in fetal alcohol spectrum disorders. FASEB J. 2023 May;37(5):e22897. doi: 10.1096/fj.202201865R. PMID: 37000494

320. Sethuram R, Bukowski M, Hernandez F, You Y, Puscheck E, **Mor G**, Jeyasuria P, Condon JC. Endoplasmic reticulum stress response and the regulation of endometrial interferon beta production. F S Sci. 2023 Apr 1:S2666-335X(23)00016-2. doi: 10.1016/j.xfss.2023.03.005. Online ahead of print. PMID: 3701181

321. Maxwell A, Adzibolosu N, Hu A, You Y, Stemmer PM, Ruden DM, Petriello MC, Sadagurski M, Debarba LK, Koshko L, Ramadoss J, Nguyen AT, Richards D, Liao A, **Mor G**, Ding J. Intrinsic sexual dimorphism in the placenta determines the differential response to benzene exposure. iScience. 2023 Feb 27;26(4):106287. doi: 10.1016/j.isci.2023.106287. eCollection 2023 Apr 21. PMID: 37153445

322. You Y, Grasso E, Alvero A, Condon J, Dimova T, Hu A, Ding J, Alexandrova M, Manchorova D, Dimitrova V, Liao A, Mor G. Twist1-IRF9 Interaction Is Necessary for IFN-Stimulated Gene Anti-Zika Viral Infection. J Immunol. 2023 May 5:ji2300081. doi: 10.4049/jimmunol.2300081. Online ahead of print. PMID: 37144865

323. Adzibolosu N, Alvero AB, Ali-Fehmi R, Gogoi R, Corey L, Tedja R, Chehade H, Gogoi V, Morris R, Anderson M, Vitko J, Lam C, Craig DB, Draghici S, Rutherford T, **Mor G.** Immunological modifications following chemotherapy are associated with delayed recurrence of ovarian cancer. Front Immunol. 2023 Jun 26;14:1204148. doi: 10.3389/fimmu.2023.1204148. eCollection 2023. PMID: 37435088

324. Dhar JP, Walline H, **Mor G**, Fathallah L, Szpunar S, Saravolatz L, Carey T. Cervical Health in Systemic Lupus Erythematosus. Womens Health Rep (New Rochelle). 2023 Jul 12;4(1):328-337. doi: 10.1089/whr.2023.0023. eCollection 2023. PMID: 37476603

325. Lin X, Li Z, Gong G, Wang H, Fang X, **Mor G**, Liao A. The immune checkpoint protein PD-1: Its emerging regulatory role in memory T cells. J Reprod Immunol. 2023 Aug 9;159:104130. doi: 10.1016/j.jri.2023.104130. Online ahead of print. PMID: 37591180

326. Anamthathmakula P, Shallie PD, Nayak N, Dhal S, Vivian JL, **Mor G**, Soares MJ, Nayak NR. Variable Cre Recombination Efficiency in Placentas of Cyp19-Cre ROSAmT/mG Transgenic Mice. Cells. 2023 Aug 18;12(16):2096. doi: 10.3390/cells12162096. PMID: 37626906

327. Fang XH, Li ZJ, Liu CY, **Mor G**, Liao AH. Macrophage memory: Types, mechanisms, and its role in health and disease. Immunology. 2024 Jan;171(1):18-30. doi: 10.1111/imm.13697. Epub 2023 Sep 13. PMID: 37702350

328. Alvero AB, Fox A, Madina B, Krady M, Gogoi R, Chehade H, Nakaar V, Almassian B, Yarovinsky T, Rutherford T, **Mor G.** Immune modulation of innate and adaptive responses restores immune surveillance and establishes anti-tumor immunological memory. Cancer Immunology Research 2023 Dec 11. doi: 10.1158/2326-6066.CIR-23-0127. Online ahead of print. PMID: 38078853

329. Gogoi RP, Galoforo S, Fox A, Morris C, Ramos H, Gogoi VK, Chehade H, Adzibolosu NK, Shi C, Zhang J, Tedja R, Morris R, Alvero AB, **Mor G.** A Novel Role of Connective Tissue Growth Factor in the Regulation of the Epithelial Phenotype. Cancers (Basel). 2023 Oct 2;15(19):4834. doi: 10.3390/cancers15194834. PMID: 37835529

330. Zhang Y, Tedja R, Millman M, Wong T, Fox A, Chehade H, Gershater M, Adzibolosu N, Gogoi R, Anderson M, Rutherford T, Zhang Z, Chopp M, **Mor G**, Alvero AB. Adipose-derived exosomal miR-421 targets CBX7 and promotes metastatic potential in ovarian cancer cells. J Ovarian Res. 2023 Nov 30;16(1):233. doi: 10.1186/s13048-023-01312-0. PMID: 38037081

331. Alexandrova M, Manchorova D, You Y, Terzieva A, Dimitrova V, **Mor G**, Dimova T. Validation of the Sw71-spheroid model with primary trophoblast cells. Am J Reprod Immunol. 2023 Dec;90(6):e13800. doi: 10.1111/aji.13800. PMID: 38009060

332. Wong T, Tedja R, Chehade H, Morris R, Alvero AB, **Mor G.** An Ex Vivo Model of Ovarian Cancer Peritoneal Metastasis Using Human Omentum. J Vis Exp. 2024 Jan 26;(203). doi: 10.3791/66031. PMID: 38345216

333. Wang H, Wang L, Gong G, Lin X, Luo J, Liu C, **Mor G**, Liao A. Interleukin-10: a novel metabolic inducer of macrophage differentiation and subsequently contributing to improved pregnancy outcomes of mice by orchestrating oxidative phosphorylation metabolism. Biol Reprod. 2024 Mar 19:ioae041. doi: 10.1093/biolre/ioae041. Online ahead of print. PMID: 38501817

334. Fox A, Leonard GD, Adzibolosu N, Wong T, Tedja R, Sharma S, Gogoi R, Morris R, **Mor G**, Fehl C, Alvero AB. Adipose microenvironment promotes hypersialylation of ovarian cancer cells. Front Oncol. 2024;14:1432333. doi: 10.3389/fonc.2024.1432333. eCollection 2024. PubMed PMID: 39104719; PubMed Central PMCID: PMC11299042.

335. Maxwell A, Swanson G, Nguyen AT, Hu , Richard d, You Y, Stephan L, Manaloto M, Liao A, Ding J, **Mor G**. Hydroquinone impairs trophoblast migration and invasion via AhR-Twist-IFITM1 axis. Placenta 2024 PMID: 39173312

336. Zhao SJ, Hu XH, Lin XX, Zhang YJ, Wang J, Wang H, Gong GS, **Mor G**, Liao AH. IL-27/Blimp-1 axis regulates the differentiation and function of Tim-3+ Tregs during early pregnancy. JCI Insight. 2024 Aug 22;9(16):e179233. doi: 10.1172/jci.insight.179233. PMID: 39171524

337. Dimova T, Alexandrova M, Vangelov I, You Y, **Mor G.** The modeling of human implantation and early placentation: achievements and perspectives**.** Hum Reprod Update. 2024 Dec 13:dmae033. doi: 10.1093/humupd/dmae033. Online ahead of print. PMID: 39673726

338. Naik VD, Millikin DJ, Moussa D, Jiang H, Carabulea AL, Janeski JD, Ding J, Chen K, Rodriguez-Garcia M, Jaiman S, Krawetz SA, **Mor G**, Ramadoss J. Sexual dimorphism in lung transcriptomic adaptations in fetal alcohol spectrum disorders. Respir Res. 2025 Jan 8;26(1):6. doi: 10.1186/s12931-025-03094-z. PMID: 39780208

339. Alvero AB, Wu S, Farrell A, Kim S, Wallbillich JJ, Winer I, Morris R, Spetzler D, Anderson ML, Puccini A, Jones NL, Herzog TJ, Thaker PH, **Mor G**, Gogoi RP. Exploring the differences between BRCA mutated and HRwild-type high grade serous ovarian cancer: A multiomic analysis. Gynecol Oncol. 2025 Mar;194:71-79. doi: 10.1016/j.ygyno.2025.02.010. Epub 2025 Feb 18. PMID: 39970633

340. Kohut A, Anderson ML, Andikyan V, Yasukawa M, Nguy L, Karachristos A, Nywening T, **Mor G**, Gogoi R, Cohen JG, Lin JF, Rutherford TJ. Evaluating the Role of Hyperthermic Intraperitoneal Chemotherapy in Cytoreductive Surgery for Advanced-Stage Ovarian Cancer. Ann Surg Oncol. 2025 Jun;32(6):4326-4334. doi: 10.1245/s10434-025-17269-x. Epub 2025 Apr 6. PMID: 40189674

341. Alexandrova M, Manchorova D, Vangelov I, Terzieva A, Dimitrova V, **Mor G**, Dimova T. First trimester extravillous trophoblast secretes HLA class I molecules via small extracellular vesicles. Placenta. 2025 Apr 26;167:11-21. doi: 10.1016/j.placenta.2025.04.023. Online ahead of print. PMID: 40300266

342. Manchorova D, Alexandrova M, Terzieva A, Vangelov I, Djerov L, Hristova I, **Mor G**, Dimova T. Study on γδT-Cell Degranulation at Maternal-Fetal Interface via iKIR-HLA-C Axis. Cells. 2025 Apr 29;14(9):649. doi: 10.3390/cells14090649. PMID: 40358173

343. Alippe Y, Hauk V, **Mor G**, Vota DM. Editorial: Host-pathogen interactions during pregnancy: mechanisms of maternal and fetal immunity. Front Immunol. 2025 Jun 10;16:1629528. doi: 10.3389/fimmu.2025.1629528. eCollection 2025. PMID: 40557141

344. Wang W, Alvero A, Qin Y, Wang M, Fox A, Li Y, Millman M, Kemper A, **Mor G**, Liu XS, Chopp M, Zhang ZG, Zhang Y. Engineered Extracellular Vesicles Enriched with miR-214 Enhance the Efficacy of Chemotherapy for Ovarian Cancer. bioRxiv [Preprint]. 2025 Jul 22:2025.07.18.665422. doi: 10.1101/2025.07.18.665422. PMID: 40777359

CHAPTER BOOKS AND EDITORIALS

1. Mor G and Eliza M (1998) Autoimmunity and Tolerance. In: Methods in MolecularMedicine. Edited by Lowrie DB and Whalen R. The Humana Press Inc.

2. Mor, G and Brown WD (1999) Fas and Fas Ligand mediated immune privileged status of the tumor. In Cancer Immunotherapy Protocols. The Humana Press Inc.

3. Mor G (2002) Immunology of Reproduction, In: Infertility and Reproductive Medicine Clinics of North America

4. Schwartz PE, Chu MC, Zheng W and Mor G (2002) Endometrial stromal tumors are they hormonally sensitive? In Hormone Replacement therapy and Cancer. Edited by Genazzani AR,The Parthenon Publishing Group

5. Mor G and Abrahams V (2002) Immunology of Implantation. In: Immunology and Allergy Clinics of North America.

6. Mor G (2002) Sex hormones and the Immune System implication formenopause and autoimmunity. Women's Health and Menopause Editor: Lobo, Crosignani, Paoletti and Bruschi Klumer Academic Publisher

7. Mor G. (Editor) (2004) Introduction to reproductive Immunology, Immunology of Implantation. Landes Bioscience Press

8. Mor G and Alvero A (Editors) (2005) Apoptosis and Cancer. Methods in Molecular Medicine

9. Mor G, Straszewski-Chavez SL, Abrahams VM (2004) Macrophage-trophoblastInteractions.

10. "Placental and Trophoblast Methods and Protocols" for Methods in Molecular Medicine Series from Humana Press, Inc. www.eurekah.com

11. Krikun G, Mor G, Lockwood C, (2004) The immortalization of human endometrial cells. Methods in Molecular Medicine Series from Humana Press, Inc

12. Abrahams V, Mor G. (2004) Tool receptors and pregnancy, Immunology of Implantation. (2004) Landes Bioscience Press, www.eurekah.com

13. Chavez S and Mor G (2004) The regulation of human trophoblast apoptosis and survival during pregnancy. Immunology of Implantation. Landes Bioscience Press, www.eurekah.com

14. Mor G, and Abrahams VM (2004) Trophoblast cells as Immune regulators. Immunology of Implantation. Landes Bioscience Press, www.eurekah.com

15. Mor G, Montagna MK and Alvero AB (2007) Modulation of Apoptosis to Reverse Chemoresistance Apoptosis and Cancer. Methods in Molecular Medicine Series from Humana Press, Inc.

16. Silasi D-A, Alvero AB, Mor J, Chen R, Fu H-H, Montagna MK and Mor G. (2007) Detection of cancer-related proteins in fresh-frozen ovarian cancer samples using Laser capture microdissection. Apoptosis and Cancer. Methods in Molecular Medicine Series from Humana Press, Inc.

17. Alvero AB, Montagna MK, and Mor G (2007) Correlation of caspase activity and in vitro chemo-response in epithelial ovarian cancer cell lines. Apoptosis and Cancer. Methods in Molecular Medicine Series from Humana Press

18. Mor G (2007) Pregnancy Reconceived. Natural History May: 36-41

19. Mor G and Abrahams V (2009) Immunology of Pregnancy. Creasy and Resnik's Maternal Fetal Medicine: Principles and practice. Sixth Edition. Saunders

20. Mor G (2010) Thirty Years of Reproductive Immunology Am J Reprod Immunol. 2010 Jan;63(1):1-3

21. Mor G (2011) Clinical Aspects of Reproductive Immunology. Am J Reprod Immunol. 66(6):451

22. Mor G (2011) Is immune contraception in the future? Am J Reprod Immunol. 66(1):1

23. **Mor G** (2011) A Message from the Editor. The Role of Mucosal Immunity in the Male and Female Reproductive Tract During HIV Infection. Am J Reprod Immunol. 65(3):181

24. Nadel G, Alvero AB & **Mor G** (2012) MIF in Ovarian Cancer: Detection and Treatment *The MIF Handbook*. Humana Press

25. Mor G and Abrahams V (2013) Immunology of Pregnancy. Creasy and Resnik's Maternal Fetal Medicine: Principles and practice. 7th Edition. Saunders

26. Gurrea Soteras M and **Mor G** (2013) Células madre en oncologia. Endocrinologia ginecológica. Ediciones Journal

27. Racicot K and **Mor G** (2015) Inflammation and placentation Crocker and Bax: The placenta and Neurodisability. Mac Keith Press London.

28. **Mor G**. Reproductive immunology in Asia: An international collaboration. Am J Reprod Immunol. 2017 Aug;78(2). doi: 10.1111/aji.12729. PMID: 28727255

29. Yang-Hartwich Y, Bingham J, Garofalo F, Alvero AB, **Mor G**. (2015) Detection of p53 protein aggregation in cancer cell lines and tumor samples. Methods Mol Biol. 2015;1219:75-86. doi: 10.1007/978-1-4939-1661-0_7. PMID: 25308263

30. Yang-Hartwich Y, Romanoff E, Bingham J, Alvero AB, **Mor G.** (2015) Detection of p53 protein transcriptional activity by chromatin immunoprecipitation. Methods Mol Biol. 2015;1219:87-93. doi: 10.1007/978-1-4939-1661-0_8. PMID: 25308264

31. Chehade H, Fox A, **Mor G.** Albero A. (2021) Determination of caspase activation by western blot. Methods Mol Biol 2255.1-12

32. Chehade H, Fox A, **Mor G.** Albero A. (2021) Subcellualr fractionation to deosntrate activation of intrinsic apoptotic pathway. Methods Mol Biol 2255. 21-26

33. Guy JL and Mor G. (2021) Transcription Factor-Binding site identification and enrichment analysis. Methods Mol Biol 2255. 241-261

34. Maxwell AJ, You Y, Aldo P, Zhang Y, ding J, Mor G. 2021. The role of the immune system during pregnancy: General concepts. Reproductive Immunology. Chapter 1: 1-21

35. Lockwood C, Copel J, Dugoff L, Louis J, Moore T, Silver R, Resnik R, Mor G. 2022. Maternal-Fetal Medicine: Principles and Practice. 9th Edition. Chapter 8.

Opinions

I study pathogens and pregnancy. Here's what I know about Covid-19. **New York Times**. Opinion Guest Assay. October 10, 2021

BOOKS

1. **IMMUNOLOGY OF PREGANCY**. Editor: Gil Mor Medical Intelligence Unit Springer, LANDES Bioscience 2006

2. **APOPTOSIS AND CANCER**. Editors: Gil Mor and Ayesha Alvero Methods in Molecular Medicine. Humana Press. 2007 Vol. 414

3. **APOPTOSIS AND CANCER**. Editors: Gil Mor and Ayesha Alvero Methods in Molecular Biology. Springer Protocols. Humana Press Second Edition 2015 Volume 1219

4. **DETECTION OF CELL DEATH MECHANISM**. Editors: Ayesha Alvero and Gil Mor Methods in Molecular Biology. Springer Protocols. Humana Press 2021 Volume 2255

5. **REPRODUCTIVE IMMUNOLOGY BASIC CONCEPTS.** Series Editor: Gil Mor. Reproductive Immunology. Editor: Gil Mor. Elsevier Academic Press 2021. Volume 1.

6. **IMMUNOLOGY OF ENDOMETRIOSIS**. Series Editor: Gil Mor. Reproductive Immunology. Editor: Kaori Koga. Elsevier Academic Press 2022. Volume 2.

7. **IMMUNOLOGY OR RECURRENT PREGNANCY LOSS AND IMPLANTATION FAILURE.** Series Editor: Gil Mor. Reproductive Immunology. Editor: Joanne Kwak-kim. Elsevier Academic Press 2022. Volume 3.

MENTORING (SINCE 1999)

Post-Doctoral fellows	Undergraduate Students
Santiago Brown PhD	Michael Ziffra BA
Sarit Ashckenasi MD	Lucy Gordon, BA
Karlijn Verwer MD	Rebecca Rosen, BA
Joon Song MD, PhD	Amanda Muñoz BA
Chim Lim MD	Ellen Morrow, BA
Ivaldo Silva MD, PhD	Rich Redlinger. BA
Xiaoying Chen MD	Kelly Poggio BA
Marijke Kamsbeeg MD	Bibi Lesh BA
Vikki Abrahams PhD	Lindsay Simon BA
Key Song PhD	Scott DeSanders BA
Wei Chen MD	Courtney Costas BA
Ayesha Alvero MD	Adam Lipworth BA
Jianjun Li MD	Serena Chen, BA
Dong Hee Wang MD	Ingrid Ramirez BA
Stefan Fest MD	Thomas Ebinger BA
Ki Hyung Kim, MD	Manish Garg MS
Karina Dahl MD	Melisa Carrasco BA
Kaori Koga, MD	Alexandra Mazur BA
Bing Peng, MD	Ifeanyi Anidi BA
Ingrid Cardenas MD	Avanti Verma
Kyongjin Kim M.D.	Noah Lebowitz
lIana Chafetz PhD	Vinicius Craveiro

Post-Doctoral fellows	Undergraduate Students
Guy Nadal PhD	Sean Barwis
Gang Yin PhD	Vera Wunsche
Yang Yang PhD	Sudhakar Nuti
Karen Racicot PhD	Sabrina Gill
Severina Haddad PhD	Amanda Kelly
Won Duk Joo, MD	Brian Griffin
Carlos Cardenas, MD	Emma Graham
JayKwon Young, MD	Liora Mor
Go Ichikawa, MD	Amanda Kelly
Roslyn Tedja PhD	Emily Romanoff
Xian-Yong Ma PhD	Jessica Schmerler
Cai Roberts PhD	Jamie Bingham
Nemin Qiu MD	Bria Greene
	Emily Romanoff
	Julia Pomerantz
	Waverly Brim
	Triet Bui
	Shivali Gupta
	Tess Cersonsky
	Nicole Martin

Medical students Residents and Fellows	Graduate Students
Mariel Eliza M.D.	Jon Nilsen PhD (Dr. Frederick Naftolin)
Wendi Brown M.D.	Shawn Straszewski PhD
Saeher Muzaffar	Rui Chen PhD
Adam Gafni-Kane	Paulomi Aldo Msc
Kafui Demasio MD	Karthika Veeraraj Msc
Donna Neale MD	Michelle Montagna Msc
Shohreh Shahabi, MD	Han-Hsuan Fu Msc
David O'Malley MD	Juanni Li PhD
Maria J. Small MD	YongHong Zhang PhD
Mike Kelly MD	Jiahui Ding, MD
Dan Arin-Silasi MD	Anthony Maxwell, PhD
Aliza Leiser MD	Anna Hu, Ms
Rinki Agarwal MD	Annie Thy Nguyen, MD, PhD
Jaime Green MD	Nicholas Adzibolosu, MD, PhD
Susan Maya MD	Hussein Chehade PhD
Emily Thomas MD	
Michelle Silasi, MD	

LECTURES:

Invited Speaker
(Main lectures 1999-2024)

2024: Invitad Speaker: Sociedad Chilena de Climaterio. X Congreso Chileno De Climaterio Y I Encuentro Flascym Zona C. July 5-6

2024: Invited Speaker: The American Society for Reproductive Immunology Scientific Program Houston, TX. May 18-23

2024: Invited Speaker: Wayne State University. 27th Annual Graduate Student Research Presentation Day Keynote Speaker. January 22

2024: Invited Speaker: Grand Rounds. Levine Cancer Institute. "Mechanism of Immune Regulation in Ovarian Cancer." January 16

2023: Invited Speaker: Grand Rounds. Wayne State University. "Mechanisms of Immune Regulation in Ovarian Cancer." October 31

2023: Invited Speaker: University of Minnesota. "Benzene Induced Maternal Inflammation: Implications for Maternal and Fetal Health." October 25-26

2023: Invited Speaker: International Society for Immunology of Reproduction. "Impact of Viral Infections During Pregnancy on Trophoblast Function. Hamburg, Germany. September 14-18.

2023: Invited Speaker: School of Basic Medicine Central South University Reversing immune tolerance in ovarian cancer. Changsha China:

2023: Invited Speaker: Jinxin Medical Innovation Research Center: Immunology of Implantation Shenzhen China.

2023: Invited Speaker: Huazhong University of Science and Technology: Regulation of viral infections during pregnancy

2023: Invited Speaker: University of Florida. "New Approaches to Improve Immune Therapy in Ovarian Cancer."

2023: Invited Speaker: 29th Annual Meeting of the Florida Society of Gynecologic Oncology. "Immune Modulation for Ovarian Cancer." Longboat Key, Florida. June 8-11.

2023: Invited Speaker: American Transplant Congress. "Pregnancy and Tolerance." San Diego, California. June 3 – 7.

2023: Invited Speaker: The American Society for Reproductive Immunology Scientific Program 2. Santa Fe, New Mexico. May 19 – 25.

2023: Invited Speaker: The University of Texas Medical Branch, Department of Obstetrics and Gynecology. Galveston, Texas. May 7-9.

2022: Invited Speaker: Inflammation and Implantation 8th Sino American 2022. " Impact of Viral Infection on Trophoblast Function. November 20.

2022: Invited Speaker: XX International Congress of Reproductive Medicine SAMeR 2022. "General Immunology". September 8.

2022: Invited Speaker: The American Urogynecologic Society (AUGS) and International Urogynecological Association (IUGA). June 14-15.

2022: Annual Meeting of NIH Immune Mechanisms at the Maternal-Fetal Interface 2022. "Mechanisms of Trophoblast-induced Immune Modulation." June 8.

2022: Annual Meeting of the American Society for Reproductive Immunology 2022 Meeting (ASRI), Nashville, Tennessee, May 2022.

2022: Invited Speaker: Endocrinology Ground Rounds Didactic Lecture, Cleveland Clinic. "The Immune System & Pregnancy: Implications in Auto Immunity." March 21.

2022: Invited Speaker: La Asociacion Latinoamericana de Endocrinologia Ginecologica ALEG. "Inflammation and Implantation: An Evolutionary Need for the Success of Pregnancy" March 17

2022: Invited Speaker: Wayne State University School of Medicine, Dept., of Obstetrics and Gynecology. "Impact of Viral Infections on the Health of the Mother and the Fetus." March 15.

2022: Invited Speaker: 6th Sino American Submit Reproductive Immunology 2022. " Impact of Viral Infection on Trophoblast Function. October 20. Zoom. 50,400 attendees

2021: Invited Speaker: Israel Society for Placenta research. Immune modulatory role of the placenta. December 7. Israel

2021: Invited Speaker: Argentine Society of Menopause. Redefining the origin and evolution of ovarian cáncer, a hormonal connection. November 19. Argentina

2021: Invited Speaker: Japanese Society annual meeting Clinical Immunology. Impact of viral infections during pregnancy on the programing of the fetal immune system. October 28-30 Japan

2021: Invited Speaker: La Sociedad Chilena de Climaterio: Avances en el diagnóstico de cancer de ovario. September 2021

2021: Invited Speaker: Ovarian Cancer Initiative Academic Mini-Meeting: Targeting Mesenchymal Cancer Stem Cells to Prevent Recurrence. June 2021

2021: Invited Speaker: NIH Strategic Workshop Preconceptional Origins of Child Health Outcomes: Physical and Chemical Exposures: Immune Aspects. June 2021

2021: Invited Speaker: Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Health Disparities Mini-Virtual Retreat: Adiposity Derived Biomarkers for Early Detection of Ovarian Cancer in African American Women. June 2021

2021: Invited Speaker: Webinar: Understand your phenotype: A COVID-19 Drug Repurposing Case Study. June 2021

2021: Invited Speaker: The Annual Meeting of The American Association of Immunologists: Virtual Immunology 2021: Effect of viral infection on fetal development. May 2021

2021: Annual Meeting of the American Society for Reproductive Immunology 2021 Virtual Meeting (ASRI) May 2021

2021: Invited Speaker: Immune Mechanisms at the Maternal-Fetal Interface, Second Annual Meeting, NICHD, DAIT, NIAID, NIH: Mechanisms of Trophoblast-Induced Immune Modulation. April 2021

2021: Invited Speaker: Wayne State University College of Nursing Office of Health Research Biological Mechanisms of Health Learning Group Seminar: The Role of Inflammation in Reproduction. Feb. 2021

2021: Invited Speaker: 6th Sino American Submit Reproductive Immunology 2021. " Trophoblast Immune function. November 7. Zoom 51,800 attendees

2020: Invited Speaker: Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine Tumor Biology & Microenvironment Program 2020 Virtual Retreat: The Role of the Microenvironment on the Epithelial-Mesenchymal Transition Process. Nov. 2020

2020: Invited Speaker: Huazhong University of Science and Technology: Infection in Pregnancy, Sept. 2020

2020: Invited Speaker: Huazhong University of Science and Technology: Fetal-Maternal Immune Interaction, Sept. 2020

2020: Invited Speaker: Huazhong University of Science and Technology: Immunology of Implantation, Sept. 2020

2020: Invited Speaker: Huazhong University of Science and Technology: General Introduction on Reproductive Immunology, Sept. 2020

2020: Invited Speaker: Wayne State University Research Grand Rounds: "Origin of Ovarian Cancer: An Endocrine Connection, Jan. 2020

2020: Invited Speaker: Wayne State University School of Medicine, Dept. Biochemistry, Microbiology and Immunology, Seminar Series: The Immune Response to Viruses and Its Importance in Pregnancy Complications, Jan. 2020

2019: Invited Speaker: Grand Rounds. The Role of the Placenta in Response to Viral Infections. University Maryland School of Medicine, Baltimore, MD

2019: Invited Speaker: XXI Congreso Ginecologia y Obstetricia. El Rol de la Infeccion en la Salud Materna y Fetal. Fundacion Santa Fe de Bogota, Centro Hospitalario Serena del Mar, Cartagena, Colombia.

2019: Invited Speaker: XXI Congreso Ginecologia y Obstetricia. Embarazo: Condicion Immunologica y Microbiana Unica. Fundacion Santa Fe de Bogota, Centro Hospitalario Serena del Mar, Cartagena, Colombia.

2019: Invited Speaker: XXI Congreso Ginecologia y Obstetricia. Origen y Progresion del Cancer de Ovario. Fundacion Santa Fe de Bogota, Centro Hospitalario Serena del Mar, Cartagena, Colombia.

2019: Invited Speaker: 10th Annual MARTS (The Michigan Alliance for Reproductive Technologies and Science) Conference. Inflammation and Implantation: An Evolutionary Need for the Success of Pregnancy, Michigan State University, E. Lansing, MI.

2019: Invited Speaker and President: The American Society for Reproductive Immunology Scientific Program 2019. Welcome Remarks. Grand Rapids, MI

2019: Invited Speaker and President: The American Society for Reproductive Immunology Scientific Program 2019. President's Distinguished Lecture, Welcome Remarks. Grand Rapids, MI.

2019: Invited Speaker, Grand Rounds Ascension St. John Hospital. Infection and Pregnancy: The Immunological Role of the Placenta. Ascension St. John Hospital, Detroit, MI.

2019: Invited Speaker, Cancer Research UK (CRUK) Marshall Symposium, Event Title: Tumour versus Host: The Battle Within. Host Versus Tumour: Tumour Microenvironment. Session Title: Lessons from the Immune System During Pregnancy. Bailiffscourt Hotel and Spak, West Sussex, UK.

2019: Invited Speaker, UTMB Microbiology & Immunology – Mini-Symposium: Immune Regulatory Function of Type 1 Interferon Beta During Pregnancy, University of Texas Medical Branch, Galveston, TX.

2019: Invited Speaker, American Thyroid Association, 89th Annual Meeting. Pregnancy: ATA Plenary Lecture: A Unique Immunological and Microbial Condition, Chicago, IL.

2019: Invited Speaker, Signing Ceremony: HUST And WSU: Introduction: The International Women's Health Research Program, Tongji Medical College, HUST, Huazhong University of Science and Technology, Wuhan, China.

2019: Invited Keynote Speaker: The 5th Conference on New Trends in Clinical and Basic Research on Reproductive Immunology: Inflammation and Implantation: An Evolutionary Need for the Success of Pregnancy, Shenzhen Zhongshan Urology Hospital, Shenzhen, China.

2019: Invited Speaker: The 14th World Congress of the International Society for Immunoloy of Reproduction. Symposium 6 Chair: Gut and Female Genital Tract Microbiome and Adverse Pregnancy Outcomes; Symposium 8 Chair: Infectious Immunity in Pregnant or Non-Pregnant Women (Influenza, CMV, HIV, HPV, etc.)

2019. Invited Speaker: The 34th Annual Meeting of the Japanese Society for Immunology of Reproduction Presentation: Role of Placental-Derived IFNBeta in the Protection of the Fetus and the Mother Against Viral Infections, Nara Kasugano International Forum, Nara City, Japan.

2019: Invited Speaker: Maternal Immunization Immunology/Ethics Consideration. The Immune System in Pregnancy: Alteratons in Immune Responses to Infectious Diseases During Pregnancy and Practical Implications for Vaccination, World Health Organization (WHO), Intercontinental Hotel, Geneva, Switzerland

2018: Invited Speaker:Biomedical Sciences Symposium. Infection and pregnancy: the role of the placenta Morsani college of Medicine, University of South Florida, Tampa Florida

2018: Invited Speaker: SAIC-SAI-SAFIS, Annual Meeting. Inflammation and Implantation: an evolucionary need for the success of the pregancy SAIC-SAI Symposium, Mar Del Plata, Argentina

2018: Invited Speaker: SAIC-SAI-SAFIS, Annual Meeting. Role of placental derived IFN-beta in the protection of the fetus and the mother against viral infections SAIC Symposium, Mar Del Plata, Argentina

2018: Invited Speaker: American Association of Immunology. Inflammation and Implantation Biomedial Researh Seminar Series. Austin, Texas

2018: Invited Speaker: Queens University. Origen of Ovarian cancer: a hormonal connection Researh Seminar Series. Department of Biomedical and Moleular Sciences. Queen's University Canada

2018: Invited Speaker: Vyle Hospital. Cancer Stem cells as the source of recurrence and chemoresistance Vejle Hospital. Vejle Denamark

2018: Invited Speaker: 38rd Annual Meeting of the American Scoeitey for Reproductive Immunology (ASRI), The role of inflammation during implantation, Shanghai, China

2018: Invited Speaker: New Mexico State University. Inflammation and Implantation Biomedial Researh Seminar Series. Las Cruces New Mexico

2018: Invited Speaker: University of South Florida,Grand Raounds. Ovarian Cancer Stem Cells, new approaches for treatment and detection Tampa Florida

2018: Invited Speaker: Ohaio State University. Pregnancy a unique immunological and microbial condition Columbus Ohaio

2017: Invited Speaker: Interdisciplinary Autumn School for Reorductive Sciences, Pregnanc: a unique immunologic anf microbial condition, Magdeburg Germany

2017: Invited Speaker: Life Conference 2017 on Infertility and High risk prepgancy, Inflammation and implantation, Bangalore, India

2017: Invited Speaker: International Federation of Placental Association (IFPA), The Unique immunological and microbial aspects of pregancy, Manchester, UK

2017: Invited Speaker: Wayne State University, Hutze Women's Hospital, The Role of Placenta as an Immune Regulatory Organ, Detroit, Michigan

2017: Invited Speaker: American Council on ECP: Vaccination for ovarian cancer: targeting chemoresistance. New York NY

2017: Invited Speaker: Wayne State University, Peninatology Research Branch, The Unique immunological and Microbial aspect of Pregnancy and Role of Polymicrobial Infection on Viral Induced Teratogenic Effect, Detroit, Michigan

2017: Invited Speaker: Tongji Medical College's 110th Anniversity Celebration, The Unique Immunologocal and Microbial Aspect of Pregnancy, Wuhan, China

2017: Invited Speaker: MRC Centre for Reproductive Health, The Unique Immunological and Microbial aspect of Pregnancy, Edinburgh, United Kingdom

2017: Invited Speaker: Seminar Series for Stanford Immunology, Role of Poly Microbed Infection During Pregnancy on Maternal and Fetal Well Being, Stanford, California

2016: Invited Speaker: 63rd Annual Scientific Meeting SRI, The Relationship Between Viral Infections and Preterm Labor, Montreal, Canada

2016: Invited Speaker: Sociedad Argentina De Endocrinologia Y Reproductiva, Inflamacion e implantacion (Inflammation and Implantation), Buenos Aires, Argentina

2016: Invited Speaker: UT Southwestern, Reproductive Biology Seminar Series, Trophoblast microbiome Interaction: A New Paradigm on Immune Regulation, Dallas, Texas

2016: Invited Speaker: IFPA, Viral Infection and the Placenta Symposium, The Role of Polymicrobial Infection on Viral-Induced Teratogenic Effects, Portland, OR

2016: Invited Speaker: 3rd Reproductive Immunology Conference, The effect of viral infection during pregnancy on fetal development, Shenzhen, China;

2016: Invited Speaker: International Conference "Human Endometrium and ongoing pregnancy", The Role of Ovulation in the Origin of Ovarian Cancer, Havana, Cuba

2016: Invited Speaker: Wheaton Franciscan Healthcare, 11st Annual Advances in Perinatal/Neonatal Care Conference, Infection in Pregnancy: Maternal and Fetal Consequences, Milwaukee, WI

2016: Invited Speaker: Faculty of Reproductive Biology Retreat, R.O. Berry Memorial Lecture, Polymicrobial Infections during pregnancy: maternal and fetal risks, Texas A&M, College Station, TX

2016: Invited Speaker: Reproductive and Developmental Sciences Program, Origins of Ovarian Cancer and Mechanisms of Recurrence, Michigan State University, Grand Rapids, MI

2016: Invited Speaker: American Society for Reproductive Immunology (ASRI 36th Annual Meeting), Viral infections during pregnancy, Baltimore, MD

2015: Invited Speaker: 62nd Annual Scientific Meeting, SRI, Trophoblast Immune Interactions, San Francisco, CA

2015: Invited Speaker, 2015 Annual Meeting, American Association of Immunologists, Role of Placenta Type I Interferon on Polymicrobial Infection-Induced Preterm Birth, New Orleans, LA

2015: Invited Plenary Lecturer, 14th International Symposium for Immunology of Reproduction, Polymicrobial Infection and Pregnancy, Varna, Bulgaria

2015: Invited Speaker, 35th Annual Meeting, American Society for Reproductive Immunology, Immunology of Gynecologic Tumors, Queens University, Kingston, Ontario, Canada

2015: Invited Speaker: New Trends in Clinical and Basic Research on Reproductive Immunology, Inflammation and Pregnancy, Chongqing City, China

2015: Invited Speaker: Inflammation and Implantation, Third Military Medical University, Chongqing; China

2015: Invited Speaker: China Human Placenta Project, Trophoblast-microbiome interaction: A new paradigm on (sic) immune regulation Guangzhoun China

2015: Invited Speaker: Eular Congress, Estrogens and the Immune System Response in Pregnancy, Rome, Italy

2015: Invited Speaker: Exploring Human Host-Microbiome Interactions in Health and Disease 2015, Role of bacteria in normal pregnancy, Cambridge, UK

2015: Invited Speaker: Provocative Ideas on (sic) Human Placental Research, Inflammation and infection: Fetal Response, Faridabad, India

2015: Invited Speaker: Sydney West Translational Cancer Research Centre, Ovarian Cancer Stem Cells: Origin and Chemoresistance, Dunedin, New Zealand

2015: Invited Speaker: City of Hope, Leading Edge Lectures, Ovarian cancer stem cells and TWIST: Implications for chemoresistance and metastasis, Los Angeles, CA

2014: Invited Speaker: SGI PREBIC, Preterm Labor: A Polymicrobial Disease?, Florence, Italy

2014: Invited Speaker: Eunice Kennedy Shriver NICHD, The Human Placenta Project: Placental Structure and Function in Real Time, Potomac, MD

2014: Invited Speaker: International Scientific Association for Probiotics and Prebiotics Conference, Aberdeen, Scotland

2014: Invited Speaker: Drug Discovery & Therapy World Congress 2014, In vitro and in vivo Efficacy of a Novel Superbenzopyran Analogue Trx1 Against Platinum-resistant Ovarian Cancer Stem Cells, Boston, MA

2014: Invited Speaker: New Trends in Clinical and Basic Research on Reproductive Immunology, Inflammation and Implantation, Shenzhen Zhongshan Urology Hospital and Reproductive Medical Centre, Third Military Medical University, China

2014: Invited Speaker: Nihon University School of Medicine, Trophoblast Immune Interaction, Tokyo, Japan

2014: Invited Speaker: University of Tokyo, Origins of Ovarian Cancer, Tokyo, Japan

2014: Invited Speaker: Joint Workshop on Immune Mechanisms at the Maternal-Fetal Interface, Uterine Function and Implantation Biology Program, NICHD, DAIT, NIAID, NIH, Inflammation and implantation: the role of dendritic cells, and Inflammation at the maternal-fetal interface, Rockville, MD

2014: Invited Speaker: 9th Annual Meeting of the Interdisciplinary Collaborative Team on Blastocyst Implantation Research, Role of Toll-like receptors in trophoblast immune regulation, Rockville, MD

2014: Invited Speaker: Joint Satellite Symposium at SGI 2014, Preterm Birth International Collaborative (PREBIC) and Myometrium/Parturition Symposium, Preterm Labor: A Polymicrobial Disease?, Florence, Italy

2013: Invited Speaker: Big City Seminars, San Francisco & San Diego, CA

2013: Invited Speaker: American Society of Reproductive Immunology Annual Meeting, Boston, MA

2013: Invited Speaker: Advanced Reproductive Medical Treatments, Rome, Italy

2013: Invited Speaker: 8th International Workshop on HIV Transmission: Principles of Intervention Workshop, Immunology of the Female Reproductive Tract, Barcelona, Spain

2013: Invited Speaker: 8th Collaborative Team Meeting, Role of Toll-Like Receptors in trophoblast immune regulation, Rockville, MD,

2013: Invited Speaker: Chinese Academy of Science, Beijing, China

2013: Invited Speaker: WIP Research Conference, Magee-Womens Research Institute, Pittsburgh, Pa

2012: Invited Speaker: American Society of Reproductive Immunology Annual Meeting, Boston, MA

2012: Invited Speaker: V SLIMP- Latin American Society for Maternal Fetal Interaction and Placenta, Viral Infection and Pregnancy and Trophoblast Immune Interactions. Sao Paulo, Brazil

2012: Invited Speaker: Multigene Conference, Biomarkers for Ovarian Cancer, Hong Kong, China

2012: Invited Speaker: Grand Rounds, University of Minnesota, Ovarian cancer stem cells: Source of recurrence and metastasis, Minneapolis, MN

2012: Invited Speaker: Grand Rounds, University of Nebraska, Is ovarian cancer a single disease? Implications for treatment and diagnosis, Omaha, Nebraska

2012: Invited Speaker: Program in Reproductive Sciences (PiRS) Series, University of Colorado, Inflammation and Pregnancy: The Good and the Bad. Denver, CO

2012: Invited Speaker: P4H International Summit on Personalized Health, Is ovarian cancer a single disease: Implications for treatment and diagnosis. Tel Aviv, Israel.

2011: Invited Speaker: Collaborative Academic Program between Second Affiliated Hospital of Xi'an Jiaotong University and Yale University, Cancer Stem Cells, Xi'an, China.

2011: Invited Speaker: University of Magdeburg, The Role of Macrophages in Pregnancy, Magdeburg, Germany

2011: Invited Speaker: A Marcus Wallenberg International Symposium in Comparative Reproductive Immunology, Linkoping University, Inflammation and implantation: the role of dentritic cells, Stockholm, Sweden

2011: Invited Speaker: 5th Meeting of the Collaborative Team on Interdisciplinary Research on Blastocyst Implantation – NIH, Inflammation and Implantation, Rockville, MD

2011: Invited Speaker: American Society of Reproductive Immunology, Ovarian Cancer Stem Cells, Salt Lake City, Utah.

2011: Invited Speaker: The Greenberg Conference, Inhibition of MIF Induces Death of Human Epithelial Ovarian Cancer Cells, Greenberg Conference Center, New Haven, CT.

2011: Invited Speaker: Grand Rounds Program, Stony Brook University Medical Center, Toll-Like Receptors in Pregnancy, Stony Brook, New York.
2010: Invited Speaker: Second International Conference on Reproductive Immunology, Inflammation and Pregnancy: The Good and the Bad. Shanghai, China.

2010: Invited Speaker: The Placenta and Neurodisability – Castang Foundation Trophoblast Cells as Immune Modulators in Pregnancy. London, England.

2010: Invited Speaker: 7th Annual Gilbert S. Greenwald Symposium on Reproduction, Trophoblast Immune Regulation: Infection and Inflammation. Kansas City, MO

2010: Invited Speaker: 4th Meeting of the Collaborative Team on Interdisciplinary Research on Blastocyst Implantation – NIH. Inflammation and Implantation. Rockville, MD

2010: Invited Speaker: Congress of Reproductive Science in 2010. Uterine, Placental and Immune Cell Interactions in Early Pregnancy. London, England

2010: Invited Speaker: International Congress of Reproductive Immunology. Trophoblast Cells as Immune Modulators in Pregnancy. Cairns, Australia

2010: Invited Speaker: Aspen Perinatal Biology Conference. Trophoblast Immune Regulation. Aspen, CO

2010: Invited Speaker: OVCAD Consortium Meeting. Ovarian Cancer Stem Cells: Origin and Recurrence: Multiplex Panel for the Detection of Ovarian Cancer. Vienna, Austria

2010: Invited Speaker: NICHD Reproductive Sciences. Function of Toll-Like Receptors throughout Gestation. Rockville, MD

2010: Invited Speaker: SAEGRE-BioPsico- Social Changes in the Woman of this Millenium-Sociedad Argentina De Endocrinologia Ginecologica y Reproductiva. Role of Ovarian Cancer Stem Cells in Recurrence and Metastasis. Buenos Aires, Argentina

2010: Invited Speaker: Avison Biomedical Symposium. Ovarian Cancer Stem Cells and Therapeutic Targets. Seoul, Korea

2009: Invited Speaker: European meeting of Obstetrics and Gynecology Krakow Poland.
2009: Invited Speaker: Nankai University. (Two seminars) Ovarian cancer stem cells and chemoresistance. Early detection of ovarian cancer. Nankai, China

2009: Invited Speaker: GAPPS International Conference on Prematurity and Stillbirth. Immunology of pregnancy. Seattle. WA.

2009: Invited Speaker: DOD Ovarian Cancer Research Program. Ovarian Cancer Stem Cells: Source of Recurrence and Chemoresistance. John Hopkins. Baltimore, MD.

2009: Invited Speaker: UWV Grand Rounds. Inflammation and pregnancy: The role of toll like receptors. Morgantown, WV.

2009: Invited Speaker: American Society for Investigative Pathology. microRNA's and ovarian cancer stem cell transition. New Orleans, LA.

2009: Invited Speaker: NIAID Workshop. Immunology of Malaria. Immunity during pregnancy. Bethesda, MD.

2009: Invited Speaker: Int. Cong on Bio-immunoregulatory Mechanisms Associated with Reproductive Organs. Trophoblast Immune Modulator in Pregnancy. New Delhi, India

2008: Invited Speaker: CRRWH Seminar Series. Inflammation and Pregnancy: the Role of Toll Like Receptors. University of Pennsylvania: Philadelphia, PA.

2008: Invited Speaker: NCI Translational Science Meeting. Translational Research Studies. Washington, D.C.

2008: Invited Speaker: Teva Pharmaceutical Ltd. Biomarkers for Early Detection. Israel

2008: Invited Speaker: ICMRS. Ovarian cancer stem cells. Wellington, New Zealand

2008: Invited Speaker: Radcliff Institute for Advanced Study. Inflammation in male and female Cardiovascular Disease. Cambridge, MA.

2007: Invited Speaker: 23th Annual Meeting of the Japanese Society for Immunology of Reproduction. Inflammation and Pregnancy: The Role of TLRs. Tokyo, Japan

2007: Invited Speaker: New York Obstetrical Society Meeting. Biomarkers for the Early Detection of Ovarian Cancer. New York, NY

2007: Invited Speaker: xSamples Technology. Biomarker Development for Cancer. Boston, MA

2007: Invited Speaker: Human Reproduction in 2007. Early Detection of Ovarian Cancer. Mykonos, Greece
2007: Invited Speaker: Human Reproduction in 2007. TLRs and Pregnancy. Mykonos, Greece

2007: Invited Speaker: Menopause Society. New Therapeutic Approaches for the Treatment of Ovarian Cancer. Mar del Plata, Argentina

2007: Invited Speaker: Meeting of the International Society for Reproductive Immunology. Trophoblast Immune Interactions. Opatja, Croatia

2007: Invited Speaker: International Meeting on Women Health. Biomarkers for Ovarian Cancer. Valencia, Spain

2007: Invited Speaker: Early Detection Research Network, NCI. Blood Biomarkers for Cancer. Denver, CO

2007: Invited Speaker: V International Meeting of Obstetrics and Gynecology. Immunology of Pregnancy. Valparaiso, Chile

2007: Invited Speaker: V International Meeting of Obstetrics and Gynecology. Inflammation and Cancer. Valparaiso Chile

2007: Invited Speaker: V International Meeting of Obstetrics and Gynecology. Early Detection of Ovarian Cancer. Valparaiso,Chile

2007: Invited Speaker: Annual Meeting of the American Society for Reproductive Immunology. TLRs and Pregnancy. Toronto, Canada

2007 Invited Speaker: V International Meeting of Obstetrics and Gynecology. Immunology of Pregnancy. Valparaiso Chile, May 2007

2006: Invited Speaker: 13th Postgraduate Course "Recent Advances in Perinatal Medicine". Erice, Italy

2006: Invited Speaker: Oncology Group. Advantages of Early Detection of Ovarian Cancer. Tel Aviv, Israel

2006: Invited Speaker: National Congress of Obstetrics and Gynecology. New Markers for Early Detection of Ovarian Cancer. Ramat Gan Israel

2006: Invited Speaker: School of Medicine. Symposium on Immunology of Pregnancy. Inflammation and pregnancy: the role of Toll Like Receptors. West Virginia University

2006: Invited Speaker: Annual Meeting, Sociedad Argentina de Endocrinologia Ginecologica y Reproductiva. Inflammation and Cancer. Buenos Aires, Argentina

2006: Invited Speaker: Annual Meeting, Sociedad Argentina de Endocrinologia Ginecologica y Reproductiva. Biomarkers for Early Detection of Ovarian Cancer. Buenos Aires, Argentina

2006: Invited Speaker: Annual Meeting, Sociedad Argentina de Endocrinologia Ginecologica y Reproductiva. Trophoblast-Immune Interactions. Buenos Aires, Argentina

2006: Invited Speaker: Annual Meeting, Sociedad Argentina de Endocrinologia Ginecologica y Reproductiva. Trophoblast Apoptosis. Buenos Aires, Argentina

2006: Invited Speaker: Array BioPharma's. Inflammation and Cancer. Denver, Colorado

2006: Invited Speaker: Apoptosis and Cancer. Wilkes-Barre University, Wilkes-Barre, PA

2005: Invited Speaker: International Meeting of Gynecology. Early Detection and Ovarian Cancer. Medellin, Colombia

2005: Invited Speaker: International Meeting of Gynecology. Immunology of Implantation. Medellin, Colombia

2005: Invited Speaker: International Meeting of Gynecology. Cancer Progression and Inflammation. Medellin, Colombia

2005: Invited Speaker: Inflammation and Cancer. Vaccination, Infection & Autoimmunity: Myth & Reality-VIAMR. Lausanne, Switzerland

2005: Invited Speaker: 11th World Congress of Menopause. Early detection in Cancer. Buenos Aires, Argentina

2005: Invited Speaker: 11th World Congress of Menopause. Inflammation and Ovarian Cancer Progression. Buenos Aires, Argentina

2005: Invited Speaker: 11th World Congress of Menopause. Isoflavones and the Treatment of Ovarian Cancer. Buenos Aires, Argentina

2005: Invited Speaker: EDRN Sterling Meeting. New Markers for the Early Detection of Ovarian Cancer. Seattle, Washington

2005: Invited Speaker: Annual Meeting of the Gynecologic Society. Apoptosis and Cancer. Guayaquil, Ecuador

2005: Invited Speaker: Annual Meeting of the Gynecologic Society. Apoptosis and Tissue Remodeling. Guayaquil, Ecuador

2005: Invited Speaker: VI Congress of Menopause. Phenoxodiol: A New Approach for the Treatment of Ovarian Cancer. Bucaramanga, Colombia

2005: Invited Speaker: VI Congress of Menopause. The Regulation of Apoptosis in Tissue Remodeling and Cancer. Bucaramanga, Colombia.

2005: Invited Speaker: Department of Physiology, Dartmouth University. New Concepts in Reproductive Immunology. Hanover, NH

2005: Invited Speaker: Annual Meeting Society of Mucosal Immunity. The Immunology of the Female Reproductive Tract. Boston, MA

2005: Invited Speaker: Immunology of Implantation. Humboldt University Berlin Germany

2005: Invited Speaker: Perinatal Research Branch, NICHD, NIH. Toll Like Receptors and Implantation. Detroit, MI

2004: Invited Speaker: MOFFITT Cancer Center. Apoptosis and Cancer: Detection and Treatment. Tampa, Florida.

2004: Invited Speaker: Sex Hormones and the Immune System. 2nd World Congress on Women Mental Health. Washington DC

2004: Invited Speaker: IX International Congress of Reproductive Immunology. The Innate Immune System: Trophoblast Survival and Apoptosis. Hakone, Japan

2004: Invited Speaker: Curso de postgrado en Climaterio. Menopause, Sex Hormones and the Immune System. Buenos Aires,Argentina

2004: Invited Speaker: IVIG. Reproductive Immunology. The Immune System and Reproduction. San Francisco, CA

2004: Invited Speaker: Nevada Cancer Institute. Apoptosis and Cancer.

2004: Invited Speaker. International al Meeting of Menopause. Sex Hormones and the Immune System. Lima, Peru

2004: Invited Speaker: International al Meeting of Menopause. Apoptosis and the Ovary. Lima, Peru

2003: Invited Speaker: Weizmann Institute of Science. Apoptosis and Cancer. Rehovot, Israel

2003: Invited Speaker: Jornadas Nacionales de Climaterio. Sex Hormones and the Immune System. Salta, Argentina

2003: Invited Speaker: Jornadas Nacionales de Climaterio. Apoptosis and the Ovary. Salta, Argentina.

2003: Invited Speaker: Apoptosis and Cancer. Northwestern University, Chicago

2003: Invited Speaker: Immunology of Implantation. Northwestern University, Chicago

2003: Invited Speaker: XII World Congress of Gestational Trophoblastic Disease. Sheraton Boston Hotel. Boston, MA

2003: Invited Speaker: Monocytes and implantation. PRB, NIH.

2002: Invited Speaker: DOD Breast cancer Training Program. Life after death? Survival by Apoptosis in Reproductive Tissues. Fox Chase Cancer Center,
Philadelphia, PA

2002: Invited Speaker: 3rd Annual Conference on Sex and Gene Expression. Sex hormones and the Immune system. The Hayes Mansion Conference Center, San Jose, California

2001: Invited Speaker: Scientific Advisory Meeting: Sex Differences in Immunology and Autoimmunity. Estrogen, macrophages and the Fas/FasL system: Understanding the Biology of Sex Differences. Boston, MA

2001: Invited Speaker: International Menopause Day. Apoptosis and Cancer. Santiago, Chile

2001: Invited Speaker: International Menopause Day. Sex Hormones and the Immune System: Cancer and Autoimmunity. Santiago, Chile

2001: Invited Speaker: 4th International Symposium Women's Health and Menopause. Sex hormones and the immune system: implications for menopause and autoimmunity. Washington, DC

2001: Invited Speaker: Menopause Society. Autoimmune diseases and Hormone Replacement Therapy. Asuncion, Paraguay

2001: Invited Speaker: Estrogen receptors α and β in reproductive tissues. Menopause Society Asuncion Paraguay

2001: Invited Speaker:. Menopause Society. Immunology of Gynecologic Cancers. Asuncion, Paraguay

2001: Invited Speaker: Annual Meeting of the American Society of Reproductive Immunology. The Fas/FasL system in reproductive Tissues: Normal Development and Autoimmunity. Santiago, Chicago

2001: Invited Speaker: Brown University Grand Rounds. Apoptosis and Cancer. Providence, RI

2001: Invited Speaker: Perinatology Research Branch, Intramural Division, NICHD. : Immunology of implantation. Detroit, MI

1999: Invited Speaker: The North American Menopause Society. Immune Disorders in Menopausal Women. New York, NY

2000: Invited Speaker: Menopause Society. Autoimmune diseases and Hormone Replacement Therapy. Santiago, Chile

2000: Invited Speaker: Menopause Society. Estrogen receptors α and β in reproductive tissues. Santiago, Chile

2000: Invited Speaker: Menopause Society. Immunology of Gynecologic Cancers. Santiago, Chile

2000: Invited Speaker: XVII Jornadas de Obstetricia y Ginecologia. Sex Hormones and the Immune System. Buenos Aires, Argentina.

2000: Invited Speaker: XVII Jornadas de Obstetricia y Ginecologia. The effect of Hormone Replacement Therapy in Autoimmune Diseases. Buenos Aires, Argentina.

1999: Invited Speaker: XVII Jornadas de Obstetricia y Ginecologia. : Immunology of Gynecologic Cancers. Buenos Aires, Argentina.

1999: Invited Speaker: Annual meeting of the American Society of Reproductive Immunology. Fas/Fas Ligand system in tumor-immune cells interaction. New York, NY

Local Lectures (WSU – 2019)

Wayne State University School of Medicine, Department Obstetrics and Gynecology, Wayne Day 2019: Risks Associated with Viral Infections During Pregnancy, Shinola Hotel, Detroit, MI, Dec. 2019.

Wayne State University School of Medicine, MD/PhD Program, Bench 2 Bedside Seminar Series: Pregnancy Reconceived: Immunological Challenges, Oct. 2019.

Wayne State University, Department of Chemical Engineering and Materials Science, Seminar Series: New Advances for the Treatment and Diagnosis of Ovarian Cancer, Sept. 2019.

Wayne State University School of Medicine, Department Physiology Seminar Series: Immune Regulatory Function of Type I Interferon During Pregnancy, Sept. 2019.

Wayne State University School of Medicine, Dept. Ob/Gyn, Division of Reproductive Endocrinology & Infertility Fellows Lecture Series: Inflammation and Implantation, Aug. 2019.

Barbara Ann Karmanos Cancer Institute Wayne State University – Ovarian Cancer Focus Group/Molecular Therapeutics Mini Symposium: New Advances for the Treatment and Diagnosis of Ovarian Cancer. May 2019.

Barbara Ann Karmanos Cancer Institute/Wayne State University Research Grand Rounds: Ovarian Cancer Stem Cells: Recurrence and Chemoresistance, April 2019.

Wayne State University School of Medicine – Detroit Medical Center (DMC) Dept. Ob/Gyn Resident and Fellow Research Day: Infection and Pregnancy: The Immunological Role of the Placenta, March 2019.

Local Lectures Yale

•Yale Cancer Center, Developmental Therapeutics Research Program: Targeting the Ovarian Cancer Stem Cells to Prevent Recurrence, November 2016

Ellen Read Leeds Sturges Memorial Lecture, Yale School of Medicine: The Origin of Ovarian Cancer and Cancer Stem Cells as the Source of Chemoresistance and Recurrence, October 2015

26th Annual Ella T. Grasso Memorial Conference: Ovarian Cancer Stem Cells, November 2010

Grand Rounds Yale Cancer Center: Ovarian Cancer Stem cells: Recurrence and Chemoresistance, February 2010

Grand Rounds Obstetrics & Gynecology: Characterization and Identification of Ovarian Cancer Stem Cells, November 2009

Grand Rounds Pathology: Ovarian Cancer Stem cells: Source of Recurrence and Chemoresistance, April 2009

Grand Rounds Yale Cancer Center: Biomarkers for the Early Detection of Ovarian Cancer, June 2007

Yale Cancer Center: Developmental and Therapeutics Research Program: TLRs, Inflammation and Cancer, January 2006

Yale Cancer Center: Ovarian Cancer Research Program: Serum Proteins Markers for Early Detection of Ovarian Cancer, March 2006

Yale Cancer Center, Therapeutic Radiology Lectures: Inflammation and Cancer, 2006

Grand Rounds Department of Obstetrics and Gynecology: Serum Protein Markers for Early Detection of Ovarian Cancer, 2006

Ovarian Cancer Research Program: Serum Protein Markers for Early Detection of Ovarian Cancer, 2005

Pharmacology: Apoptosis and Cancer, 2004

Immunobiology Seminar Series Lectures: A lethal talk: Fas-FasL in Tumor Immune cells Interaction, 1999
OB/Gyn Residents' Seminar: Immunology of Reproduction, 1999, 2000, 2001 and 2002

Gynecologic Oncology Residents' Lecture: Apoptosis and Cancer, 2001

Grand Rounds Yale Cancer Center: Life after death? Survival by Apoptosis in Reproductive Tissues, 2002

Grand Rounds Pathology: Apoptosis and Cancer, 2003

Grand Rounds Department of Obstetrics and Gynecology: Phenoxodiol: A New Approach for the Treatment of Ovarian Cancer, 2002

PRESENTATIONS AT MEETINGS (up to 2005)

1. Mor G, Abrahams V, Straszewski-Chavez S. (2005) The Innate Immune System: Trophoblast Survival and Apoptosis. American Journal of Reproductive Immunology 52 (supplement 1): 15.
2. Abrahams VM, Straszewski-Chavez SL, Bole-Aldo P, Romero R, Mor G (2005) Trophoblast cells regulate an immune response through TLR-4 induced cytokine production. Journal of the Society for Gynecological Investigation 2005; 12(2) (supplement 1): 306A.
3. Straszewski-Chavez SL, Visitin IP, Mor G. (2005) XAF1 induces XIAP cleavage and first trimester trophoblast cell apoptosis by acting through the mitochondrial pathway. American Journal of Reproductive Immunology 53(6): 284.
4. Straszewski-Chavez SL, Abrahams VM, Aldo PB, Mor G (2005) Characterization of a novel telomerase-immortalized human first trimester trophoblast cell line. American Journal of Reproductive Immunology 53(6): 285.
5. Abrahams VM, Aldo PB, Straszewski-Chavez SL, Romero R, Mor G. (2005) Toll-like receptor expression and regulation in first trimester trophoblast cells. American Journal of Reproductive Immunology 53(6): 279.
6. Straszewski-Chavez SL, Abrahams VM, Aldo PB, Mor G (2005) The PI3K/Akt pathway inhibits trophoblast apoptosis by regulating $FLIP_S$ and XIAP expression. Placenta 26(8-9): A.60.
7. Straszewski-Chavez SL, Abrahams VM, Aldo PB, Mor G (2005) Isolation and characterization of a novel telomerase-immortalized human first trimester trophoblast cell line. Placenta 26(8-9): A.62.
8. Abrahams VM, Straszewski-Chavez SL, Bole-Aldo P, Romero R, Mor G (2004) Trophoblast apoptosis is induced through Toll-like receptor 2, but not Toll-like receptor 4: A novel mechanism for first trimester pregnancy failure. Journal of the Society for Gynecological Investigation 11(2) (supplement 1): 318A.
9. Abrahams VM, Kim YM, Straszewski-Chavez SL, Romero R, Mor G (2004) Efficient clearance of apoptotic cells by macrophages at the maternal-fetal interface is critical for successful pregnancy. Journal of the Society for Gynecological Investigation 11(2) (supplement 1): 281A.
10. Chavez S, Abrahams V, Mor G (2004) XIAP-associated factor 1 (XAF1) is a novel regulator of trophoblast apoptosis. Placenta 25: A14.

11. Alvero A, Chen W, Sartorelli A, Schwartz P, Rutherford T, Mor G (2004) Triapine induces apoptosis in chemoresistant ovarian cancer cells. AACR 95th Annual Meeting Orlando FL Abstract # 4897

12. Rutherford T, O'Malley D, Makkenchery , Baker L, Azodi M, Schwartz P, Mor G (2004) Phenoxodiol Phase Ib/II Study in Patients with Recurrent Ovarian Cancer that are Resistant to ≥ Second Line Chemotherapy. Society for Gynecologic Investigation Houston Texas Abstract # 254

13. Mor G, Sapi E, Chen W, O'Malley D, Kamsteeg M, Rutherford T, (2004) Phenoxodiol a chemosensitizer in Taxotere-resistant Ovarian Cancer Cells. Society for Gynecologic Investigation Houston Texas. Abstract # 984

14. Strasewski-Chavez S, Abrahams V, Mor G (2004) TNFα induces trophoblast apoptosis by upregulating XIAP-Associated Factor 1 (XAF-1) Society for Gynecologic Investigation Houston Texas. Abstract # 315

15. Krikun, G., Mor, G., Guller, S., Schatz, F., Sapi, E., Qumsiyeh, M., Lockwood, C. (2004) A novel immortalized endometrial stromal cell line with normal progrestational response Society for Gynecologic Investigation Houston Texas. Abstract # 340

16. Abrahams, VM, Mee-Kim Y., Strasewski-Chavez, S., Romero R., Mor G. (2004) Efficient clearance of apoptotic cells by macrophages at the maternal-fetal interface is critical for successful pregnancy. Society for Gynecologic Investigation Houston Texas. Abstract # 616

17. Rutherford T, O'Malley D, Makkenchery, Baker L, Azodi M, Schwartz P, Mor G (2004) Phenoxodiol Phase Ib/II Study in Patients with Recurrent Ovarian Cancer that are Resistant to ≥ Second Line Chemotherapy. AACR 95th Annual Meeting Orlando FL Abstract #4457

18. Mor G, Ying X, Dwipoyono B. Sapi, E, Kamsteeg M, Rutherford T, (2003) Resistance of Ovarian Cancer Cells to Taxotere (Docetaxel) is XIAP Dependent. Society for Gynecologic Investigation Washington DC, Abstract #460)

19. O'Malley D, Flick M, Rodov, S, Kacinsk B, Schwartz P, Rutherford T, Mor G (2003) Correlation of in vitro apoptosis and clinical response to chemotherapy in ovarian cancer patients. Society for Gynecologic Investigation Washington DC , Abstract #459)

20. Mor G, Kamsteeg M, Sapi E, Shahabi S, Rutherford T (2003) Phenoxodiol, an isoflavone analogue induces apoptosis in chemoresistant ovarian cancer cells. Society for Gynecologic Investigation Washington DC, Abstract #461)

21. Mor G, Kamsteeg M, Sap, E, Shahabi S, Rutherford T (2003) Phenoxodiol, a new approach for the treatment of ovarian cancer. AACR Toronto Abstract # 644

22. O'Malley D, Kamsteeg M, Chen W, Schwartz P, Rutherford T, Mor G (2003) Phenoxodiol and ovarian cancerAnnual Meeting of the American Society for Reproductive Immunology. AJRI 49: Abstract # 372

23. Straszewski S, Abrahams V, Mor G (2003) XIAP confers trophoblast cell resistance to Fas-mediated apoptosis Annual Meeting of the American Society for Reproductive Immunology. AJRI 49: Abstract #326

24. Abrahams V, Mor G (2003) Trophoblast cells secrete an active form of FasL: New insights into implantation Annual Meeting of the American Society for Reproductive Immunology. AJRI 49: Abstract # 324

25. Mor G, Straszeweski S, Song J, Lareef M, Russo J (2002) The regulation of FLIP in Human Breast epithelial cells SGI, Los Angeles Abstract # 4

26. Song J, Sapi E, Mor G (2002) Fas Ligand activation by estrogen receptors at the ERE and AP-1 sites SGI, Los Angeles Abstract # 573

27. Hanczaruk B, Sapi E, Rutherford T, Mor G (2002) Regulation of the Fas/FasL system by progesterone in human ovarian cells SGI, Los Angeles Abstract # 850
28. Song J, Cho M, Chen S, Mor G, Naftolin F (2002) The aromatase inhibitor methytestosterone inhibits testosterone-induced breast cancer cell proliferation. SGI, Los Angeles Abstract # 875
29. Neale D, Demasio K, Illuzi J, Romero R, Mor G (2002) trophoblast viability: can it be used as a predictor of preeclampsia? Society for maternal-Fetal medicine New Orleans, Abstract # 31 (American Journal of Obstetrics and Gynecology (185, #6)
30. Song J, Aschkenazi S, Rutherford T, Naftolin F, Mor G (2001) Differential Activation of the Fas Ligand Promoter by SERMs is Dependent on the Estrogen Receptors ERA and ERB Subtype. SGI, Toronto, Abstract t# [811]
31. Song J, Naftolin F, Aschkenazi S, Rutherford T, Mor G (2001) Effect of Estrogen on Fas Ligand Promoter Activity. SGI, Toronto, Abstract t# [816]
32. Palter SF, Ergur AR, Kayisli U, Lin C, Mor G (2001) Time-Course of Human Xenograft Folliculogenesis. SGI, Toronto, Abstract t# [763]
33. Aschkenazi S, Rutherford T, Song J, Lim C, Mor G (2001) Thalidomide Induces Fas-Mediated Apoptosis in Epithelial Ovarian Cancer. SGI, Toronto, Abstract t# [72]
34. Song J, Aschkenazi S, Naftolin F, Mor G(2001) Sex Hormones, Apoptosis and the Fas/Fas Ligand System in Normal Endometrial Tissue Remodeling. SGI, Toronto, Abstract t# [438]
35. Ergur AR, Kayisli U, Amama E, Mor G, Palter SF (2001) Effects of Host Sex on Human Ovarian Xenograft Folliculogenesis and Apoptosis in Immunodeficient Mice. SGI, Toronto, Abstract t# [41]
36. Garcia-Velasco JA, Simon C, Mor G, Arici A (2001) Soluble Fas Ligand Is Elevated in Peritoneal Fluid and Serum Of Women with Endometriosis. SGI, Toronto, Abstract t# [383]
37. Aschkenazi S, Rutherford T, Sapi E, Song J, Mor G (2001) Cytotoxicity to Taxol in Epithelial Ovarian Cancer Cells Is Mediated by the Fas/Fas Ligand System: In Vitro Assessment of Drug Sensitivity. SGI, Toronto, Abstract t# [277]
38. Silva I, Mor G, Naftolin F (2001) Anti-Inflammatory Effect of Estrogen on Microglia Activation through Down Regulation of CD40 Pathway. SGI, Toronto, Abstract t# [250]
39. Aschkenazi S, Mor G (2001) TH-1 and TH-2 Type Cytokines Regulates Fas-Mediated Apoptosis in First TrimesterTrophoblast Cells: Role of the Fas/Fas Ligand System in Implantation. SGI, Toronto, Abstract t# [226]
40. Song J, Aschkenazi S, Naftolin F, Mor G (2001) Sex hormones, apoptosis and the fas/fas ligand system in normal endometrial tissue remodeling. SGI, Toronto SGI, Toronto, Abstract t# 438
41. Redlinger R, Poggio K, Muñoz A, Mor G (2000) The role of the Fas/FasL system in the estrogen-induced thymic alteration. . American Society for Reproductive Immunology. Jacksonville, Florida, Abstract #2
42. Aschkenazi, SO, Verwer KMA, Foellmer H, Mor G (2000) Differential effects of T-Helper-1 and T Helper-2 type cytokines on normal human trophoblast expression of Fas and Fas ligand: Possible role in implantation. American Society for Reproductive Immunology. Jacksonville, Florida, Abstract #25
43. Muñoz AA, Redlinger R, Kohen F, Mor G (2000) differential expression of estrogen receptors α and β in the thymus. American Society for Reproductive Immunology. Jacksonville, Florida, Abstract #27
44. Mor G, Song J, Brown W, Naftolin F (2000) Estrogen and the FAS/FAS Ligand System in Breast Cancer Cells: Functional Differences between Estradiol and Tamoxifen. Blue Ribbon presentation. SGI Chicago IL, Abstract # 8

45. Rutherford T, Sapi E, Brown W, Verwer K, Munoz A, Mor G (2000) Fas and Fas Ligand Expression in Normal and Pathologic Ovarian Tissue. SGI Chicago IL, Abstract # 9
46. Brown W, Mor G, Rutherford T, Tartaro K, Sapi E (2000) Fas Ligand Expression Is Regulated by Estrogens in Normal and Neoplastic Ovarian Epithelia. SGI Chicago IL, Abstract # 41
47. Song J, Sapi E, Nilsen J, Lim HC, Naftolin F, Mor G (2000) The Role of the Fas/Fas Ligand System in Breast Tissue: Normal Differentiation Versus Breast Cancer. . SGI Chicago IL, Abstract # 531
48. Sbracia M, Poverini R, Rossi A, DeFelici M, Scarpellini F, Aragona C, Micara G, Mor G (2000) FAS-Receptor/FAS-Ligand System Regulates with an Autocrine/Paracrine Mechanisms the Apoptosis in Human Pre-Embryos. SGI Chicago IL, Abstract # 605
49. Brown WD, Sapi E, Verwer KMA, Mor G (1999) Fas Ligand regulation in an ovarian organ culture system: Implications for ovarian cancer. American Society for Reproductive Immunology. Cooperstown, NJ; Abstract # P-9
50. Verwer KMA, Brown WD, Foellmer HG, Mor G (1999) Macrophage derived growth factors modulate Fas Ligand expression in cultured trophoblast cells: A role in implantation. American Society for Reproductive Immunology. Cooperstown, NJ; Abstract # P-10
51. Mor G, Brown S, Rosen R, Song, J, Brown WB, Naftolin F (1999) Regulation of Fas Ligand expression in breast cancer cells by estrogen: Functional differences between estradiol and tamoxifen. American Society for Reproductive Immunology. Cooperstown, NJ; Abstract # O-9
52. Zaltsman Y, Mor G, Ben-Hur H, Gayer N, Nevo N, Kohen F (1999) Hormonal Regulation of Fas Ligand in the rat prostate: Implications for prostate cancer. Endocrine Society, San Diego CA.
53. Nilsen J, Mor G, Naftolin F (1999) Raloxifene is an estrogen agonist, inducing neurite outgrowth in PC12 cells. Society for Gynecologic Investigation, Atlanta, Georgia. Abstract # 723
54. Garcia-Velasco J, Arici A, Naftolin F, Zreik, T, Mor G (1999) Macrophage-Derived growth factors modulate Fas ligand expression in endometrial stromal cells: a role in endoemtriosis. Society for Gynecologic Investigation, Atlanta, Georgia. Abstract #
55. Hsu CD, Gutierrez LS, Meaddough E, Basheera H, Lu LC, Copel JA, Harirah H, Mor G (1999) Expression of Fas ligand by preeclamptic placenta. Society for Maternal-Fetal Medicine. San Francisco. Abstract #
56. Mor G, Gutierrez LS, Eliza M, Kahyaogili F, Arici A (1998) Induction of apoptosis mediated by the Fas-fas ligand system in human placental trophoblast and gestational trophoblastic disease. Society for Gynecologic Investigation. 45 th Annual Meeting. Atlanta, Georgia. Abstract # 55.
57. Senturk LM, Mor G, Gutierrez LM, Zeyneloglu HB, Bahtiyar MO, Arici A (1997) Monocyte Chemoattractant Protein-1 expression in human corpus luteum. American Society for Reproductive Medicine. 53Rd Annual Meeting. Cincinnati, Ohio.
58. Diano S, Mor G, Horvath T, Register T, Adams M, Naftolin F (1997) Estrogen formation by coronary arteries? .The presence of immunoreactive-Aromatase (irARO) and estrogen receptors (irER) in monkey and human coronary arteries. 8th Annual Meeting, NAM, Boston, MA.
59. Ben-Hur, H, Mor G, Blickstein I, Likhman I, Amir-Zaltsman Y, Sharp A, Insler V, Globerson A & Kohen F (1993) Expression of estrogen receptors [ER] in human monocytes in relation to menopause and hormone replacement therapy. In: 23rd Annual Meeting of the Israel Immunological Society, #43. Ben-Gurion University, Ber-Sheba, Israel.
60. Mor G, Amir-Zaltsman Y, Ben-Hur H, Sharp A & Kohen F (1993).Expression of Estrogen receptors in Human Peripheral mononuclear cells is associated mainly with monocytes. In: 23rd Annual Meeting of the Israel Immunological Society, #54. Ben-Gurion University, Ber-Sheba, Israel.

61. Mor G, Amir-Zaltsman Y, Bernard G& Kohen F (1993) Evidence for the presence of estrogen receptors in monocytes. In: 75th Annual Meeting of the Endocrine Society. Las Vegas, Nevada.
62. Ben-Hur H, Mor G, Blickstein I, Dagani, R., Insler V & Kohen F (1991-1992) Immunofluorescence studies of estrogen and progesterone receptor distribution in the human endometrium using anti-idiotypic antibodies. In: Annual Meeting of the Israel Endocrine Society. Jerusalem, Israel.
63. Mor, G, Kukulansky T, Kohen F & Globerson A (1991) Patterns of estrogen Receptor expression on thymocytesfrom young and old mice. In: Israel Immunological Society, 21st Annual Meeting. Rehovot, Israel.
64. Amir-Zaltsman, Y, Mor G, Barnard G, Gayer B, Lichter S, & Kohen F (1991) Anti-idiotypic antibodies against anti-estradiol: Preliminary characterization and probes for the study of the estrogen receptor. In: Endocrine Society, Annual Meeting. Washington.
65. Amir-Zaltsman, Y, Levi L, Mor G, Ben-Aroya N, Koch Y & Kohen F (1990-1991) Anti-idiotypic antibodies against anti-buserelin: Probes for the study of the GnRH receptor. In: Annual Meeting of the Israel Endocrine Society. Tel-Aviv, Israel.
66. Mor, G, Fajer A, Barnard B, Gayer B, Lichter S, & Kohen F (1990-1991) Monoclonal anti-idiotypic antibodies against anti-estradiol: use in the direct localization of estrogen receptor. In: Annual Meeting of the Israel Endocrine Society. Tel-Aviv, Israel.
67. Mor G, Fajer A, Barnard G, & Kohen F (1990) Use of fluorescent labeled monoclonal anti-idiotypic steroidal antibodies in the direct localization of cytoplasmatic and nuclear estrogen receptor. In: The Endocrine Society, 72 Annual Meeting. Atlanta, Georgia.
68. Fajer A, Barnard, G, Mor G, & Kohen F (1989) Use of anti-idiotypic antibodies in the localization by immunofluorescence of parenterally administered monoclonal antibodies to estradiol in female rats. In: The Endocrine Society 71st Annual Meeting. Washington.
69. Mor G, Amir-Zaltsman Y, Bernard G, Gayer B, Lichter S, Osher S & Kohen F (1992) Characterization of an anti-idiotypic antibody that recognizes estrogen receptors. In: 74th Annual Meeting of the Endocrine Society, (pp. #731). San Antonio,Texas.
70. Mor G, Saphier D & Feldman S (1985) Effects of corticosterone (CS) upon paraventricular nucleus (PVN) multi-unit activity (MUA) following neurogenic stimulation. In: Annual Meeting of the Israel Endocrine Society, Abstr. # 76. Tel Aviv, Israel.
71. Naftolin F, Mor G, Luquin S, Fager A, Lewis C, Feefe D, Kohen F & Garcia-Segura L (1993) Synaptic Plasticity in the hypothalamus arcuate nucleus during the estrus cycle is induced by estrogen and limited to the periventricular zone of reaction. In: 74th Annual Meeting of the Endocrine Society, #1804. Las Vegas, Nevada.
72. Saphier, D, Abramsky O, Mor, G, & Ovadia H (1986) A physiological correlate of an immune response. In: 6th International Congress of Immunology. Toronto, Canada.
73. Saphier D, Mor G & Feldman S (1986) Effects of corticosterone on paraventricular nucleus multiple unit activity responses to neural stimuli in conscious animals. In: 30th International Congress of Physiological Sciences. Vancouver, Canada.